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Introduction 
 
Cardiovascular disease is the leading cause of death in industrialized countries. In the 
Netherlands approximately 50,000 patients die each year from cardiovascular disease, which is 
35% of all deaths 1. In the United States, this number is over 930,000 patients per year 2. 
Cardiovascular disease includes all diseases of the heart or blood vessels. This thesis 
concentrates on arterial stenosis in the cardiovascular system, specifically in the coronary 
arteries, the carotid arteries, the peripheral arteries, and the renal arteries. Arterial stenosis in 
these areas may lead to severe morbidity due to, for example, myocardial infarction, stroke, limb 
amputation, or renal dysfunction, and thus has an enormous impact on the quality of life of the 
patient and may lead to death3-6. Therefore, it is important to diagnose cardiovascular disease 
accurately, so that adequate treatment can be initiated.   
 
Imaging technologies for cardiovascular disease studied in this thesis 
 
The first abdominal aortography was performed in 1929 and catheterization and 
angiography have been developed since that time 7. In the 1960s conventional angiography 
became clinically useful to diagnose the presence and extent of arterial stenosis in the arterial 
system. However, conventional angiography carries a risk of morbidity and mortality due to the 
use of contrast agents and radiation exposure8. In addition, the test is costly and burdensome to 
the patient, because it requires several hours of hospitalization. Therefore, the focus is currently 
on the development and improvement of non-invasive imaging technologies with the ultimate 
goal to replace conventional angiography.  
An enormous variety of non-invasive imaging tests exists to determine the presence or 
extent of cardiovascular disease. Tests that are routinely used in coronary artery disease include 
stress echocardiography and stress single-photon-emission computed tomography9. These tests 
are relatively inexpensive. In contrast to angiography, however, these tests use indirect 
measures of arterial stenosis, such as wall motion scores or perfusion scores, which are 
functional measures of myocardial ischemia. During the last decade, the role of electron-beam 
computed tomography (EBCT) has been studied for the diagnosis and prognosis of coronary 
artery disease10. Although calcium scoring on EBCT is generally used to determine prognosis in 
a patient with coronary artery disease, it can also be used to estimate the degree of arterial 
stenosis. EBCT has a very short scanning time, but requires special equipment. A new 
technological development involves computed tomographic angiography that has been adapted 
for diagnosing coronary artery disease11. This technology is becoming more widely available 
and can provide three-dimensional images of the heart. For each of theses non-invasive imaging 
technologies diagnosing coronary artery disease is a technological challenge due to the 
continuous beating of the heart, respiratory motion, and the small vessel size. 
For the diagnosis of peripheral, carotid, and renal artery disease duplex ultrasonography has 
since long been used12-14. Duplex ultrasonography is inexpensive but depends on the expertise of 
the operator. New technological developments for these anatomical areas also include computed 
tomographic angiography and (contrast enhanced) magnetic resonance angiography15. These 
tests are able to provide a roadmap of the vascular tree, like conventional angiography. The 
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trade-off between spatial and temporal resolution in these techniques, however, may lead to a 
reduced imaging quality. 
During the last decade numerous studies have been published on the diagnostic 
performance of non-invasive imaging tests for cardiovascular disease. The question remains 
which studies provide the best-available evidence for the clinician and which test should be 
chosen in a particular clinical setting.  
 
Methods of diagnostic test evaluation used in this thesis 
 
Several methods have been developed to compare the performance of imaging tests for the 
diagnosis of cardiovascular disease. Traditionally, the determination of sensitivity and 
specificity of a new technology have been used to demonstrate good diagnostic performance. 
However, studies have shown that these measures may be affected by the choice of patient 
population and the clinical setting in which the test is performed 16. Furthermore, if sensitivity of 
test A is higher than test B, but specificity of test A is lower than test B, it is still not clear which 
test has the best diagnostic performance. Therefore, positive and negative predictive values, 
likelihood ratios, and diagnostic odds ratios have been evaluated in addition to measures of 
sensitivity and specificity.  
To summarize the currently available evidence on the diagnostic performance of non-
invasive imaging tests published in the literature a systematic review can be performed. In a 
systematic review the available evidence on the subject of interest is systematically collected 
from the literature using in- and exclusion criteria17. Outcome measures of interest, for example 
measures of sensitivity and specificity, are extracted from the included studies and a summary 
measure of diagnostic performance is calculated. Traditionally, pooling the measures of 
sensitivity and specificity independently, weighted for sample size, has been performed. 
During the last decade, summary receiver operating characteristic (SROC) analysis has been 
used to summarize measures of sensitivity and specificity taking into account their inverse 
relationship18. SROC analysis is a regression technique that accounts for changes in the cut-off 
value of the test and offers the opportunity to adjust for study characteristics. The area under the 
SROC curve can be used as an overall measure of diagnostic performance.  
A large number of diagnostic imaging tests have been published showing a good diagnostic 
performance for the diagnosis of cardiovascular disease. From a health care policy perspective, 
however, the value of a diagnostic test should not only reflect the diagnostic performance, but 
also the cost and risks associated with the test and the treatments that may be induced by the 
test, the pre-test probability of disease, and the health related quality of life of the patient. Cost-
effectiveness analysis can be performed to integrate these variables and to guide the decisions 
on which test should be used in specific clinical settings19. 
Using the outcomes of a cost-effectiveness analysis in combination with a SROC analysis, the 
optimal sensitivity and specificity for a specific clinical setting can be calculated20. For each 
potential combination of sensitivity and specificity on the SROC curve the net health benefit, a 
measure that integrates cost and effectiveness, is calculated for a specific patient population21. 
The operating point on the SROC curve with the maximum net health benefit is defined as the 
optimal operating point. Furthermore, using the ROC curve from a single study, the optimal 
cut-off value of a test can be calculated for a specific clinical setting. 
Introduction 
13  
Depending on the referral pattern and test protocols used in clinical settings, diagnostic test 
evaluations may generate biased results22. It has been recognized that in particular verification 
bias may have a large influence on measures of diagnostic performance. Verification bias exists 
if patients are referred to the reference test based on the results from the test under evaluation. 
As a result of verification bias sensitivity may be inflated and specificity deflated if positive test 
results are verified preferentially. If data are collected on all patients undergoing the test that is 
evaluated, it is possible to correct for verification bias under the assumption that the probability 
of verification and the disease status are conditionally independent23. 
Despite substantial clinical research, uncertainty remains about which test should be chosen 
in a specific clinical setting. Future quantitative clinical research can help resolve this 
uncertainty. To estimate which variables in diagnostic test evaluations have the largest impact 
on the choice of the optimal test strategy, value of information analysis can be performed 24. 
Using value of information analysis the expected benefit of various study parameters can be 
estimated for future test evaluations. 
 
Aim and outline of this thesis 
 
The aim of this thesis was to assess diagnostic imaging technologies for the diagnosis of 
cardiovascular disease using various methods of diagnostic test evaluations and to determine 
the optimal diagnostic test strategy in specific clinical settings. A secondary aim was to develop 
the methods available for the assessment of diagnostic imaging technology, including meta-
analytical and decision analytical techniques. 
In this thesis several methods of diagnostic test evaluation are described and applied to the 
field of diagnostic imaging technologies in cardiovascular disease: from systematic review and 
comparison of the sensitivity, specificity, and diagnostic odds ratios in chapters 2 and 3, to cost-
effectiveness analysis in chapters 4 and 5. In addition, methods of test optimization are 
described for the determination of the optimal sensitivity and specificity in chapter 6 and 
optimizing cut-off values of diagnostic tests in chapters 7 and 8. Chapter 9 focuses on potential 
biases that may affect the results of diagnostic test evaluations, in particular verification bias. In 
chapter 10 value of information analysis is used to determine which study parameters should be 
evaluated in future research on imaging technologies for coronary artery disease. 
Each method discussed in this thesis has its specific benefits and limitations. In the general 
discussion these will be put into perspective in order to select a methodology of diagnostic test 
evaluation that may help solve a specific clinical problem. 
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Abstract 
 
Objectives: The purpose of this study was to review the literature and to compare the diagnostic 
performance of stress echocardiography, stress single-photon-emission computed tomography 
(SPECT), and electron-beam computed tomography (EBCT) for the assessment of coronary 
artery disease using meta-analytic techniques.  
Background: Current guidelines suggest that a non-invasive imaging test should be performed 
to determine whether patients with suspected coronary artery disease should undergo coronary 
angiography. 
Methods: We searched PubMed from January 1990 through May 2003 for meta-analytic studies 
on the diagnostic performance of imaging tests for coronary artery disease. Meta-analyses were 
selected that used angiography as reference standard and that presented the absolute numbers 
of true-positive, false-positive, true-negative, and false-negative results of the source studies. 
Data were extracted on the level of the meta-analysis and the level of the source studies included 
in each meta-analysis. Duplicate source studies were excluded. A summary-receiver-operating-
characteristic analysis was performed on the source data. 
Results: Seven meta-analyses were selected, including 246 patient series with 24,761 patients. 
The coronary tests showed little differences in diagnostic performance. The diagnostic odds 
ratios of exercise, dobutamine, and dipyridamole echocardiography were higher than the 
corresponding stress SPECT tests and EBCT, but not significantly. The diagnostic performance 
was significantly better in studies with a high proportion of men and significantly declined over 
the years. 
Conclusions: We conclude that the differences in diagnostic performance between imaging tests 
for coronary artery disease are small, that the diagnostic performance of imaging tests is 
significantly better in men than in women, and that the diagnostic performance has declined 
over the years. 
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Introduction 
 
Coronary artery disease is the main cause of death in industrialized countries. Coronary 
events can be minimized if patients suspected of coronary artery disease are correctly and safely 
diagnosed and treatment is initiated accordingly. The accepted reference standard for the 
diagnosis of coronary artery disease is coronary angiography. However, coronary angiography 
is costly and severe complications occur in almost 0.5% of patients undergoing coronary 
angiography.1 Therefore, non-invasive tests with optimal sensitivity and specificity should be 
performed to determine which patients should undergo coronary angiography. Current 
guidelines recommend the use of non-invasive imaging tests, such as stress echocardiography 
and stress SPECT, prior to coronary angiography in patients suspected of coronary artery 
disease.2 The role of EBCT for the diagnosis of coronary artery disease is controversial. Its use is 
both discouraged 3 and recommended 4 for patients suspected of coronary artery disease. 
A number of studies have been published in which the sensitivity and specificity of non-
invasive imaging tests have been evaluated. In the last decade, several meta-analyses have been 
performed summarizing the published data for each test. However, direct comparison of test 
accuracy measurements from various studies is complicated, because several factors that are 
associated with patient selection and study design may have differed between the studies. 
Furthermore, it is uncertain whether the sensitivity or specificity should take priority in a 
particular clinical setting. Therefore, it is useful to combine the sensitivity and specificity into 
one estimate of test performance, such as the diagnostic odds ratio. The potential bias of clinical 
factors and study characteristics on the diagnostic odds ratio can be accounted for in a linear 
regression analysis using the methods of summary receiver operating characteristics analysis 
(SROC).5-7 We questioned whether significant differences existed in the diagnostic performance 
of stress echocardiography, stress SPECT, and EBCT, when adjusting for study characteristics.  
The purpose of this study was to review the literature on non-invasive imaging tests for the 
diagnosis of coronary artery disease, to compare the diagnostic performance of the tests, and to 
identify study characteristics that may influence the diagnostic performance. 
 
 
Methods 
 
Study selection 
A literature search was performed in PubMed from January 1990 through May 2003 to 
identify meta-analyses on the diagnostic performance of non-invasive imaging tests for the 
diagnosis of coronary artery disease. We used the following search terms: meta-analysis or 
systematic review or structured review and imaging test. We also checked the references of the 
included articles for additional meta-analyses. Articles in the English language were included if 
they met the following inclusion criteria: (a) the diagnostic performance of imaging tests for 
coronary artery disease was studied, (b) meta-analytic methods were used, (c) coronary 
angiography was used as reference standard, (d) the absolute numbers of true-positive, false-
negative, true-negative and false-positive results of the source studies were available or 
derivable from the meta-analyses, and (e) it was published after 1990. If inclusion criterion d was 
not met, the authors were requested to provide these data. Because of the rapid advances in 
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imaging technology, meta-analyses published before 1990 were excluded. If a meta-analysis 
compared an imaging technology with a technology that is no longer in use or with a non-
imaging technology, only the data on the newer imaging technology were included.  
 
Data extraction 
The data were extracted on two levels: on the level of the meta-analysis and on the level of 
the source studies that were included in each meta-analysis. The following data were extracted 
per meta-analysis: author, journal, year of publication, type of test, number of studies included, 
total number of patients, summary estimates of sensitivity and specificity, and details of the 
meta-analytic methods. In addition to the study identification and study size, the mean age of 
the patients, the proportion of men included, the type of stress used, and the absolute number of 
true-positive, false-negative, false-positive, and true-negative test results were extracted per 
source study. If source studies of meta-analyses overlapped and the data presented in the meta-
analyses were identical, the duplicate data were excluded. If discrepancies existed between 
duplicate source studies, the original publication of the source study was retrieved and, based 
on the original paper, the discrepant source data were excluded. If a meta-analysis was done on 
the same source studies for several definitions of significant disease, the data were extracted 
only for one definition: this definition was 50-100% stenosis in at least one coronary artery. 
However, in some meta-analyses, the definition of significant disease was not used as selection 
criterion, but as a covariate in the analysis. The non-invasive imaging tests included exercise 
echocardiography, pharmacological stress echocardiography, exercise SPECT, pharmacological 
stress SPECT, and EBCT. 
 
Data-synthesis 
Pooled weighted analysis 
First, the data were evaluated on the level of the meta-analysis. The published summary 
estimates of sensitivity and specificity were plotted per test type with 1-specificity on the 
horizontal axis and sensitivity on the vertical axis. If the meta-analysis did not present summary 
estimates of sensitivity and specificity, the pooled values of sensitivity and specificity were 
calculated from the absolute numbers of true and false test results of the source studies. Because 
most of the meta-analyses presented fixed summary estimates, we calculated the pooled values 
of sensitivity and specificity weighted for sample size only. After exclusion of the duplicate 
studies, we re-calculated the pooled values of sensitivity and specificity per test type using a 
random effects meta-analysis to account for heterogeneity between studies. 
 
SROC analysis 
We performed a random effects SROC analysis on the data set of source studies to calculate 
the relationship between sensitivity and specificity, taking into account the differences in 
positivity criterion and other factors of heterogeneity between settings. In an SROC analysis the 
true-positive rate (TPR) (sensitivity), and the false-positive rate (FPR) (1-specificity), are 
transformed into the logit form.6,8 Then, a linear regression analysis is performed on the 
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variables D and S, D representing the natural logarithm of the diagnostic odds ratio and S 
functioning as proxy for the positivity criterion of the diagnostic test. D and S are defined as the 
difference and the sum of the logit transformations of TPR and FPR respectively, in formula:  
 
D= 
FPR
FPR
TPR
TPR
−
−
− 1
ln
1
ln  
S= 
FPR
FPR
TPR
TPR
−
+
− 1
ln
1
ln  
 
To prevent undefined values for D and S due to 0’s in the equations, 0.5 was added to the 
absolute numbers of true-positive, false-positive, true-negative and false-negative test results for 
the calculation of D and S. The regression analysis was weighted with the inverse of the variance 
of D. We used a random effects model, which takes into account the variability between studies.9 
All data were analyzed in a linear regression model in which D, the log of the diagnostic odds 
ratio, was modeled as a function of the explanatory variable that indicated the type of test, i.e. 
exercise, dobutamine, adenosine, and dipyridamole echocardiography; exercise, dobutamine, 
adenosine, and dipyridamole SPECT; and EBCT. The diagnostic performance of each test is 
represented by the relative odds ratio: a relative odds ratio equal to 1 indicates similar 
performance, a relative diagnostic odds ratio larger than 1 indicates better performance, and a 
relative diagnostic odds ratio smaller than 1 indicates inferior performance as compared with 
the test that was chosen as reference. Additional covariates were added to the model to evaluate 
the influence of clinical factors and study characteristics on diagnostic performance. The 
following covariates were evaluated: total number of patients in the study, mean age, 
proportion of men included, proportion of diseased patients, and the year of publication of the 
study. The year of publication of the study was chosen as a proxy for potential secular changes. 
First, we evaluated the individual effect of each variable on the diagnostic performance in the 
model that always included S. Starting with the variables with the lowest residual between-
study variance (determined by tau-squared), the significant variables were added to the 
multivariable model in a stepwise forward manner. A significance level of 0.05 was used. Tau-
squared, the residual between-study variance calculated with the restricted maximum 
likelihood method, was used as a measure of the model fit. A lower tau-squared indicates less 
residual between-study variance and therefore a better model fit and a better explanatory power 
by the model of the heterogeneity across studies. We used STATA 8.0 for the random effects 
analyses. 
 
 
Results 
 
Study selection 
The search strategy resulted in 120 abstracts of which 12 meta-analyses were found that 
reported on coronary artery disease.3,10-20 Of the 12 meta-analyses, one study was excluded 
because it was published before 1990.11 One meta-analysis did not report the absolute numbers 
of true-positive, false-positive, true-negative, and false-negative test results of the source 
studies.14 The author of this meta-analysis was requested to provide the missing information and  
Chapter 2 
22 
Ta
bl
e 
1:
 O
ve
rv
ie
w
 o
f t
he
 in
cl
ud
ed
 m
et
a-
an
al
ys
es
 
 M
et
a-
an
al
ys
is
 
P
ub
l 
ye
ar
 
Ty
pe
 o
f T
es
t 
N
o.
 
se
rie
s 
N
o.
 
pa
tie
nt
s 
P
oo
le
d 
S
en
s 
P
oo
le
d 
S
pe
c 
S
ig
ni
fic
an
t p
re
di
ct
or
s 
S
R
O
C
 a
na
ly
si
s 
D
is
cu
ss
io
n 
/ C
on
cl
us
io
n 
Fl
ei
sc
hm
an
n 
19
98
 
E
xe
rc
is
e 
E
ch
o 
 
E
xe
rc
is
e 
 S
P
E
C
T 
24
 
27
 
26
37
 
32
37
 
85
 
87
 
77
 
64
 
Te
st
, a
ge
, s
et
tin
g,
 
pu
bl
ic
at
io
n 
ye
ar
  
D
is
cr
im
in
at
or
y 
ca
pa
bi
lit
ie
s 
 
E
xe
rc
is
e 
E
ch
o 
> 
E
xe
rc
is
e 
SP
E
C
T 
O
’R
ou
rk
e 
20
00
 
E
B
C
T 
16
 
36
83
 
91
 
49
 
C
al
ci
um
 s
co
re
 >
10
0 
H
ig
h 
se
ns
iti
vi
ty
, b
ut
 lo
w
 s
pe
ci
fic
ity
 
P
ic
an
o 
20
00
 
D
ip
yr
id
am
ol
e 
E
ch
o 
D
ob
ut
am
in
e 
E
ch
o 
38
 
59
 
28
56
 
50
82
 
73
 
81
 
91
 
83
 
n/
a 
C
om
pa
ra
bl
e 
di
ag
no
st
ic
 a
cc
ur
ac
y 
B
er
ry
 
20
01
 
E
B
C
T 
7 
12
46
 
94
 
48
 
N
o.
 o
f s
lic
es
 
S
pe
ci
fic
ity
 E
B
C
T 
is
 lo
w
 
D
e 
A
lb
uq
ue
rq
ue
 
Fo
ns
ec
a 
20
01
 
D
ip
yr
id
am
ol
e 
E
ch
o 
 
E
xe
rc
is
e 
E
ch
o 
8 8 
53
3 
53
3 
72
 
79
 
92
 
82
 
n/
a 
S
im
ila
r d
ia
gn
os
tic
 a
cc
ur
ac
y 
 
K
im
 
20
01
 
A
de
no
si
ne
 E
ch
o 
D
ip
yr
id
am
ol
e 
E
ch
o 
D
ob
ut
am
in
e 
E
ch
o 
A
de
no
si
ne
  S
P
E
C
T 
D
ip
yr
id
am
ol
e 
S
P
E
C
T 
D
ob
ut
am
in
e 
S
P
E
C
T 
6 20
 
40
 
9 21
 
14
 
51
6 
18
35
 
40
97
 
12
07
 
14
64
 
10
66
 
72
 
70
 
80
 
90
 
89
 
82
 
91
 
93
 
84
 
75
 
65
 
75
 
D
ef
in
iti
on
 o
f d
is
ea
se
, 
pr
ev
al
en
ce
 
H
ig
he
st
 c
om
bi
na
tio
n 
of
 s
en
si
tiv
ity
 
an
d 
sp
ec
ifi
ci
ty
: d
ob
ut
am
in
e 
E
ch
o 
N
al
la
m
ot
hu
 
20
01
 
E
B
C
T 
14
 
16
62
 
92
 
51
 
S
am
pl
e 
si
ze
 >
10
0 
R
ea
so
na
bl
e 
di
ag
no
st
ic
 p
er
fo
rm
an
ce
 
  Pu
bl
 y
ea
r, 
pu
bl
ic
at
io
n 
ye
ar
; S
en
s,
 s
en
si
tiv
ity
; S
pe
c,
 s
pe
ci
fic
ity
; S
R
O
C
, s
um
m
ar
y 
re
ce
iv
er
 o
pe
ra
tin
g 
ch
ar
ac
te
ris
tic
; E
ch
o,
 e
ch
oc
ar
di
og
ra
ph
y;
 E
B
C
T,
 e
le
ct
ro
n-
be
am
 c
om
pu
te
d 
to
m
og
ra
ph
y;
 S
P
E
C
T,
 s
in
gl
e-
ph
ot
on
 e
m
is
si
on
 c
om
pu
te
d 
to
m
og
ra
ph
y;
 n
/a
, n
ot
 a
pp
lic
ab
le
 
 
Non-invasive imaging tests for coronary artery disease: where do we stand? 
23  
responded. Two meta-analyses were excluded because they did not use angiography as 
reference test, because an emergency setting was evaluated.13,16 Two meta-analyses were 
excluded because they were duplicates of other meta-analyses: one was a consensus document 
published twice3, the second a critique on meta-methodology.15 Because these meta-analyses 
included the same source data and provided the same pooled values of sensitivity and 
specificity as the original meta-analyses,12,18 the studies were excluded from further analysis.  
Ten non-invasive imaging tests were evaluated in the 7 remaining meta-analyses including 
310 patient series, of which 64 identical series were excluded. The final data set consisted of 246 
patient series, including 24,761 patients. 
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Figure 1: Pooled summary estimates of sensitivity and specificity of stress echocardiography, stress SPECT, and 
EBCT for the diagnosis of coronary artery disease obtained from meta-analyses. The test characteristics are listed in 
table 1.  
EBCT, electron beam computed tomography; Echo, echocardiography; SPECT, single-photon emission computed 
tomography 
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Comparison of test characteristics 
Table 1 gives an overview of the meta-analyses that were included in the current study. The 
table shows the pooled values of sensitivity and specificity per meta-analysis, which were 
reported or calculated from the source data. In Figure 1 these values are plotted in ROC space 
per type of test. An interesting result is that the summary estimates from 7 different meta-
analyses together have the shape of an SROC curve. Furthermore, the EBCT and stress SPECT 
tests are clustered at the right tail of this hypothetical SROC curve indicating high sensitivity 
and reduced specificity, whereas the stress echocardiography tests are clustered at the left tail 
indicating high specificity and reduced sensitivity. At the upper left of the dots there is room for 
improvement of both the sensitivity and specificity of the imaging tests for coronary artery 
disease.  
Table 2 shows the pooled sensitivity and specificity per test type calculated using a random 
effects meta-analysis after exclusion of duplicate studies. The results again indicate a higher 
specificity for the stress echocardiography tests and a higher sensitivity for the corresponding 
stress SPECT tests and EBCT.  
Figure 2 shows the summary estimates of the diagnostic log odds ratio, which incorporates 
both sensitivity and specificity, and the corresponding 95% confidence interval for each type of 
test. Note that all confidence intervals overlap each other indicating no statistical difference 
between the tests. Adenosine SPECT testing showed relatively high diagnostic performance 
compared with the other tests, but there was considerable heterogeneity in these studies which 
is denoted by the wide confidence interval. The diagnostic odds ratios of exercise, dobutamine, 
and dipyridamole echocardiography were higher than the corresponding stress SPECT tests and 
EBCT, but not significantly. 
In the regression analysis significant predictors of diagnostic performance were the type of 
test, the year of publication, and the proportion of men. Adenosine SPECT performed 
significantly better than exercise SPECT. There were no significant differences between the other 
coronary tests. The relative odds ratios are shown in table 3. Correction for publication year 
reduced the width of the confidence intervals but did not alter the significance of the differences 
between the test types. The effect of publication year on diagnostic performance is shown in 
figure 3. The area under the SROC curve significantly declined when comparing early-published 
studies and studies published 10 years later. The proportion of men was available in only 161 of 
the 246 studies. The difference between adenosine SPECT and exercise SPECT remained 
significant in this subgroup. In addition, there was a trend towards better diagnostic 
performance (p<0.10) for exercise echocardiography versus exercise SPECT (relative odds ratio 
(ROR) 1.65; 95% CI 0.98-2.77), for adenosine SPECT versus dobutamine SPECT (ROR 2.01; 95% 
CI 0.89-4.62), and for adenosine SPECT versus EBCT (ROR 2.10; 95% CI 0.91-4.85) in this 
subgroup analysis. 
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Table 2: Pooled sensitivity, specificity, and corresponding 95% confidence intervals per type of test using 
a random effects meta-analysis 
 
Test  N Sensitivity (%) 95% CI  Specificity (%) 95% CI 
Exercise echo 28 83.8 80.3-87.3  80.0 74.5-85.5 
Adenosine echo 6 74.2 62.8-85.5  91.2 86.3-96.0 
Dipyridamole echo 49 72.1 68.6-75.6  94.5 92.7-96.3* 
Dobutamine echo 72 81.2 0.79-83.5  84.1 81.8-86.5* 
Exercise SPECT 27 87.6 84.9-90.2  69.4 60.7-78.2 
Adenosine SPECT 8 90.9 89.0-92.7†  76.5 64.7-88.2 
Dipyridamole SPECT 21 92.0 88.8-95.2†  73.8 64.2-83.5 
Dobutamine SPECT 14 85.3 79.9-90.6  76.3 72.0-80.6 
EBCT 21 93.1 90.7-95.6‡  54.5 45.3-63.8‡ 
 
CI, confidence interval; N, number of studies included; echo, echocardiography; SPECT, single-photon emission 
computed tomography 
* non-overlapping confidence intervals indicating a statistically higher specificity than the corresponding SPECT test 
† non-overlapping confidence intervals indicating a statistically higher sensitivity than the corresponding 
echocardiography test 
‡ non-overlapping confidence intervals indicating a statistically higher sensitivity than all other tests, except for 
dipyridamole SPECT and a statistically lower specificity than all other tests except for exercise SPECT 
 
 
Table 3: Multivariable model for coronary tests (n=246) 
 
 Regression coefficient Relative Odds Ratio 95% CI 
Constant 2.92    
S -0.024 0.98 0.88 – 1.08 
Type of test 
Exercise Echo 
Adenosine Echo 
Dipyridamole Echo 
Dobutamine Echo 
Exercise SPECT 
Adenosine SPECT 
Dipyridamole SPECT 
Dobutamine SPECT 
EBCT (Reference) 
 
0.24 
0.33 
0.33 
0.20 
-0.13  
0.68 
0.11 
0.03 
0 
 
1.27 
1.39 
1.39 
1.22 
0.88 
1.97 
1.12 
1.03 
1 
 
0.74 – 2.18 
0.54 – 3.56 
0.76 – 2.56 
0.75 – 1.99 
0.52 – 1.49 
0.94 – 4.14 
0.61 – 2.05 
0.55 – 1.95 
 
Study characteristics 
Publication year-1990 
 
-0.051 
 
0.95 
 
0.91 – 1.00 
 
Echo, echocardiography; Ex, exercise; Ad, adenosine; Dip, dipyridamole; Dob, dobutamine; Publication year-1990, 
publication year after 1990 
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Figure 2: Summary diagnostic log odds ratios (boxes) and 95% confidence intervals (horizontal lines) for 
each type of test. The area of each box is inversely proportional to the variance in the test group, hence 
giving more visual prominence to test groups where the effect is more precisely estimated.  
Ex, exercise; Ad, adenosine; Dip, dipyridamole; Dob, dobutamine; Echo, echocardiography 
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Figure 3: Summary receiver operating characteristic curves for exercise echocardiography (Ex Echo) adjusted for the 
year of publication. The upper curve represents the studies published in 1990 and the lower curve represents studies 
published in the year 2000. In 10 years time the area under the curve has significantly declined. 
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Discussion 
 
In this study we combined data from 7 meta-analyses that included 24,761 patients, who 
underwent 8 different non-invasive imaging technologies for coronary artery disease. The 
analysis showed that the differences in diagnostic performance between the coronary tests were 
small. We showed that stress SPECT and EBCT are more sensitive tests while stress 
echocardiography is more specific. If a very sensitive test is used, the number of false-negative 
test results is minimized, resulting in fewer missed diagnoses of truly diseased patients, but it 
also increases the number of patients that unnecessarily will be referred to invasive coronary 
angiography. If a very specific test is used, the number of false-positive test results is minimal 
resulting in less unnecessary angiographies, but it may also delay the diagnosis in patients with 
false-negative test results. Which of these options should take priority depends on the costs and 
consequences of false test results in a specific clinical setting, which should be studied in cost-
effectiveness analyses.   
In general, we found that the diagnostic performance of stress echocardiography tended to 
be higher than that of stress SPECT and EBCT, but not significantly. The American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines have discouraged the use of 
EBCT for screening and diagnosing subjects suspected of coronary artery disease because of the 
low specificity of this test, which may unnecessarily increase the number of patients referred for 
further medical testing.3 In the recently updated guidelines, however, it is acknowledged that in 
clinical practice asymptomatic patients often present with abnormal EBCT results. For these 
patients further non-invasive diagnostic work-up is advised.2 Stress echocardiography and 
stress SPECT are both recommended as initial test in patients with suspected coronary artery 
disease.2 The availability of equipment, practice style, and local expertise usually dictate which 
test is used in a specific clinical setting. In the literature we found that apart from stress 
echocardiography and stress SPECT, these patients are also evaluated with EBCT. Therefore we 
thought it was justified to compare the performance of all these imaging techniques.  
Our findings indicate that there is room for improvement of the diagnostic performance of 
imaging tests in coronary artery disease. The limiting factor in current imaging technology for 
evaluation of the degree of stenosis in the coronary arteries is that indirect measures of arterial 
disease are used, such as myocardial wall motion abnormalities, perfusion abnormalities, and 
the presence of coronary calcium, whereas in coronary angiography, the reference standard, the 
vessel lumen and blood flow through the vessel are directly visualized. Consequently, stress 
echocardiography and stress SPECT are more useful tests for functional risk assessment rather 
than evaluation of the degree of stenosis. Alternatively, it is debated whether angiographic 
evidence of coronary stenosis is a good reference standard for the diagnosis of coronary artery 
disease because this reference standard does not reflect the functional importance of the 
stenosis.21 Another limitation of imaging the coronary arteries for evaluation of stenosis is the 
continuous beating of the heart and respiratory motion which both cause motion artifacts. 
Furthermore, the small vessel size of the coronary arteries requires a very high resolution of 
imaging technology. More advanced technologies, like contrast-enhanced magnetic resonance 
angiography (MRA) and computed tomographic angiography (CTA) are still under 
development for diagnosing coronary artery disease. Nevertheless, preliminary results show 
that there is a great potential for these techniques to improve non-invasive diagnostic testing in 
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coronary artery disease.22,23 These non-invasive angiography techniques directly image the 
vessel lumen similar to intra-arterial angiography.  
 
We did not exclude studies based on the quality of the data reported. Jüni et al. showed that 
studies should not be excluded based on composite quality scores, because many quality scales 
are more closely related to reporting quality rather than to the internal validity of studies.24 
Instead, relevant methodological aspects should be assessed individually and their influence on 
effect sizes explored. Therefore, we only included studies that used the same reference standard 
and accounted for differences in methodological quality by adding covariates to our statistical 
analysis, such as the number of patients included, proportion of diseased patients, gender and 
publication year.  
The year of publication was a significant negative predictor in the coronary tests, indicating 
a decline in diagnostic accuracy over time despite improvements in imaging technology. This 
could be the result of selection bias in diagnostic test evaluations. First test results of a new 
technology, which are primarily optimistic, are usually obtained in highly selected patients 
using strict in- and exclusion criteria, but when in use longer and applied to a broader patient 
spectrum the results may become less impressive. Another potential explanation could be the 
effect of publication bias. Stern and Simes have shown that positive results are not only more 
likely to be published than negative results, but they also have a significantly shorter time to 
publication.25 The decline is probably not due to a change in practice patterns, because such 
changes were not observed in a study by Miller et al, who evaluated temporal trends in clinical 
characteristics, stress test results and use of invasive procedures over a 10-year period.26 Gender 
also significantly influenced diagnostic performance of coronary testing: diagnostic performance 
was better in men than in women. The diagnosis of coronary artery stenosis in women has been 
thought to be more difficult than in men, owing to the overall lower prevalence and severity of 
coronary disease in women, as well as more subtle clinical presentations.27 
Our study showed that the differences among the stress tests were small. Only adenosine 
SPECT showed significantly better diagnostic performance than exercise SPECT, also when 
correcting for publication year or the proportion of men included. Because the patient 
population undergoing pharmacological imaging, i.e. patients who cannot perform a physical 
stress test, is usually different from the population undergoing exercise testing, this finding may 
have little relevance to clinical practice. However, a few head-to-head comparisons have been 
performed comparing exercise and adenosine SPECT, showing contradictory results.28-31 When 
correcting for the proportion of men included, we found that adenosine SPECT also tended to be 
better than other types of SPECT testing. Current ACC/AHA practice guidelines do not dictate 
whether adenosine or dipyridamole should be used in SPECT testing, whereas the use of 
dobutamine in combination with SPECT is only recommended if vasodilators are contra-
indicated.32 Our findings may suggest that adenosine should be preferred over dipyridamole if 
pharmacological stress SPECT is considered. However, these results should be interpreted with 
caution, because the number of adenosine studies was small and the heterogeneity between 
studies was large. 
 
A limitation of this study was that by using data published in meta-analyses as the basis for 
our statistical analyses, the most recent studies on imaging tests are not included. Another 
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limitation is that we could not evaluate the effect of all significant predictors from each 
individual meta-analysis, because these predictors were not commonly published. Furthermore, 
publications from one research group that were excluded from a meta-analysis because of 
overlapping data may have been included in another meta-analysis. Therefore, even though we 
took care to exclude duplicate data sets, some residual overlap may have existed in the final 
data set.  
 
A problem that is often present in diagnostic test comparisons is the possibility of 
verification bias. Verification bias may occur when patients are referred to the reference test 
based on the results of the non-invasive test under investigation. Sensitivity may be inflated and 
specificity deflated if patients with a positive test result are more likely to be verified. 
Verification bias may have been present in the source data of our study and thus in our 
summary estimates of sensitivity and specificity of the diagnostic tests. Consequently, tests 
should not be compared based on point estimates of sensitivity and specificity alone. In our 
meta-analysis, however, we focused on the diagnostic odds ratio, a measure in which sensitivity 
and specificity are combined. The diagnostic odds ratio is unbiased if the verification rate is not 
directly influenced by the unknown disease status of the patient.33 The same assumption of 
conditional independence between the verification rate and the disease status is used in studies 
in which the measures of sensitivity and specificity are corrected for verification bias.34 Our 
approach is supported by the results of Lijmer and coworkers, who have shown that the relative 
diagnostic odds ratio in studies with partial verification was similar to studies with complete 
verification.5  
 
In conclusion, our results show that in coronary artery disease, the differences in diagnostic 
performance between imaging tests are small. Diagnostic performance of non-invasive imaging 
tests is significantly higher in men than in women suspected of coronary artery disease. Since 
the established coronary tests show a decline in diagnostic performance over time, future 
research should be directed to development and improvement of new technologies, like CTA 
and contrast-enhanced MRA, for the diagnosis of coronary artery disease. 
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Abstract 
 
Purpose: The purpose of this study was to review the literature and to compare the diagnostic 
performance of computed tomographic angiography (CTA), magnetic resonance angiography 
(MRA), and duplex ultrasonography across anatomic regions for the assessment of peripheral, 
renal, and carotid artery disease, using meta-analytic techniques. 
Materials and methods: We searched PubMed from January 1990 through May 2003 for meta-
analytic studies. Meta-analyses on the diagnostic performance of imaging tests for arterial 
disease were selected that used angiography as reference standard and that presented the 
absolute numbers of true-positive, false-negative, true-negative and false-positive results of the 
source studies. Data were extracted on the level of the meta-analysis and on the level of the 
source studies that were included in each meta-analysis. Duplicate source studies were 
excluded. We combined data from 10 meta-analyses with a total of 260 patient series including 
14,640 patients and 52,976 arterial segments. A summary-receiver-operating-characteristic 
(SROC) analysis was performed on the source data using a weighted random-effects model.  
Results: The diagnostic performance was significantly better for contrast-enhanced MRA 
(relative odds ratio (OR) 4.08; 95% confidence interval (95% CI) 2.38-6.99) and CTA (OR 12.49; 
95% CI 3.10-50.35) versus duplex ultrasonography, and significantly worse for renal (OR 0.59; 
95% CI 0.36-0.97), and carotid artery disease (OR 0.60; 95% CI 0.39-0.92) versus peripheral 
disease. Diagnostic performance increased with the number of arterial segments analyzed (OR 
1.06 per 100 segments; 95% CI 1.01-1.12).  
Conclusions: Our study suggests that CTA and contrast-enhanced MRA have better diagnostic 
performance than non-enhanced MRA and duplex ultrasonography for the diagnosis of arterial 
disease. 
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Introduction 
 
In patients with arterial disease in the peripheral, renal, or carotid arteries the planning of 
revascularization procedures requires precise localization and determination of severity of 
arterial stenoses. The accepted reference standard for the diagnosis of arterial disease in each of 
these anatomic regions is intra-arterial angiography. However, because of the risks and costs 
associated with this invasive procedure, intra-arterial angiography is not suitable as initial test. 
For this reason, non-invasive imaging technologies, such as duplex ultrasonography, magnetic 
resonance angiography (MRA), and computed tomographic angiography (CTA) are increasingly 
used in the diagnostic work-up in patients with peripheral, renal, and carotid artery disease. 
Over the years, a number of studies have been published in which the diagnostic 
performance of non-invasive imaging tests has been evaluated for peripheral, renal and carotid 
artery disease. A broad spectrum of values for sensitivity and specificity has been reported in 
various studies on diagnostic testing. In the last decade, several meta-analyses have been 
performed summarizing the published data for each test and for each anatomic region. To 
understand the role of non-invasive tests for arterial disease we were interested in comparing 
the diagnostic performance of various non-invasive tests across anatomic regions. Furthermore, 
we questioned whether the diagnostic performance could be predicted by study characteristics. 
Therefore, we set out to review systematically all published meta-analyses on imaging the 
peripheral, renal, or carotid arteries by duplex ultrasound, CTA, and/or MRA, in order to 
quantify the diagnostic performance across anatomic regions. We followed the recently 
published standards for reporting of diagnostic accuracy and the guidelines for meta-analyses of 
observational studies when appropriate for a meta-analysis on diagnostic testing.1,2 
The purpose of this study was to provide an overview of the diagnostic performance of non-
invasive imaging tests in peripheral, renal, and carotid artery disease, to compare the diagnostic 
performance across anatomic regions, and to identify study characteristics that may influence 
the diagnostic performance. 
 
 
Materials and Methods 
 
Study selection 
A literature search was performed in PubMed from January 1990 through May 2003 to 
identify meta-analyses on the diagnostic performance of non-invasive imaging tests for the 
diagnosis of arterial disease. We used the following search terms: meta-analysis or systematic 
review or structured review and imaging test. We also checked the references of the included 
articles for additional meta-analyses. Articles were included if they met the following inclusion 
criteria: (a) the diagnostic performance of imaging tests for peripheral, renal, or carotid artery 
disease was studied, (b) meta-analytic methods were used, (c) angiography was used as 
reference standard, (d) the absolute numbers of true-positive, false-negative, true-negative and 
false-positive results of the source studies were available or derivable from the meta-analyses, 
and (e) it was published after 1990. If inclusion criterion d was not met, the authors were 
requested to provide these data. Because of the rapid advances in imaging technology, meta-
analyses published before 1990 were excluded. If a meta-analysis compared an imaging 
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technology with a technology that is no longer in use or with a non-imaging technology, only 
the data on the newer imaging technology were included.  
 
Data extraction 
The data were extracted on two levels: on the level of the meta-analysis and on the level of 
the source studies that were included in each meta-analysis. The following data were extracted 
per meta-analysis: author, journal, year of publication, type of test, anatomic region, number of 
studies included, total number of patients, total number of arterial segments, summary 
estimates of test characteristics and meta-analytic methods. In addition to the study 
identification and study size, the publication year, the number of arterial segments, mean age, 
percentage of men, and the absolute number of true-positive, false-negative, false-positive, and 
true-negative test results were extracted per source study. If source studies of meta-analyses 
overlapped and the data presented in the meta-analyses were identical, the duplicate data were 
excluded. If discrepancies existed between duplicate source studies, the original publication of 
the source study was retrieved and, based on the original article, the discrepant source data 
were excluded. The anatomic regions considered were the carotid, renal, and peripheral regions. 
If a meta-analysis was done on the same source studies for several definitions of significant 
stenosis, the data were extracted only for one definition: for peripheral and renal artery disease 
this definition was 50-100% stenosis and for carotid artery disease it was 70-99% stenosis, in 
accordance with the indications for further diagnostic work-up or therapeutic intervention.3-6 
The non-invasive imaging tests included duplex ultrasonography, (contrast-enhanced (CE-)) 
MRA, and CTA. 
 
Data-analysis 
Comparison of meta-analyses 
First, the data were evaluated on the level of the meta-analysis. The published summary 
estimates of sensitivity and specificity were plotted per test type and grouped per anatomic 
region, with 1-specificity on the horizontal axis and sensitivity on the vertical axis. If the meta-
analysis did not present summary estimates of sensitivity and specificity, the pooled values of 
sensitivity and specificity were calculated from the absolute numbers of true and false test 
results of the source studies. Because most of the meta-analyses presented fixed summary 
estimates, we calculated the pooled values of sensitivity and specificity weighted for sample size 
only. 
 
Summary receiver operating characteristic (SROC) analysis 
We performed a random effect SROC analysis on the data set of source studies to calculate 
the relationship between sensitivity and specificity, taking into account the differences in 
positivity criterion and other factors of heterogeneity between settings.7-9 In an SROC analysis 
the true-positive rate (TPR) (sensitivity), and the false-positive rate (FPR) (1-specificity), are 
transformed into the logit form. Then, a linear regression analysis is performed on the variables 
D and S, D representing the natural logarithm of the diagnostic odds ratio and S functioning as 
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proxy for the positivity criterion of the diagnostic test. D and S are defined as the difference and 
the sum of the logit transformations of TPR and FPR respectively, in formula:  
 
D= 
FPR
FPR
TPR
TPR
−
−
− 1
ln
1
ln  
S= 
FPR
FPR
TPR
TPR
−
+
− 1
ln
1
ln  
 
To prevent undefined values for D and S due to 0’s in the equations, 0.5 was added to the 
absolute numbers of true-positive, false-negative, true-negative and false-positive test results for 
the calculation of D and S. The regression analysis was weighted with the inverse of the variance 
of D. We used a random effects model, which takes into account the variability between 
studies.10 All data were analyzed in a linear regression model in which D, the log odds ratio, 
represented the diagnostic performance depending on a variable indicating the type of test. The 
differences between the tests are represented by the relative odds ratios, with a value equal to 1 
indicating no difference in diagnostic performance, a value larger than 1 indicating better 
performance and values smaller than 1 indicating reduced performance. Additional covariates 
were added to the model to evaluate the influence of other factors on diagnostic performance 
and to correct for confounders when comparing tests. The following covariates were considered: 
the anatomic region (peripheral, renal, or carotid), the number of patients tested, the number of 
arterial segments included, the number of arterial segments per patient, the mean age of the 
patients, the proportion of segments diseased, the proportion of men, and the year of 
publication. First, we evaluated the individual effect of each variable on the diagnostic 
performance in the model that always included S. Starting with the variables with the lowest 
residual between-study variance (determined by tau-squared), the significant variables were 
added to the multivariable model in a stepwise forward manner. A significance level of 0.05 was 
used. Tau-squared, the residual between-study variance calculated with the restricted maximum 
likelihood method, was used as a measure of the model fit. A lower tau-squared indicates less 
residual between-study variance and therefore a better model fit and a better explanatory power 
by the model of the heterogeneity across studies. We used STATA 8.0 for the statistical analyses. 
 
 
Results 
 
Study selection 
The search strategy resulted in 120 abstracts of which 12 meta-analyses were found that 
reported on peripheral, renal, or carotid arterial disease.11-22 Of the 12 meta-analyses, one study 
was excluded because it was published before 1990.21 Four meta-analyses did not report the 
absolute numbers of true-positive, false-positive, true-negative, and false-negative test results of 
the source studies.11,12,14,22 The authors of these meta-analyses were requested to provide the 
missing information, of which 3 responded. Thus, 1 meta-analysis was excluded for missing 
data of source studies.22 Of the remaining 10 meta-analyses, 2 studies focused on carotid artery 
disease, 6 on peripheral arterial disease and 2 on renal artery disease. Six non-invasive tests were 
evaluated in these 10 meta-analyses.  
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Two of the tests included in an analysis of renal artery disease were excluded, the captopril test 
(non-imaging) and captopril renal scintigraphy19 because these tests are not used for peripheral 
and carotid arterial disease . The remaining 4 imaging tests, duplex ultrasonography, CTA, 
MRA, and contrast-enhanced MRA, were studied in 330 patient series, of which 70 duplicate 
series were excluded (21%). The final data set consisted of 260 patient series, 94 on peripheral, 66 
on renal, and 100 on carotid artery disease, including 14,640 patients and 52,976 arterial 
segments. 
Comparison of meta-analyses 
Table 1 gives an overview of the meta-analyses that were included in the current study. The 
table shows the pooled values of sensitivity and specificity per meta-analysis, which were 
reported or calculated from the source data. The majority of the meta-analyses concluded that 
the diagnostic performance of contrast-enhanced MRA was significantly higher than non-
enhanced MRA and duplex ultrasonography. Comparing the analytical methods we found that 
two14,20 out of the 10 meta-analyses performed only a pooled analysis and did not perform a 
SROC analysis. Furthermore, we observed a very high number of arterial units analyzed per 
patient in the peripheral arterial disease studies compared with the renal and carotid regions.  
In Figure 1 the sensitivity and specificity summary estimates that were obtained from the 
meta-analyses are plotted in ROC space per anatomic region. They are all scattered over the 
upper left corner of ROC space, indicating high diagnostic performance. 
SROC analysis 
Figure 2 presents the summary estimates of the log odds ratio for each test per anatomic 
region. The peripheral tests showed higher diagnostic log odds ratios than the renal and carotid 
tests. Furthermore, there was a trend towards higher diagnostic log odds ratios for MRA, 
contrast-enhanced MRA and CTA compared with duplex ultrasonography. In carotid artery 
disease, the number of contrast-enhanced MRA studies was small and the heterogeneity was 
substantial. The CTA-studies, only available for renal artery disease, showed the best diagnostic 
performance. 
These results were in agreement with the results of the multivariable regression analysis, in 
which the type of test, anatomic region and total number of segments analyzed were significant 
predictors of diagnostic performance (table 2). CTA and contrast-enhanced MRA were 
significantly better than non-enhanced MRA and duplex ultrasonography, corrected for the 
anatomic region and the total number of arterial segments analyzed. Publication year, the 
number of patients, the number of arterial segments per patient, age, percentage of men, and 
percentage of diseased segments did not influence diagnostic performance significantly. 
In Figure 3 the SROC curves are plotted per test and per anatomic region assuming a study 
with 100 arterial segments analyzed. The upper curves of MRA and duplex ultrasonography 
represent testing for peripheral arterial disease and the lower curves for renal artery disease. 
Each pair of curves together forms an SROC area. The curves for carotid arterial disease lie 
within these SROC areas. The SROC curves for CTA and contrast-enhanced MRA are closest to 
the upper left corner of SROC space, indicating excellent diagnostic performance. Diagnostic 
performance of non-enhanced MRA did not differ significantly from duplex ultrasonography 
and is therefore not shown in this figure.  
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Figure 1: Pooled summary estimates of sensitivity and specificity of several non-invasive imaging tests for 
peripheral, renal, and carotid artery disease obtained from published meta-analyses. The tests are listed 
in table 1. 
Log Odds Ratio
0 1 2 3 4 5 6 7 8
 Combined
 CTA, Renal
 CE-MRA, Renal
 MRA, Renal
 DUS, Renal
 CE-MRA, Carotid
 MRA, Carotid
 DUS, Carotid
CE-MRA, Peripheral
 MRA, Peripheral
 DUS, Peripheral
 
Figure 2: Summary diagnostic log odds ratios (boxes) and 95% confidence intervals (horizontal lines) for each non-
invasive test for peripheral, renal, and carotid artery disease. The area of each box is inversely proportional to the 
variance in the test group, hence giving more visual prominence to test groups where the effect is more precisely 
estimated. 
DUS, duplex ultrasonography; (CE-) MRA, (contrast-enhanced) magnetic resonance angiography; CTA, computed 
tomographic angiography 
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Figure 3: Summary receiver operating characteristic curves for renal CTA, and SROC areas for duplex 
ultrasonography and contrast-enhanced MRA for a study population of 100 arterial segments. CTA, computed 
tomographic angiography; CE-MRA, contrast-enhanced magnetic resonance angiography; DUS, duplex 
ultrasonography 
 
Table 2: Multivariable model for non-invasive imaging tests for arterial disease (n=260 series) 
 
 Regression coefficient Relative Odds Ratio 95% CI 
Constant 4.26   
S -0.084 0.92 0.80 – 1.05 
Type of test 
CTA 
CE-MRA 
MRA 
DUS (Reference) 
 
2.53 
1.40 
0.38 
0 
 
12.49 
4.08 
1.46 
1 
 
3.10 – 50.35 
2.38 – 6.99 
0.95 – 2.23 
 
Anatomic region 
Carotid 
Renal 
Peripheral (Reference) 
 
-0.51 
-0.53 
0 
 
0.60 
0.59 
1 
 
0.39 – 0.92 
0.36 – 0.97 
 
Study characteristics 
No of segments/100 
 
0.062 
 
1.06 
 
1.01 – 1.12 
 
95% CI, 95% confidence interval; DUS, duplex ultrasonography; CTA, computed tomographic angiography; (CE-) 
MRA, (contrast-enhanced) magnetic resonance angiography; No of segments/100, total number of arterial segments 
per 100 extra segments 
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Discussion 
 
In this study we combined data from 10 meta-analyses containing 260 patient series, 
including 14,640 patients and 52,976 arterial segments. We compared the diagnostic 
performance of 4 non-invasive imaging technologies for peripheral, renal, and carotid artery 
disease. Our study suggests that contrast-enhanced MRA and CTA have significantly better 
diagnostic performance than non-enhanced MRA and duplex ultrasonography for the diagnosis 
of arterial disease, adjusted for the anatomical regions. These findings are consistent with the 
results of the individual meta-analyses on non-invasive imaging in peripheral and renal artery 
disease. In both meta-analyses available on carotid artery disease, however, contrast-enhanced 
MRA did not perform significantly better than non-enhanced MRA, probably due to the low 
number of source studies available.11,12 Our analyses showed that despite a substantial 
heterogeneity in the carotid studies, the same effect was seen in the carotid studies as in the 
renal and peripheral studies indicating a better performance if contrast enhancement is used in 
MRA testing. With contrast-enhanced MRA and CTA the vessel lumen is visualized with 
contrast medium as in intra-arterial angiography, the reference standard. With duplex 
ultrasonography and non-enhanced MRA physical characteristics of the blood flow are used to 
image the lumen and to determine stenosis severity. Contrast-enhancement diminishes the 
possibility of flow-related artifacts, which may explain the better diagnostic performance.23 
However, the diagnostic performance of non-invasive angiography is not equivalent to intra-
arterial angiography. There is some debate whether intra-arterial angiography is the best 
reference standard for arterial disease. Some studies have shown that intra-arterial angiography 
may underestimate the degree of stenosis compared with non-invasive techniques.24,25 
Furthermore, characterization of plaque morphology is not possible using intra-arterial 
angiography in contrast to non-invasive imaging techniques.  
When comparing the performance of non-invasive imaging technologies across anatomic 
regions we found that the best diagnostic performance was obtained for the peripheral arteries. 
There were no differences in diagnostic performance between the renal and carotid arteries. One 
explanation for this finding could be that in peripheral arterial disease the sensitivity and 
specificity are inflated due to the subdivision of the arteries into multiple segments. However, 
the difference still existed after correction for the number of arterial segments studied. Another 
explanation for the worse performance of duplex ultrasonography and non-enhanced MRA in 
the renal arteries could be the presence of accessory renal arteries. In the carotid arteries slow 
flow or turbulent flow near the carotid bifurcation may cause overestimation of stenosis when 
non-enhanced imaging techniques are used. In contrast, the peripheral arteries are 
predominantly not tortuous, unidirectional, and have steady nonturbulent flow, and thus 
provide an ideal environment for non-enhanced imaging techniques.26 
The inclusion of studies in the current analysis was not based on the quality of the data 
reported. Jüni et al. showed that studies should not be excluded based on composite quality 
scores, because many quality scales are more closely related to reporting quality rather than to 
the internal validity of studies.27 Instead, relevant methodological aspects should be assessed 
individually and their influence on effect sizes explored. Therefore, we only included meta-
analyses that used the same reference standard and we accounted for differences in 
methodological quality by adding covariates to our statistical analysis, such as the number of 
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patients or arterial segments included, percentage diseased, gender and publication year. Only 
the number of arterial segments studied significantly influenced diagnostic performance: the 
more segments studied, the higher the diagnostic performance. Dividing the arterial tract into 
multiple segments may raise estimates of sensitivity and specificity by increasing the sample 
size and mutual dependence within the sample. For example, including the arteries on the 
asymptomatic side overestimates test specificity, because the number of true negative results is 
increased. Similarly, dividing a severely and extensively diseased arterial tree into multiple 
segments overestimates test sensitivity because the number of true positive results is increased. 
Therefore, one must be careful when interpreting optimistic results of studies with a small 
number of patients that include both symptomatic and asymptomatic sides or divide the arteries 
into a high number of segments. In our opinion, the choice of whether the patient, side, or 
segment should be used as the unit of measurement in the calculations of test sensitivity and 
specificity depends on the associated clinical decision. If the decision is patient-based, e.g. 
whether or not to proceed to diagnostic angiography, the analysis should be performed with 
patients as the unit of measurement. If the decision is based on the arterial segment, e.g. whether 
or not to insert a stent, the analysis should be performed at the segmental level. If the 
asymptomatic side is irrelevant to the clinical decision, as is usually the case in carotid and 
peripheral arterial disease, then only the symptomatic side should be included. 
 
In the current study we performed an overall analysis of the results from the source studies 
that were included in various meta-analyses. The overlap of source studies in these meta-
analyses was substantial; we had to exclude 70 studies out of 330 (21%) of the source studies 
because of identical data. However, publications from one research group that were excluded 
from a meta-analysis because of partially overlapping data may have been included in another 
meta-analysis. Therefore, even though we took care to exclude duplicate data sets, some residual 
overlapping data may have existed in the final data set.  
A limitation of using data published in meta-analyses as the basis for our statistical analyses 
is that the most recent studies on imaging tests are not included. Furthermore, CTA studies were 
analyzed in only one meta-analysis on renal artery disease and therefore these results should be 
interpreted with caution. Another limitation is that we could not evaluate the effect of all 
significant predictors from each individual meta-analysis, because these predictors were not 
commonly published.  
A problem that is often present in diagnostic test comparisons is the possibility of 
verification bias. Verification bias may occur when patients are referred to the reference test 
based on the results of the non-invasive test under investigation. Sensitivity may be inflated and 
specificity deflated if patients with a positive test result are more likely to be verified. 
Verification bias may have been present in the source studies reporting the sensitivity and 
specificity of a diagnostic test. However, we used from each study the diagnostic odds ratio, in 
which sensitivity and specificity are combined. The diagnostic odds ratio is unbiased if the 
verification rate is not directly influenced by the unknown disease status of the patient.28 Our 
approach is supported by the study from Lijmer and coworkers who have shown that the 
relative diagnostic odds ratio in studies with partial verification was comparable with studies 
with complete verification.29 
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In conclusion, our results suggest that CTA and contrast-enhanced MRA have better 
diagnostic performance than non-enhanced MRA and duplex ultrasonography for the diagnosis 
of arterial disease, adjusted for anatomical region. When comparing tests for arterial disease, the 
number of arterial segments studied should be taken into account: studies using a high number 
of arterial segments may overestimate diagnostic performance. 
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Abstract 
 
Context: Many studies have been performed to estimate the sensitivity and specificity of 
pharmacological stress testing, but little is known about the cost-effectiveness of these tests. 
Objective: To estimate and compare the cost-effectiveness of adenosine, dipyridamole and 
dobutamine stress in combination with either echocardiography or single-photon-emission 
computed tomography (SPECT). 
Design, Setting, and Patients: Cost-effectiveness analysis using a Markov decision model to 
compare six pharmacological stress testing strategies with routine coronary angiography and no 
imaging in patients presenting with chest pain. Several cohorts of patients were compared, 
defined by age, sex, and the type of chest pain. The analyses were performed from a societal 
perspective.  
Main Outcome Measures: Lifetime costs, quality-adjusted life-years (QALYs) saved, and 
incremental cost-effectiveness ratios. 
Results: Pharmacological echocardiography cost $31,700 - $33,100 per QALY saved in 55-year-
old men and $37,100 - $42,300 per QALY in 65-year-old women with atypical angina. 
Pharmacological SPECT was only cost-effective in men with atypical angina if its cost was less 
than $420 or if angiography cost more than $5,000, whereas in women pharmacological SPECT 
cost more than $60,000 per QALY compared with echocardiography. Routine angiography was 
the optimal strategy in both men and women with typical chest pain ($25,400 per QALY in men 
and $31,200 in women). The optimal test strategy depended mostly on the pre-test probability of 
disease and the willingness-to-pay threshold.  
Conclusions: Pharmacological stress echocardiography is cost-effective for the diagnosis of 
coronary artery disease in middle-aged men and women at intermediate risk of coronary artery 
disease if society is willing to pay more than $30,000 per QALY saved. Adenosine SPECT may 
be cost-effective for patients at intermediate risk in specific clinical situations or at higher 
willingness-to-pay thresholds. Routine coronary angiography is the optimal test strategy for 
patients with typical angina. 
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Introduction 
 
Non-invasive stress testing is commonly used for the diagnosis of coronary artery disease in 
patients presenting with chest pain. Exercise testing is preferable if the patient can exercise to an 
appropriate level of cardiovascular stress. However, between one-third and one-half of patients in 
most centers are not able to exercise adequately and are therefore referred for pharmacological 
stress testing.1  
The commonly used stress agents are the coronary vasodilators, adenosine and dipyridamole, 
and the catecholamine dobutamine, which are used in combination with echocardiography or 
single-photon-emission computed tomography (SPECT). Dobutamine is primarily used in 
combination with echocardiography, especially in the United States.2,3 Vasodilators are the agent of 
choice in SPECT testing,2,4 but dobutamine can also be used.5 In Europe, however, the coronary 
vasodilators are also used in combination with echocardiography.6 
Little information exists to guide the clinician about which test to order or to inform policy 
makers about which tests are cost-effective. A recent meta-analysis compared the sensitivity and 
specificity of pharmacological stress tests and showed that maximum specificity can be attained by 
vasodilator echocardiography, maximum sensitivity by vasodilator SPECT, and a best compromise 
between sensitivity and specificity by dobutamine echocardiography.7 However, to determine 
which tests are most valuable in clinical practice we need to take into account not only the 
diagnostic accuracy of each test, but also the risks and costs of the test, and the effects of true- or 
false-positive, and true- or false-negative test results on subsequent treatment and long-term 
follow-up. A cost-effectiveness model integrates all relevant effects and costs and has the ability to 
determine the optimal diagnostic strategy out of various alternatives using a decision-analytic 
approach.  
To explore the relative merit of pharmacological imaging tests in diagnosing coronary artery 
disease, we evaluated the cost-effectiveness of adenosine, dipyridamole, and dobutamine stress in 
combination with echocardiography or SPECT compared with initial testing with coronary 
angiography and a strategy without diagnostic imaging. 
 
 
Methods 
Target population 
We focused on patients presenting with non-specific chest pain, atypical angina, or typical 
angina, as defined in the Coronary Artery Surgery Study (CASS) study.8 In CASS, chest pain was 
defined as typical angina if it was substernal, was associated with physical exertion and was 
relieved by nitroglycerin. Atypical chest pain was defined as symptoms meeting two out of the 
three criteria, while nonspecific chest pain met only one of three. The type of chest pain 
determined the pre-test probability of coronary artery disease, which was 18%, 71%, and 95% in 
men and 10%, 48%, and 81% in women for patients with nonspecific chest pain, atypical angina, 
and typical angina respectively.8 We modeled several cohorts of patients, defined by age, sex, and 
type of chest pain. As a base case a cohort of 55-year-old men with atypical angina was analyzed. 
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Markov Model 
We modified and updated a previously developed Markov decision model9 to estimate the 
lifetime costs and quality-adjusted life expectancy of pharmacological stress testing and the 
resulting treatment in patients presenting with chest pain. Six pharmacological stress test strategies 
were compared with direct coronary angiography or no imaging test at all: adenosine, 
dobutamine, and dipyridamole stress each in combination with echocardiography and SPECT. 
Each of the stress test strategies had 5 possible outcomes: true-positive, false-positive, true-
negative, false-negative, or non-diagnostic. 
We assumed that a stress test would be followed by coronary angiography if the test result was 
positive or non-diagnostic. The angiogram result was categorized into no disease, single, double, 
or triple vessel disease or left main coronary disease. The prevalence of each of these categories, 
stratified by age, sex, and type of chest pain was based on the CASS registry data.8 We assumed 
that patients diagnosed with single vessel or double vessel coronary disease would undergo a 
percutaneous coronary intervention (PCI), whereas in patients with triple vessel or left main 
coronary artery disease coronary artery bypass grafting (CABG) would be performed. A PCI 
included percutaneous transluminal coronary angioplasty (PTCA) with routine stenting in 70% of 
the cases and PTCA without stenting in 30%.10 Patients with a negative stress test result and 
patients with no coronary artery disease on angiography were treated medically. Figure 1 presents 
the flow of patients undergoing the diagnostic and therapeutic procedures. 
For each treatment strategy, long-term survival was modeled based on the initial patient 
variables (age, sex, extent of coronary artery disease). Risk reductions by treatment strategies were 
calculated based on 10-year survival data reported in a systematic review of clinical trials 11. Risk 
reductions of stenting versus PTCA were obtained from a meta-analysis on clinical trials 
comparing stenting and PTCA procedures.10 Nonfatal myocardial infarction and revascularization 
procedures during follow-up were modeled to evaluate their effects on costs and quality of life. We 
allowed differences in revascularization probabilities among the three treatments to persist for 10 
years. The risks and risk reductions for the base case, stratified for the extent of coronary artery 
disease are presented in table 1.9 
Test characteristics 
The sensitivity and specificity estimates for each stress test were obtained from a recent meta-
analysis.7 These are shown in table 2. We assumed that stress SPECT results were non-diagnostic in 
1.3%12 of the cases and stress echocardiography results in 10%,13 independent of the type of 
pharmacological stress agent used.  
Stress testing involves risks of morbidity and mortality. The rates of non-fatal myocardial 
infarctions associated with each pharmacological agent were obtained from large safety 
studies12,14,15 and were assumed to depend only on the type of stress agent used and not on the type 
of imaging (Table 3). The mortality rates associated with stress testing are very low and can only be 
detected in very large studies. In the largest safety study including 73,806 patients a mortality rate 
of 0.0095% (i.e. less than 1 in 10,000) was found in dipyridamole myocardial perfusion imaging.14 
As no such large studies could be found reporting mortality rates for the other stress agents we 
assumed that the mortality risk was negligible for each stress agent. 
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Figure 1: Flow chart of test procedures and subsequent treatment for patients presenting with chest pain. CAD, coronary 
artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting 
 
 
Costs 
The cost estimates of the diagnostic tests and treatment procedures were obtained from the 
Medicare-allowed global reimbursement rates based on the 2002 Current Procedural Terminology 
code system for outpatient procedures and the 2002 Diagnosis Related Group codes for in-patient 
procedures, including the technical and professional fees. For stress echocardiography the 
reimbursement rate was $241 and for stress SPECT it was $599. The Medicare reimbursement for 
stress testing did not depend on the pharmacological stress agent used. The lifetime costs were 
calculated by accumulating the costs of diagnostic testing, the costs of possible complications, costs 
of treatment and possible events, and the annual cost of medical care for chest pain, including 
follow-up visits, subsequent testing and medical treatment. All costs were adjusted to 2002 U.S. 
dollars using the medical care component of the Consumer Price Index and were discounted at an 
annual rate of 3%. The cost estimates are shown in table 4. 
 
Stress test 
True/False Positive Non-diagnostic True/ False Negative 
Coronary angiography No disease/Any CAD: 
Medical treatment 
Single- or double-
vessel disease: PCI 
Triple-vessel or Left- 
main disease: CABG
No disease: 
Medical treatment 
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Table 1: Selected model variables with ranges for single-/double-, and triple-vessel/left main coronary artery 
disease for the base case (mainly from reference 9, table 1) 
 
 
* Based on an odds ratio of 0.54 for the revascularization rate of PTCA without stent (30%) versus PTCA with stent 
(70%);10 
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; PTCA, 
percutaneous transluminal coronary angioplasty; n/a, not applicable 
 
Table 2: Test characteristics (from reference 7, table 2) 
 
Test Sensitivity (%)  (95% CI) Specificity (%)  (95% CI) 
Stress echocardiography 
  
Adenosine 72   (62-79) 91   (88-93) 
Dipyridamole 70   (66-74) 93   (90-95) 
Dobutamine 80   (77-83) 84   (80-86) 
   
Stress SPECT 
  
Adenosine 90   (89-92) 75   (70-79) 
Dipyridamole 89   (84-93) 65   (54-74) 
Dobutamine 82   (77-87) 75   (70-79) 
95% CI, 95% confidence interval; SPECT, single-photon emission computed tomography 
Variable Single/double vessel disease Triple vessel/ left main disease 
Risk ratio of mortality 2.3 (1.9-2.8) 3.6 (3.1-4.1) / 9.6 (6.1-14.3) 
Annual risk of nonfatal MI 0.022 (0.016-0.029) 0.028 (0.021-0.035) 
Annual risk of revascularization 
Medical therapy 
CABG 
PCI 
 
0.010 (0.001-0.022) /0.042 (0.028-0.056) 
n/a 
0.025 (0.018-0.033)* 
 
0.075 (0.061-0.089) 
0.018 (0.011-0.025) 
n/a 
Risk reduction of mortality (%) 
CABG 
PCI 
 
n/a 
15 (0-49) 
 
48 (32-64) / 67 (43-87) 
n/a 
Risk reduction of MI (%) 
CABG 
PCI 
 
n/a 
17 (12-22) 
 
42 (29-55) 
n/a 
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Table 3: Risk of pharmacological stress testing (from references 11, 13, and 14) 
 
Pharmacological stress agent Risk of non-fatal MI (%)   (95% CI) 
Adenosine 0.011     (0.008-0.027) 
Dipyridamole 0.018     (0.000-0.032) 
Dobutamine 0.025     (0.000-0.073) 
MI, myocardial infarction; 95% CI, 95% confidence interval 
 
Table 4: Cost estimates in the model based on the 2002 Medicare allowed global reimbursement rates 
 
Variable Cost ($) Range 
Stress echocardiography 241 170 - 315  
Stress SPECT 599 420 - 780 
Coronary angiography:  
Out-patient 
In-patient 
 
2,395 
5,030 
 
1,675 – 3,115 
3,521 – 6,540 
PCI:   
PTCA 
PTCA with stent 
 
9,945 
11,600 
 
6,960 – 1,295 
8,120 – 15,080 
CABG 23,052 16,135 – 29,970 
Myocardial infarction 6,690 4,683 – 8,697 
Annual cost 
No angina 
Mild angina 
Severe angina 
 
200 
2,000 
4,375 
 
140 - 260 
1,400 – 2,600 
3,063 – 5,688 
 
Stress SPECT, stress single-photon-emission computed tomography; PCI, percutaneous coronary intervention; PTCA, 
percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting 
Quality of life 
We estimated the quality-adjusted life expectancy by modeling annual transitions between 4 
different health states: no chest pain, mild chest pain, severe chest pain, and death. Quality of life 
without chest pain was valued as 0.87, mild chest pain was valued as 0.82, and severe chest pain as 
0.67 compared with perfect health.9 These health values are based on a survey of patients with 
chronic stable angina by using the standard gamble method, where 0 represents death and 1 
represents perfect health 16. The transitions from one chest pain state to another as a result of 
treatment were based on the CASS quality of life study.17 We assumed that a PCI procedure was 
85% as effective as CABG for immediate change in chest pain severity and that the effects were 
similar during follow-up.18 Furthermore, we assumed that the differences in effects among the 
three treatments persisted for 10 subsequent years. To incorporate the inconvenience of treatment 
or experiencing an adverse event, we subtracted life days from the quality-adjusted life 
expectancy. One day was subtracted for each angiogram performed, 2.5 days for each PCI, 30 days 
for each CABG, and 10 days each time a non-fatal MI occurred. 
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Sensitivity analysis  
To evaluate the effect of varying the baseline estimates over plausible ranges on our results we 
performed one- and two-way sensitivity analyses. Ranges were based on the 95% confidence 
intervals of the baseline estimates. For the cost-estimates, we used a range of 30% above and below 
the baseline estimate. Furthermore, we performed a sensitivity analysis including only the 
pharmacologic stress tests recommended by the American College of Cardiology and the 
American Heart Association (ACC/AHA), i.e. dobutamine echocardiography and adenosine or 
dipyridamole SPECT. 
 
  
Table 5: Results for a cohort of 55-year-old men with non-specific chest pain, atypical, and typical angina 
 
55-year-old men Cost ($) Effect  (QALYs) ICER ($/QALY) 
Non-specific chest pain    
No imaging 24,500 14.967 . 
Dipyridamole Echo 26,600 15.001 60,483 
Adenosine Echo 26,700 15.002 ED 
Dobutamine Echo 27,000 15.005 99,186 
Dobutamine SPECT 27,400 15.005 ED 
Adenosine SPECT 27,500 15.009 150,555 
Dipyridamole SPECT 27,800 15.008 D 
Coronary angiography 29,000 15.100 1,165,159 
Atypical angina    
No imaging 26,250 12.670 . 
Dipyridamole Echo 32,300 12.860 31,767 
Adenosine Echo 32,400 12.865 ED 
Dobutamine Echo 33,100 12.884 33,051 
Dobutamine SPECT 33,500 12.885 ED 
Adenosine SPECT 34,100 12.905 ED 
Dipyridamole SPECT 34,100 12.902 D 
Coronary angiography 34,900 12.929 40,401 
Typical Angina    
No imaging 27,600 11.221 . 
Dipyridamole Echo 35,900 11.543 ED 
Adenosine Echo 36,100 11.551 ED 
Dobutamine Echo 36,900 11.582 ED 
Dobutamine SPECT 37,300 11.584 ED 
Dipyridamole SPECT 38,100 11.614 ED 
Adenosine SPECT 38,200 11.619 ED 
Coronary angiography 38,800 11.662 25,431 
 
ED, extended dominated; D, dominated; Echo, echocardiography; SPECT, single-photon emission computed 
tomography; ICER, incremental cost-effectiveness ratio; QALY(s), quality-adjusted life year(s) 
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Results 
Base case 
The results of the base case (55-year-old men with atypical angina) are presented in the middle 
section of table 5. The incremental costs associated with each test strategy relative to the increment 
in effectiveness determine which test strategy is optimal – contingent on the societal willingness to 
pay for a quality-adjusted life year (QALY). Only dipyridamole SPECT was clearly dominated by 
other test strategies in the base case, meaning that it was more expensive and less effective than 
other strategies. Adenosine echocardiography and dobutamine or adenosine SPECT were weakly 
dominated by the other strategies, which means that the incremental cost-effectiveness ratio was 
higher than for a more effective strategy.  
Cost-effective non-invasive strategies for the base case were dipyridamole and dobutamine 
echocardiography with incremental cost-effectiveness ratios of respectively $31,800 and $33,100 
per QALY. Routine coronary angiography was more effective than the non-invasive imaging 
strategies in the base case, but at a higher cost ($40,400 per QALY). 
Other cohorts 
In 65-year-old women with atypical angina, the ranking of the tests was the same as in men, 
but at higher incremental cost-effectiveness ratios (Table 6). Furthermore, adenosine SPECT was 
cost-effective in this cohort, if society would be willing to pay at least $61,500 per QALY compared 
with dobutamine echocardiography. 
In patients with non-specific chest pain the ranking of the imaging strategies was the same as in 
the base case, but all imaging strategies cost more than $60,000 per QALY in men (Table 5) and 
more than $77,000 in women (Table 6).  
In patients with typical angina routine coronary angiography was the optimal strategy at a cost of 
$ 25,400 per QALY in men (Table 5). All non-invasive strategies were ruled out because they had 
higher incremental cost-effectiveness ratios than angiography. In women with typical angina, 
however, dipyridamole and dobutamine echocardiography were cost-effective strategies, both 
costing less than $ 30,000 per QALY, whereas angiography cost $31,200 per QALY (Table 6). 
 
 
Sensitivity analysis 
Prevalence 
The incremental cost-effectiveness ratios were sensitive to the prevalence of disease. The 
optimal test strategies for the base case are plotted in figure 2 as a function of the prevalence for 
several willingness-to-pay thresholds. At a very low prevalence of coronary artery disease (<0.10) 
or if society is willing to pay less than $30,000 per QALY saved, managing the patient medically 
without diagnostic imaging or revascularization was preferred. For a higher willingness-to-pay 
threshold, for example $50,000 per QALY, dipyridamole echocardiography was the optimal 
imaging strategy at a low to intermediate pre-test probability of disease, dobutamine 
echocardiography at an intermediate pre-test probability, and coronary angiography was optimal 
at a high prevalence. If society is willing-to-pay more than $53,000 per QALY, adenosine SPECT 
becomes the optimal strategy at an intermediate pre-test probability of disease. 
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Test characteristics 
If the baseline estimates of sensitivity and specificity of the pharmacological SPECT tests were 
varied over their 95% confidence intervals, there were no changes in the rankings of the 
incremental cost-effectiveness ratios. 
Varying the sensitivity and specificity of the pharmacological echocardiography tests, however, 
resulted in small changes of the rankings of the echocardiography tests. Dobutamine 
echocardiography was always cost-effective, except if the sensitivity of adenosine 
echocardiography exceeded 79%. In addition to dobutamine and dipyridamole echocardiography, 
adenosine echocardiography was cost-effective if the sensitivity or specificity of dobutamine 
echocardiography decreased. Furthermore, adenosine echocardiography replaced dipyridamole 
echocardiography if the sensitivity or specificity of adenosine echocardiography increased or if the 
sensitivity or specificity of dipyridamole echocardiography decreased. 
Changes in the rate of non-diagnostic test results over a plausible range associated with the type of 
imaging did not influence the ranking of the tests. 
Cost 
Varying the cost of stress echocardiography over a range of 30% above and below the baseline 
estimates had no effect on the cost-effectiveness or ranking of the tests.  
In the base case, i.e. 55-year-old men with atypical angina, adenosine SPECT was only cost-
effective if its cost was lower than $420 or if the cost of angiography was higher than $5,000. For 
example, if all patients need to be hospitalized for a diagnostic coronary angiogram, which has a 
cost of $5,030 per hospitalization, adenosine SPECT was a potentially cost-effective alternative with 
an incremental cost-effectiveness ratio of $52,600 per QALY compared with dobutamine 
echocardiography. 
Selection of tests recommended by the ACC/AHA 
In a sensitivity analysis we also compared a selection of tests in the base case, namely 
dobutamine echocardiography, adenosine SPECT, and dipyridamole SPECT, which are 
recommended by the ACC/AHA, compared with the no-imaging strategy and with routine 
coronary angiography. Dobutamine echocardiography had an incremental cost-effectiveness ratio 
of $31,900 per QALY compared with the no-imaging strategy. Routine coronary angiography cost 
$40,400 per QALY compared with dobutamine echocardiography. The dipyridamole SPECT 
strategy was more expensive and less effective than adenosine SPECT. Adenosine SPECT was 
more costly and more effective than dobutamine echocardiography, but its incremental cost-
effectiveness ratio was higher than the more effective coronary angiography strategy. 
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Table 6: Results for a cohort of 65-year-old women with non-specific chest pain, atypical, and typical angina 
 
65-year-old women Cost ($) Effect  (QALYs) ICER ($/QALY) 
Non-specific chest pain    
No imaging 20,600 12.780 . 
Dipyridamole Echo 22,200 12.800 77,194 
Adenosine Echo 22,200 12.801 ED 
Dobutamine Echo 22,500 12.802 152,623 
Dobutamine SPECT 22,900 12.802 ED 
Adenosine SPECT 23,000 12.805 226,809 
Dipyridamole SPECT 23,300 12.804 D 
Coronary angiography 24,600 12.804 D 
Atypical angina    
No imaging 21,000 11.305 . 
Dipyridamole Echo 25,500 11.427 37,067 
Adenosine Echo 25,600 11.430 ED 
Dobutamine Echo 26,100 11.442 42,280 
Dobutamine SPECT 26,600 11.442 ED 
Adenosine SPECT 27,000 11.455 61,512 
Dipyridamole SPECT 27,100 11.453 D 
Coronary angiography 28,100 11.470 79,807 
Typical Angina    
No imaging 22,800 9.612 . 
Dipyridamole Echo 30,400 9.877 28,890 
Adenosine Echo 30,600 9.883 ED 
Dobutamine Echo 31,400 9.909 29,172 
Dobutamine SPECT 31,800 9.910 ED 
Dipyridamole SPECT 32,500 9.935 ED 
Adenosine SPECT 32,600 9.939 ED 
Coronary angiography 33,400 9.973 31,225 
 
ED, extended dominated; D, dominated; Echo, echocardiography; SPECT, single-photon emission computed 
tomography; ICER, incremental cost-effectiveness ratio; QALY(s), quality-adjusted life year(s) 
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Figure 2: Sensitivity analysis of the pre-test probability of coronary artery disease and the willingness-to-pay threshold. 
Shaded regions indicate the optimal approach for the base case. 
QALY, quality-adjusted life-year; Dip echo, dipyridamole echocardiography; Dob echo, dobutamine echocardiography; 
Ad SPECT, adenosine single-photon-emission computed tomography 
 
 
 
Discussion 
 
We developed a decision-analytic model to integrate the best available evidence on the costs 
and health outcomes associated with various pharmacological stress tests and their associated 
follow-up treatments.  We found that pharmacological stress echocardiography is cost-effective in 
both men and women at low to intermediate risk of coronary artery disease, if society is willing to 
pay at least $30,000 per QALY saved. In particular clinical situations pharmacological SPECT may 
be cost-effective if society is willing to pay more than $50,000 per QALY saved. Routine coronary 
angiography was cost-effective in both men and women with typical angina. 
In addition, we found that the choice of the most cost-effective imaging strategy was primarily 
determined by the pre-test probability of disease and the threshold amount that society is willing 
to pay per quality-adjusted life-year saved. The rankings of the different tests corresponded with 
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the sensitivity of each test: the higher the sensitivity of the test, the more cost-effective it is to 
utilize the test at a higher prevalence of disease. Tests that are more specific are associated with 
more favorable cost-effectiveness ratios at lower pre-test probabilities of disease. In patients with 
non-specific chest pain, for example, who have a low pre-test probability of disease, stress 
echocardiography (more specific) resulted in more favorable cost-effectiveness ratios than stress 
SPECT (more sensitive). In general we found that the lifetime outcomes associated with very 
sensitive but less specific test strategies are more expensive, but also more effective in a high risk 
population because more patients will be tested positive, diseased or not, and consequently 
referred to angiography, which will provide the final diagnosis.  
Comparison to previous studies 
In a previous cost-effectiveness study comparing exercise echocardiography and exercise 
SPECT, our group found that exercise SPECT had less favorable incremental cost-effectiveness 
ratios than exercise echocardiography.9 Kim et al. found similar results in a cost-effectiveness study 
on exercise testing in women.19 Furthermore, Garber and coworkers found that the incremental 
cost-effectiveness ratio of SPECT ranged between $64,000 to nearly $150,000 per QALY gained 
compared with stress echocardiography.20 In the latter study no distinction was made between the 
types of pharmacological and exercise stress. Our results on pharmacological stress SPECT are 
consistent with the results of these studies. Specifically, dobutamine has similar physiological 
effects compared with exercise and, meta-analyses suggest similar sensitivity of exercise in 
conjunction with echocardiography and SPECT, but lower specificity with SPECT than with 
echocardiography.7,21,22 This explains why the dobutamine SPECT strategy was never optimal.   
In contrast, a recent cost-effectiveness study concluded that pharmacological stress SPECT was 
more cost-effective than pharmacological stress echocardiography.23 However, in that study the 
authors assumed that the sensitivity and specificity estimates of SPECT and echocardiography 
were equal. Meta-analysis of the published data7 suggests that stress echocardiography is a more 
specific test, whereas stress SPECT is a more sensitive test. Our findings show that 
pharmacological echocardiography is generally cost-effective for the evaluation of patients with 
non-specific and atypical angina and that pharmacological SPECT may be cost-effective for 
particular clinical settings in patients with atypical angina. 
 
Selection of pharmacological stress agent 
In the United States, dobutamine is the recommended stress agent that is primarily used in 
combination with echocardiography, whereas in Europe both dobutamine and dipyridamole 
echocardiography are commonly used.2,6,24 Our study suggests that both pharmacological agents 
can be cost-effective, but dipyridamole is associated with more favorable cost-effectiveness ratios 
in patients at lower pre-test probability compared with dobutamine, likely related to the higher 
specificity of dipyridamole and higher sensitivity of dobutamine.  
Adenosine echocardiography and dobutamine and dipyridamole SPECT did not emerge as 
optimal imaging strategies in the baseline analysis compared with the other strategies. Because the 
mechanism of action of the vasodilators dipyridamole and adenosine is similar, we expected that 
dipyridamole could be replaced by adenosine or vice versa with little additional cost or change in 
effectiveness. We did see this effect in echocardiography: sensitivity analyses showed that small 
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changes in the cost of the test or the test characteristics determined whether the incremental cost-
effectiveness ratio of adenosine or dipyridamole echocardiography was most favorable. In SPECT 
testing, however, we found that the cost-effectiveness of dipyridamole SPECT was never optimal. 
This can be explained by the lower point estimate for specificity of dipyridamole SPECT as 
compared with adenosine SPECT.7 Therefore, our results suggest that adenosine should be used 
rather than dipyridamole in combination with SPECT testing. However, this result should be 
considered with caution. The estimates of sensitivity and specificity of the diagnostic tests in our 
model were obtained from a meta-analysis.7 In this meta-analysis only 15 studies were available on 
adenosine testing compared with 54 on dobutamine and 41 on dipyridamole testing. Publication 
bias and spectrum bias may have influenced the estimates of the test characteristics, especially for 
adenosine testing. These biases may occur when only positive results of a new test are published 
using highly selected patients. Subsequent publications of studies that use less selected patients 
may report lower values of test performance. If the reported sensitivity and specificity of 
adenosine SPECT decreases in further studies to be more similar to dipyridamole SPECT, then the 
cost-effectiveness ratios associated with adenosine SPECT may become less favorable.  
If we only compared the tests recommended by the ACC/AHA, i.e. dobutamine 
echocardiography, adenosine SPECT, and dipyridamole SPECT, we found that dobutamine 
echocardiography was a cost-effective non-invasive imaging strategy. Pharmacological stress 
SPECT was not preferred as initial imaging strategy because of its high cost. 
 
Potential implications for clinical management 
The present study has the following implications with respect to the evaluation of coronary 
artery disease in patients presenting with chest pain. In patients with non-specific chest pain with a 
pre-test probability of 10-30%, dipyridamole or adenosine echocardiography was the optimal 
imaging strategy for the selection of candidates for coronary angiography and subsequent 
treatment. In patients presenting with atypical angina with a pre-test probability of 30-80%, 
dobutamine echocardiography was generally the optimal imaging strategy. If society is willing to 
pay more than $50,000 per QALY saved and in specific clinical situations, adenosine SPECT or 
routine coronary angiography may be cost-effective in patients with atypical angina. For example, 
if a diagnostic coronary angiography is considered which requires hospitalization for a specific 
patient with atypical angina, adenosine SPECT may be a cost-effective alternative.  Patients with 
typical angina, with a pre-test probability of 80-100%, should routinely be referred to coronary 
angiography. 
 
Limitations 
A limitation of our study is that we only compared stress tests that use pharmacological agents 
to induce stress, which is applicable for patients with limited exercise capacity. However, we 
assumed that the prevalence of coronary artery disease and the risks and benefits of treatment for 
our target population was the same as for all patients presenting with chest pain. Because patients 
with limited exercise capacity may have more comorbidity, we may have overestimated the effect 
of treatment in these patients. However, this overestimation would be equal for all test strategies 
and would therefore not impact the relative outcomes. 
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Another limitation is that our study is a synthesis of the published data on the risks, benefits, 
and costs of different diagnostic and therapeutic options in patients with coronary artery disease. 
Due to the rapid changes and improvements in imaging technology and coronary interventions, 
such as the use of contrast agents and harmonic imaging in echocardiography, new isotopes and 
attenuation correction in SPECT, and the use of new drug-eluting stents in PCI, some of our data 
may not reflect current practice in highly specialized care environments. To test the robustness of 
our conclusions, we examined, where possible, the effect of varying our estimates over plausible 
ranges on the outcomes of our study. We found that these sensitivity analyses did not change the 
results substantially, which implies that the conclusions remained the same. 
 
Conclusions 
In conclusion, pharmacological stress echocardiography is cost-effective for the diagnosis of 
coronary artery disease in middle-aged men and women at low and intermediate risk of coronary 
artery disease if society is willing to pay more than $30,000 per QALY saved. Adenosine SPECT 
can be cost-effective for patients at intermediate risk of coronary artery disease if society is willing 
to pay more than $50,000 per QALY saved in particular clinical situations. Routine coronary 
angiography is the optimal test strategy for patients with typical angina. Careful pretest risk 
determination is essential to optimal use of cost-effective diagnostic strategies. 
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Abstract 
  
Background: Many studies have been performed on the diagnostic value of electron-beam 
computed tomography (EBCT) in patients suspected of coronary artery disease, but little is known 
about its cost-effectiveness.  
Objectives: The aim of this study was to evaluate the cost-effectiveness of EBCT compared with 
exercise echocardiography and exercise single-photon-emission computed tomography (SPECT) in 
patients presenting with chest pain to identify those who should undergo coronary angiography 
for the diagnosis of coronary artery disease. 
Methods: We used a Markov decision model to estimate the lifetime costs and effects for different 
test strategies and clinical follow up from the health care perspective. As a base case we evaluated 
a cohort of 55-year-old men with atypical chest pain. 
Results: In the base-case, the EBCT strategy was slightly more effective than exercise 
echocardiography and exercise SPECT at a relatively high cost and therefore extended dominated 
by the more effective coronary angiography. In cohorts of 65-year-old women with atypical chest 
pain the incremental cost-effectiveness ratio of EBCT was $66,600 per quality-adjusted life-year 
(QALY) saved compared with exercise echocardiography. Sensitivity analyses showed that EBCT 
may be a cost-effective strategy for men with a 40%-65% pre-test probability of coronary artery 
disease at a cost of at least $47,500 per QALY. If society is willing to pay $50,000 per QALY or less, 
the strategy with optimal cost-effectiveness for patients with non-specific chest pain was the no 
imaging test strategy, for patients with atypical chest pain it was exercise echocardiography, and 
for patients with typical chest pain the optimal strategy was routine coronary angiography. 
Conclusions: Using EBCT to decide which patients with chest pain should undergo coronary 
angiography for the diagnosis of coronary artery disease is, in general, not cost-effective. In a 
selected group of patients with an intermediate pre-test probability of disease EBCT provides a 
small health benefit at a relatively high cost. 
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Introduction 
 
Coronary calcification on electron-beam computed tomography (EBCT) is commonly used to 
identify patients with coronary artery disease who are at high risk of developing a myocardial 
infarction. The same technology is also used as a diagnostic test in patients with chest pain 
suspected of having coronary artery disease.1-9  
The Society for Atherosclerosis Imaging (SAI) stated that there is evidence and/or general 
agreement that EBCT is useful and effective as an initial diagnostic test in ambulatory adults <= 65 
years of age with atypical chest pain symptoms, in the absence of established cardiovascular 
disease, and as a supplementary diagnostic test in similar patients with indeterminate stress test 
results.10 A recent meta-analysis showed that sensitivity and specificity of EBCT in symptomatic 
patients are comparable with other diagnostic tests.11 Similar meta-analytic results were found by 
the American College of Cardiology and the American Heart Association.12 They concluded that 
EBCT is not superior to other currently available diagnostic procedures but, given its relatively low 
cost and ease of implementation, recommended more research into its potential cost-effectiveness 
as a diagnostic tool.  So far, however, only the initial costs and effects of EBCT have been studied 
compared with other test strategies.13,14 No information is available on the long-term cost-
effectiveness of EBCT.  
The purpose of the current study was to evaluate the long-term cost-effectiveness of EBCT for 
the diagnosis of coronary artery disease compared with other imaging strategies in patients 
presenting with chest pain.  
 
 
Methods 
Target population 
We analyzed several cohorts of patients suspected of coronary artery disease, defined by age, 
gender, and type of chest pain. Chest pain was categorized into nonspecific, atypical, or typical 
chest pain as in the Coronary Artery Surgery Study (CASS). Nonspecific, atypical, or typical chest 
pain was present if respectively one, two, or three of the following criteria were met: the chest pain 
is located substernally, follows physical exertion, and is relieved by nitroglycerin. The prevalence 
of coronary artery disease in patients with nonspecific, atypical, and typical chest pain was 
respectively 18%, 71%, and 95% in 55-year-old men and 10%, 48%, and 81% in 65-year-old 
women.15 As a base case, we evaluated a cohort of 55-year-old men with atypical chest pain. 
Markov decision model 
We revised a previously developed Markov decision model16 to compare the cost-effectiveness 
of five diagnostic imaging strategies: (1) EBCT, (2) exercise echocardiography, (3) exercise SPECT, 
(4) coronary angiography, and (5) no imaging. If the test result of EBCT, exercise echocardiography 
or exercise SPECT was negative, no additional test was performed and the patient was treated 
medically. If the non-invasive test result was positive or non-diagnostic, it was followed by 
coronary angiography to reach the final diagnosis. In accordance with the guidelines of the Society 
of Atherosclerosis Imaging10 we also studied the cost-effectiveness of EBCT as a supplementary 
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test if exercise echocardiography or SPECT were non-diagnostic, followed by angiography if EBCT 
was positive or non-diagnostic.  
Coronary angiography was considered the reference standard with 100% sensitivity and 100% 
specificity and was assumed to be interpretable in all cases. Significant coronary artery disease was 
defined as at least 50% diameter stenosis in at least one coronary artery. The result of coronary 
angiography was quantified as no, single-, double-, or triple-vessel disease, or left main coronary 
artery disease. The prevalence of the underlying coronary artery disease status was obtained from 
the Coronary Artery Surgery Study registry.15 We assumed that patients diagnosed with triple-
vessel or left main coronary artery disease underwent coronary artery bypass graft surgery 
(CABG) and patients with single- or double-vessel disease underwent a percutaneous coronary 
intervention (PCI), consisting of percutaneous transluminal coronary angioplasty (PTCA) with 
additional stent implantation in 70% of cases.17 Patients with no or non-significant disease were 
treated medically. We also modeled possible events such as nonfatal myocardial infarction and 
revascularization procedures occurring after the initial treatment decision to evaluate their effects 
on cost and quality of life. 
 
Test characteristics 
Sensitivity and specificity estimates of EBCT, exercise echocardiography and exercise SPECT 
for diagnosing patients suspected of coronary artery disease were obtained from meta-analyses.11,18 
EBCT was considered positive for significant coronary artery disease if the coronary calcium score 
was greater than zero.1 Presence of new or worsening regional wall motion abnormalities after 
exercise was defined as a positive exercise echocardiogram. Using SPECT, a perfusion defect at rest 
or after exercise indicated significant coronary artery disease. 
Based on the study by Rumberger et al, we assumed that EBCT was non-diagnostic in 2% of cases 
and has no associated morbidity or mortality.13 The test characteristics are shown in Table 1. 
 
 
Table 1: Test characteristics 
 
 EBCT Ex Echo Ex SPECT 
Sensitivity (%, range) 92 (91-94) 85 (83-87) 87 (86-88) 
Specificity (%, range) 51 (48-55) 77 (74-80) 64 (60-68) 
Mortality (%, range) 0  (0-0.005) 0.005 (0.002-0.008) 0.005 (0.002-0.008) 
Morbidity (%, range) 0  (0-0.05) 0.05 (0.02-0.08) 0.05 (0.02-0.08) 
Non-diagnostic (%, range) 2 (1-3) 10 (5-15) 2 (1-3) 
 
EBCT, electron-beam computed tomography; Ex Echo, exercise echocardiography; Ex SPECT, exercise single-photon-
emission computed tomography 
 
 
Cost-effectiveness calculations 
Outcomes of the Markov decision model were defined in terms of lifetime costs and quality 
adjusted life years (QALYs). The incremental cost-effectiveness ratio (ICER) was calculated for 
each diagnostic strategy, which was defined as the difference in costs divided by the difference in 
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QALYs compared with the next less expensive strategy. Strategies were dominated if they were 
more costly and less effective compared with another strategy or extended dominated if the 
incremental cost-effectiveness ratio was greater than a more effective strategy. The analysis was 
performed from the perspective of the health care system.  
 
 
Table 2: Estimates of cost and utility 
 
Variable Estimate Range 
Cost ($)   
EBCT 271 190 - 352 
Exercise echocardiography 241 169 - 313 
Exercise SPECT 599 419 - 779 
Coronary angiography:  
Out-patient 
In-patient 
 
2,395 
5,030 
 
1,675 - 3,115 
3,521 - 6,540 
PCI:   
PTCA 
PTCA with stent 
 
9,945 
11,600 
 
6,960 - 1,295 
8,120 - 15,080 
CABG 23,052 16,135 - 29,970 
Myocardial infarction 6,690 4,683 - 8,697 
Annual cost 
No angina 
Mild angina 
Severe angina 
 
200 
2,000 
4,375 
 
140 - 260 
1,400 - 2,600 
3,063 - 5,688 
Utility   
No chest pain symptoms 
Mild chest pain symptoms 
Severe chest pain symptoms 
0.87 
0.81 
0.67 
0.77 - 1.00 
0.68 - 1.00 
0.40 - 0.98 
EBCT, electron-beam computed tomography; exercise SPECT, exercise single-photon-emission computed tomography; 
PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery 
bypass grafting 
 
Cost calculation 
The cost estimates of the diagnostic tests and treatment procedures were obtained from the 
Medicare reimbursement system (Table 2). For outpatient procedures we used the 2002 Current 
Procedural Terminology (CPT) coding system including the technical and professional fees. For 
inpatient procedures, we used the 2002 Diagnosis Related Group (DRG) coding system plus the 
professional fees according to the CPT system. We assumed that the Medicare reimbursement for 
EBCT would be equal to the reimbursement for a CT of the chest. The lifetime costs were 
calculated by summing the cost of the tests, the cost of possible test complications, the cost of 
treatment following the test results, the cost of possible events, and the annual cost of medical care 
for chest pain, including medications, subsequent tests and outpatient visits. All costs were 
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adjusted to 2002 U.S. dollars using the medical care component of the Consumer Price Index and 
were discounted at an annual rate of 3%.  
Effect calculation 
Quality of life without chest pain was valued at 87% of the quality of life in full health, with 
mild chest pain at 81%, and with severe chest pain at 67%.16 These health values are based on a 
survey of patients with chronic stable angina by using the standard gamble method, where 0 
represents death and 1 represents perfect health.19 The change in severity of chest pain due to 
treatment was estimated using the CASS quality of life study.20 This study reported the proportion 
of patients for each chest pain severity level over time, stratified by underlying coronary artery 
disease status and initial treatment. We assumed that a PCI procedure was 85% as effective as 
CABG for immediate change in chest pain severity and that the effects on symptoms were similar 
thereafter.21 The differences among the three treatment strategies were modeled to persist for 10 
subsequent years.  
Mortality risk ratios, mortality risk reductions, and the risk for nonfatal myocardial infarction 
or revascularization procedures during follow-up depended on the extent of coronary artery 
disease and type of initial treatment (Table 3).20,22-25 
 
 
Table 3: Selected model variables for single-/double-, and triple-vessel/left main coronary artery disease for 
the base case16 
 
Based on an odds ratio of 0.54 for the revascularization rate of PTCA without stent (30%) versus PTCA with stent 
(70%)17;  
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; PTCA, 
percutaneous transluminal coronary angioplasty; N/a, not applicable 
 
Sensitivity analysis 
We performed sensitivity analyses on all of the variables in our model to assess the effect of 
varying baseline estimates within plausible ranges on our results. All the costs were varied using a 
Variable Single/double vessel disease Triple vessel/ left main disease 
Risk Ratio of mortality 2.3 (1.9-2.8) 3.6 (3.1-4.1) / 9.6 (6.1-14.3) 
Annual Risk of non-fatal MI 0.022 (0.016-0.029) 0.028 (0.021-0.035) 
Risk Reduction of mortality (%) 
CABG 
PCI 
 
n/a 
15 (0-49) 
 
48 (32-64) / 67 (43-87) 
n/a 
Risk Reduction of MI (%) 
CABG 
PCI 
 
n/a 
17 (12-22) 
 
42 (29-55) 
n/a 
Annual Risk of revascularization 
Medical therapy 
CABG 
PCI 
 
0.010 (0.001-0.022) /0.042 (0.028-0.056) 
n/a 
0.025 (0.018-0.033)* 
 
0.075 (0.061-0.089) 
0.018 (0.011-0.025) 
n/a 
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range of +/- 30% of the base-case estimates. The ranges of the test characteristics, risk ratios and 
annual risks were based on 95% confidence intervals. The ranges of the utilities were obtained 
from the 25th and 75th percentiles of the data. 
 
 
Results 
 
Cost-effectiveness analysis 
Table 4 shows the quality-adjusted life expectancy, lifetime costs, and incremental cost-
effectiveness ratios of the test strategies for 55-year-old men presenting with nonspecific, atypical, 
or typical chest pain. Table 5 shows the results for three cohorts of 65-year-old women. The results 
of the base case, 55-year-old men with atypical chest pain, are shown in the middle section of table 
4. 
In the base case, the EBCT strategy provided a slightly higher effectiveness compared with 
exercise echocardiography and SPECT at a relatively high cost. The incremental cost-effectiveness 
ratios (ICER) of EBCT, and of exercise SPECT, were higher than the more effective angiography 
strategy, meaning that the EBCT and exercise SPECT strategies were extended dominated. Exercise 
echocardiography and routine coronary angiography were both cost-effective strategies in the base 
case, if society is willing to pay $30,000 to 40,000 per QALY.  
In 65-year-old women with atypical chest pain the incremental cost-effectiveness ratio of EBCT 
was $66,600 per QALY compared with exercise echocardiography, which had an ICER of $37,900 
per QALY compared with no imaging. In both men and women with nonspecific chest pain all 
imaging strategies had ICERs of more than $50,000 per QALY.  In patients with typical chest pain, 
however, routine coronary angiography was the optimal strategy in 55-year-old men, whereas 
both exercise echocardiography and angiography were cost-effective strategies in 65-year old 
women. 
In the secondary analysis in which EBCT was implemented as a supplementary test if exercise 
echocardiography or SPECT was non-diagnostic, we found that the combination strategies were 
less costly than the single test strategies, but also less effective, and therefore ruled out by extended 
dominance. 
 
 
Sensitivity analysis 
Test characteristics 
We performed sensitivity analyses on the test characteristics of EBCT to assess the effect of 
varying baseline estimates over their 95% confidence intervals on our results. EBCT was cost-
effective compared with exercise echocardiography if the sensitivity was equal to or more than 
93% (ICER $40,100 per QALY). Varying the specificity of EBCT over its 95% confidence interval 
had no influence on our results. If the cost of EBCT was less than $240, EBCT was a cost-effective 
strategy compared with exercise echocardiography, having an ICER of $40,000 per QALY. Varying 
the percentage of non-diagnostic EBCT tests, the morbidity, or the mortality associated with EBCT-
testing did not change our conclusions. 
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Table 4: Results for a cohort of 55-year-old men with non-specific chest pain, atypical, and typical angina 
 
55-year-old men Cost ($) Effect  (QALYs) ICER ($/QALY) 
Non-specific chest pain    
No imaging 24,500 14.967 . 
Exercise Echo 27,200 15.007 68,108 
Exercise SPECT 27,800 15.007 ED 
EBCT 27,900 15.010 213,147 
Coronary angiography 29,000 15.013 465,551 
Atypical angina    
No imaging 26,300 12.670 . 
Exercise Echo 32,500 12.897 31,867 
Exercise SPECT 33,900 12.899 ED 
EBCT 34,100 12.912 ED 
Coronary angiography 34,900 12.932 40,525 
Typical Angina    
No imaging 27,600 11.221 . 
Exercise Echo 37,500 11.604 ED 
Exercise SPECT 37,900 11.608 ED 
EBCT 38,100 11.630 ED 
Coronary angiography 38,800 11.665 25,263 
 
ED, extended dominated strategy, i.e. the incremental cost-effectiveness ratio is higher than the next more effective 
strategy. 
QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; Echo, echocardiography; SPECT, single-
photon emission computed tomography; EBCT, electron-beam computed tomography 
 
 
Pre-test probability of coronary artery disease 
If the pre-test probability of coronary artery disease was 65% or less EBCT was a cost-effective 
strategy in the base case (ICER $47,500 per QALY) compared with exercise echocardiography. 
Figure 1 shows the optimal strategy as a function of the pre-test probability of coronary artery 
disease and the willingness-to-pay threshold. The figure shows that the EBCT strategy was the 
optimal strategy for a small proportion of patients with atypical chest pain at a relatively high cost 
per QALY. 
Health utilities 
The ranking of the incremental cost-effectiveness ratios was insensitive to the values of the 
health utilities assigned to patients without chest pain, with mild, and with severe chest pain 
resulting after treatment. However, the incremental cost-effectiveness ratios of the tests changed. If 
no adjustments were made for quality of life, the incremental cost-effectiveness ratios for exercise 
echocardiography and angiography were $46,100 and $58,300 per life year saved respectively. 
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Table 5: Results for a cohort of 65-year-old women with non-specific chest pain, atypical, and typical angina 
 
65-year-old women Cost ($) Effect  (QALYs) ICER ($/QALY) 
Non-specific chest pain    
No imaging 20,600 12.780 . 
Exercise Echo 22,700 12.804 89,726 
Exercise SPECT 23,300 12.804 ED 
EBCT 23,400 12.806 346,491 
Coronary angiography 24,600 12.807 1,037,588 
Atypical angina    
No imaging 21,000 11.305 . 
Exercise Echo 26,500 11.450 37,887 
Exercise SPECT 27,000 11.451 ED 
EBCT 27,200 11.460 66,562 
Coronary angiography 28,100 11.472 78,162 
Typical Angina    
No imaging 22,800 9.612 . 
Exercise Echo 31,900 9.927 28,822 
Exercise SPECT 32,300 9.930 ED 
EBCT 32,600 9.948 ED 
Coronary angiography 33,400 9.976 30,874 
 
ED, extended dominated strategy, i.e. the incremental cost-effectiveness ratio is higher than the next more effective 
strategy. 
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; Echo, echocardiography; SPECT, single-
photon emission computed tomography; EBCT, electron-beam computed tomography 
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Figure 1: Sensitivity analysis on pre-test probability of disease and the willingness-to-pay threshold. Shaded regions 
indicate the optimal test strategy for the base case. 
Exercise Echo, exercise echocardiography; EBCT, electron-beam computed tomography. 
 
 
Discussion  
 
This study showed that the cost-effectiveness of EBCT to refer patients to coronary 
angiography for the diagnosis of coronary artery disease depended mostly on the pre-test 
probability of disease and the willingness-to-pay threshold. EBCT was only cost-effective for a 
small range of patients with atypical chest pain at an intermediate pre-test probability of disease 
(40%-65%) if society is willing to pay more than $47,500 per QALY saved. Exercise 
echocardiography was optimal at a lower willingness-to-pay threshold for a broader range of 
patients with atypical chest pain (pre-test probability 20%-80%). The high sensitivity of EBCT and 
the associated low specificity explain these results: in the EBCT strategy a large proportion of the 
patients, diseased or not, will be referred to coronary angiography, which is costly but the most 
effective test in patients at high risk of having coronary artery disease. Therefore, routine coronary 
angiography dominated the EBCT strategy for patients at high risk of coronary artery disease 
(70%-100%). 
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The results of the current study differed from two previous studies that evaluated the short-
term cost-effectiveness of EBCT.13,14 Raggi et al. studied the cost-effectiveness of EBCT compared 
with exercise electrocardiography in patients with chest pain at low to intermediate pre-test 
probability of coronary artery disease.14 The authors concluded that the diagnostic pathway based 
on EBCT provides a substantial cost benefit over the exercise electrocardiography strategy. 
However, only initial costs of the diagnostic pathway were evaluated in their study and other 
imaging tests were not included. 
Rumberger et al found that EBCT was cost-effective in patients with a moderate disease 
prevalence (<70%) compared with exercise electrocardiography, exercise SPECT and exercise 
echocardiography. This result was obtained by increasing the cut-off value of a positive EBCT-test 
from a calcium score>0 to a score of 37, 80, or 168.13 Higher cut-off values are associated with a 
relatively lower sensitivity and higher specificity. Furthermore, in their analysis cost-effectiveness 
was defined as the total direct costs of the diagnostic work-up divided by the total number of 
patients correctly diagnosed with disease. This criterion for cost-effectiveness does not account for 
long-term effects and also emphasizes optimizing specificity to avoid the expense of angiography. 
 
A limitation of the current study is that tests such as exercise SPECT and exercise 
echocardiography are physiologic tests that measure myocardial ischemia, whereas EBCT is based 
on anatomical findings. In the literature, however, tests for the diagnosis of coronary artery disease 
are compared with the same reference standard: coronary angiography, which is limited to 
diagnosing the presence and extent of luminal stenosis. Our decision model did not incorporate 
the functional information provided by exercise testing. Despite the anatomical reference, 
however, exercise echocardiography was the most efficient imaging test in most cohorts.   
Another limitation of our study is that we did not model the prognostic value conditional on 
the amount of coronary calcium identified with EBCT, which is the more common usage of this 
technology. Nevertheless, our analysis does consider prognosis by modeling life expectancy 
conditional on identifying coronary artery disease and the probability of severe disease.  
A limitation of every decision model is that input variables are retrieved from various data 
sources. We derived the test characteristics from meta-analyses, which provided summary 
estimates from the published literature. Verification bias and publication bias may have affected 
these estimates. Furthermore, test characteristics, risks, and cost variables may change over time, 
when the test is applied to a wider patient spectrum. To account for the uncertainty of the variables 
in our model we used sensitivity analyses and found the results of exercise echocardiography to be 
robust, whereas the incremental cost-effectiveness ratio of EBCT was sensitive to changes in cost, 
sensitivity and pre-test probability of disease.  
Recent technological developments in scanning techniques for CAD have been spiral and 
multi-detector computed tomography (MDCT) adapted to acquire cardiac images. The advantages 
of MDCT over EBCT are that MDCT scanners are less expensive and are becoming more widely 
available. Currently, the test characteristics of spiral CT and MDCT for coronary imaging are being 
investigated. A recent study that compared spiral CT and EBCT using a working phantom heart 
showed that spiral CT had a significantly higher sensitivity and specificity than EBCT.26 Other 
studies showed very high correlation coefficients for spiral (MD)CT and EBCT in calcium 
measurements, varying from 0.90 to 0.99.27-30 Furthermore, the ability of MDCT angiography 
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techniques to help identify both calcified and noncalcified atherosclerotic plaque components is 
emerging.31, 32 Because MDCT scanners are less expensive than EBCT scanners and because the 
diagnostic performance of MDCT may be better than EBCT, MDCT may become a cost-effective 
test for CAD. If more patient data become available the cost-effectiveness of MDCT could be 
compared with other imaging strategies.  
In conclusion, our results suggest that using EBCT to decide which patients with chest pain 
should undergo coronary angiography is not cost-effective. In a selected group of patients with an 
intermediate pre-test probability of disease EBCT provides a small health benefit at a relatively 
high cost. 
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Abstract 
 
Purpose: To estimate the optimal test characteristics of electron-beam computed tomography 
(EBCT) for the workup of patients suspected of coronary artery disease based on a cost-
effectiveness analysis and to compare these with pooled published values of sensitivity and 
specificity. 
Methods: A Markov decision model was developed to model lifetime effectiveness, lifetime costs, 
and net health benefits of the true- and false-positive and true- and false-negative test outcomes 
and subsequent treatment for patients suspected of coronary artery disease. The sensitivity of 
EBCT was modeled as a function of the false positive rate using summary receiver operating 
characteristic (SROC) analysis. Using sensitivity analysis on the false-positive rate, the net health 
benefit was calculated for each combination of sensitivity and specificity on the SROC curve. The 
optimal test characteristics of EBCT were determined at the point on the SROC curve where the net 
health benefit reached its maximum. Optimal test characteristics were evaluated for 6 cohorts 
depending on age, sex, and type of chest pain. The analyses were performed from the health-care 
perspective. We assumed a threshold willingness-to-pay of $50,000 per quality-adjusted life year 
(QALY) gained. The published data on sensitivity and specificity were also pooled, weighted by 
sample size, and compared to the optimal test characteristics derived from the cost-effectiveness 
analysis.   
Results: For the workup of a cohort of 55 year-old men with atypical angina (pre-test probability is 
0.71), the optimal operating point for EBCT was found at a sensitivity of 93% and specificity of 
34%.For a cohort of 65-year-old women with atypical angina  (pre-test probability is 0.48) the 
optimal sensitivity and specificity were 87% and 73% respectively. Pooled published data 
demonstrated a sensitivity of 92% and a specificity of 51% for EBCT. In patients with non-specific 
chest pain no imaging was optimal, whereas in patients with typical chest pain routine coronary 
angiography was the optimal strategy. With an increase in the willingness-to-pay to $75,000 per 
QALY the optimal sensitivity increased to 99%, whereas specificity decreased to 14% in 55-year-old 
men with atypical angina. 
Conclusions: Optimal test characteristics based on cost-effectiveness analysis differ from pooled 
values of sensitivity and specificity. They depend on the setting in which the test is used and on 
the willingness-to-pay threshold. This study suggests that, where possible, the interpretation of 
test results should be adjusted to optimize the use of such tests. 
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Introduction 
 
In cost-effectiveness models that evaluate the performance of diagnostic tests normally fixed 
values of sensitivity and specificity are used. Generally, published pooled values of sensitivity and 
specificity are obtained from a meta-analysis. However, pooled values of sensitivity and specificity 
indicate neither the variability of the test characteristics nor the best combination of sensitivity and 
specificity for a particular clinical setting. To evaluate the uncertainty around these estimates 
sensitivity analyses are often performed over the 95% confidence intervals of the point estimates. 
This, however, disregards the inverse relationship between sensitivity and specificity and ignores 
the possibility of adjusting the interpretation of the test results so as to optimize the test 
characteristics.   
The inverse relationship between sensitivity and specificity can be calculated using (summary) 
receiver operating characteristic ((S)ROC) analysis. Furthermore, various methods have been 
reported in the literature to determine the optimal combination of sensitivity and specificity on the 
SROC curve of a diagnostic test. Some investigators have used the point on the SROC curve that is 
closest to the upper left corner as ‘optimal’ operating point1, the so-called J-point. Others have used 
the operating point with a likelihood ratio equal to 1.2 Other criteria for determining the optimal 
operating point include selection of the Q-point: the point where sensitivity equals specificity3, 
maximizing accuracy or the sum of sensitivity plus specificity,4,5 or accepting a preset level of 
sensitivity (or specificity) and determining the corresponding specificity (or sensitivity 
respectively).6 All these methods minimize the number of false-positive and false-negative test 
results. However, none of these methods accounts for the fact that the consequences of a false-
negative test result in those with the disease may be far worse than a false-positive test result in 
those without the disease or vice-versa. Therefore, depending on the prevalence of disease and the 
consequences of the test result, the sensitivity should be maximized in a particular clinical setting, 
whereas the specificity should be optimized in another setting.  
The aim of this study was to determine the optimal combination of sensitivity and specificity of 
electron-beam computed tomography (EBCT) testing for patients with chest pain based on a cost-
effectiveness analysis. A secondary objective was to compare outcomes of the cost-effectiveness 
model using the optimal test characteristics and the pooled published values of sensitivity and 
specificity. 
 
 
Methods 
 
Target population 
We focused on patients presenting with non-specific chest pain, atypical angina, or typical 
angina, as defined in the Coronary Artery Surgery Study (CASS).7 Chest pain was defined as 
typical angina for pain that is substernal, follows physical exertion, and is relieved by 
nitroglycerin. If two of these criteria were met, chest pain was defined as atypical angina and if 
only one criterion applied it was defined as nonspecific chest pain. We considered 6 cohorts of 
patients defined by age, sex, and type of chest pain. Cohorts of 55 year-old men and 65-year-old 
women were evaluated because these are the average ages at which men and women present with 
chest pain. The pre-test probabilities of coronary artery disease (CAD) in 55-year-old men with 
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typical, atypical, and nonspecific chest pain, based on the CASS, were respectively 95%, 71% and 
18%. For 65-year-old women the pre-test probabilities were somewhat lower: 81%, 48% and 10% 
respectively.7 As a base case we evaluated a cohort of 55-year-old men with atypical chest pain. 
 
Markov model 
We updated a Markov model8 to evaluate the cost-effectiveness of EBCT compared with no 
imaging and routine coronary angiography for the diagnosis of CAD in patients presenting with 
chest pain. The model estimated the lifetime costs and quality-adjusted life years (QALYs) for 
cohorts of patients with a true- or false-positive and those with a true- or false-negative test result 
for CAD from the perspective of the health care system.8 Patients with a negative EBCT result were 
treated medically, whereas patients with a positive or non-diagnostic test result were referred to 
coronary angiography, which provided the final diagnosis. Based on coronary angiography, 
patients were stratified into categories of no, single-, double-, and triple-vessel or left main disease. 
The post-catheterization treatment strategy in the model was coronary artery bypass graft surgery 
(CABG) for triple-vessel or left main coronary artery disease, percutaneous coronary intervention 
(PCI) for single- or double-vessel stenosis and medical therapy if no significant CAD was found. 
Significant angiographic disease was defined as the presence of a luminal stenosis of 50% or more 
in at least one coronary artery. Nonfatal myocardial infarction and revascularization procedures 
occurring after the initial treatment decision were modeled to evaluate their effects on cost and 
quality of life. We estimated the quality-adjusted life expectancy by modelling annual transitions 
between 4 different health states: no chest pain, mild chest pain, severe chest pain, and death. 
Quality of life with no symptoms was valued at 0.87, with mild chest pain at 0.81, and with severe 
chest pain at 0.67 on a scale from 0, representing death, to 1, representing full health, based on a 
standard gamble evaluation in patients with chronic angina.8,9  
We transformed the two outcomes of the Markov model, costs and QALYs, into one balanced 
health measure: the net health benefit (NHB).10 The NHB was defined as the lifetime effectiveness 
(QALYs) minus the lifetime costs ($), the latter divided by the societal willingness-to-pay (WTP) 
threshold to save one QALY ($/QALY), in formula: 
 
  
 thresholdWTP
Cost -QALYs  NHB =    (eq 1) 
 
The net health benefit is expressed in QALY-equivalents. We considered 3 generally accepted 
thresholds of societal willingness-to-pay: $25,000, $50,000 and $75,000 per QALY gained.11  
 
 
Data sources 
 
Test characteristics 
Sensitivity and specificity estimates of EBCT and pooled values of sensitivity and specificity for 
diagnosing patients suspected of coronary artery disease were obtained from a published meta-
analysis.12 A standard method of EBCT calcium scoring was used that defined significant CAD 
based on a calcium score >0.13  
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Table 1: Test characteristics of EBCT and coronary angiography. The sensitivity of EBCT can be calculated 
using equation 2 and the intercept and slope of the SROC curve for each value of the specificity. 
 
 EBCT CAG 
Costs ($) 271 2,395* 
Intercept SROC curve, i 2.310 n/a 
Slope SROC curve, b 0.09875 n/a 
Mortality (%) 0 0.1 
Morbidity (%) 0 1.6 
Uninterpretable test result (%) 2 0 
 
* cost for outpatient CAG procedure (70% of CAG procedures); inpatient CAG cost $5,030 (30% of CAG procedures) 
EBCT, electron-beam computed tomography; CAG, coronary angiography; SROC, summary receiver operating 
characteristic; n/a, not applicable 
 
 
Figure 1: Net health benefit (NHB) plotted for each combination of sensitivity and 1-specificity on the summary 
receiver operating characteristic curve (NHB-SROC curve) for the base case at a willingness-to-pay threshold of $50,000 
per QALY gained. 
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The cost estimates of the diagnostic tests and treatment procedures were obtained from the 
Medicare-allowed global reimbursement rates based on the 2002 Current Procedural Terminology 
(CPT) code system for outpatient procedures and the 2002 Diagnosis Related Group (DRG) codes 
for in-patient procedures, including the technical and professional fees. We assumed that the 
Medicare-allowed reimbursement for EBCT would be equal to the reimbursement for a CT of the 
chest. All costs were adjusted to 2002 U.S. dollars using the medical care component of the 
Consumer Price Index and were discounted at an annual rate of 3%. Furthermore, we assumed 
that EBCT was uninterpretable in 2% of cases and has no associated morbidity or mortality.14 The 
test characteristics are shown in Table 1.  
 
 
SROC analysis and calculation of the optimal operating point on the SROC curve 
 
The published sensitivity and specificity estimates were re-analyzed with a summary receiver 
operating characteristic (SROC) analysis using a random effects model, which accounts for the 
variation among studies (STATA 7.0).15,16 Each point on an SROC curve represents a combination 
of sensitivity (or true-positive rate (TPR)) and 1-specificity (or false-positive rate (FPR)) at a certain 
threshold value of a diagnostic test.  
 
In a SROC analysis, the TPR and the FPR are transformed into their logit form. Subsequently, 
the difference (D) of the logit transformations, which is equal to the diagnostic odds ratio, and the 
sum (S) of the logit transformations, a proxy for the cut-off value of the test, are calculated. Then, a 
linear regression analysis is performed, in which D is the dependent variable and S is a predictor, 
weighted for the inverse of the variance of D. The coordinates of the SROC curve can be calculated 
by back transformation and rearrangement of the regression equation using the following formula: 
 
1)1/()1(
)1/(
1
*1
1
−
−+
−



 


−
+
=
bb
bi
FPR
FPRe
TPR   (eq 2) 
 
in which i is the intercept and b the slope of the regression model. This formula was entered into 
the Markov model as variable for the TPR of EBCT. A sensitivity analysis on the FPR was 
performed. For each possible value of the FPR the model calculated the associated TPR and the 
resulting net health benefits. The optimal combination of the true- and false-positive rate, or the 
optimal operating point, was defined as the point on the SROC curve where the net health benefit 
reaches its maximum. This analysis was repeated for the six cohorts and for the three willingness-
to-pay thresholds for the base case.  
The optimal combination of sensitivity and specificity or the optimal operating point on the 
SROC curve is determined by the prior probability of disease, and the long-term risks, benefits and 
costs associated with the test outcomes. In particular, a trade-off needs to be made between the net 
loss due to false-positive (FP) test results relative to true-negative (TN) test results and the net loss 
due to false-negative (FN) test results relative to true-positive (TP) test results17,18, in formula: 
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Results 
 
Optimal operating points 
For each combination of sensitivity and 1-specificity on the SROC curve the associated net 
health benefit was calculated for each of the six cohorts. The results of the base case are plotted in a 
three-dimensional graph, which shows the SROC curve in the x-y plane and the net health benefit 
on the z-axis (NHB-SROC curve; Figure 1). The top of the NHB-SROC curve represents the 
maximum net health benefit that can be attained with EBCT at the optimal combination of 
sensitivity and specificity for the base case.  
Figure 2 shows for each of the six cohorts the net health benefit as a function of the false-
positive rate at a willingness-to-pay threshold of $50,000 per QALY. For simplicity the sensitivity is 
not plotted in these graphs. In patients with non-specific chest pain the net health benefit reached 
its maximum at a FPR of 0%, or a specificity of 100% with an associated sensitivity of 0%, which 
implies that the test should not be performed at all. Using these test characteristics all patients 
would have a negative test result and would be treated medically. As a result, the no imaging 
strategy was the optimal strategy for these cohorts. In patients with typical chest pain, however, 
the maximum net health benefit was reached at a FPR of 100% or a specificity of 0% with an 
associated sensitivity of 100%, which implies that in these patients EBCT should not be performed 
either, because all patients would have a positive test result and would be referred to coronary 
angiography for the final diagnosis. The optimal test strategy for patients with typical chest pain 
was therefore routine coronary angiography. EBCT was only cost-effective in cohorts of patients 
with atypical chest pain. For a 55-year-old male the maximum net health benefit was 12.232 
QALYs, which was attained at a sensitivity of 93% and a specificity of 34% at a willingness-to-pay 
threshold of $50,000 per QALY. For a 65-year-old female with atypical chest pain the maximum net 
health benefit was 10.918 QALYs, which was achieved at a sensitivity of 87% and a specificity of 
63%. In the cohort of 65-year-old women with atypical angina EBCT showed a higher net health 
benefit than coronary angiography over a large part of the SROC curve. This implies that EBCT 
was the optimal strategy for this cohort if the FPR of EBCT ranged between 15% and 80%, which is 
equal to a specificity of 20%-85% with an associated sensitivity ranging from 99% to 61%.  Routine 
coronary angiography was the optimal strategy for the remainder of the SROC curve, thus at a 
very low or very high FPR of EBCT. 
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Male, 55 years, typical angina
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Figure 2: NHB-SROC curves for 3 cohorts of 55-year-old men and 3 cohorts of 65-year-old women with non-specific, 
atypical, and typical angina at a willingness-to-pay threshold of $50,000 per QALY. 
Estimation of optimal test characteristics based on cost-effectiveness analysis: flexible versus fixed test characteristics 
 
87 
Pooled weighted analysis 
The pooled sensitivity and specificity of EBCT were 92.3% (95% CI 90.7-94.0) and 51.2% (95% 
CI 47.2-54.9) respectively.12 The net health benefit of EBCT at this combination of sensitivity and 
specificity was 12.230 QALYs for the cohort of 55-year-old men with atypical angina at a 
willingness-to-pay threshold of $50,000 per QALY. For the cohort of 65-year-old women with 
atypical angina, the net health benefit was 10.917 QALYs (Table 2). The outcomes in Table 2 show 
that for each of the willingness-to-pay thresholds, the net health benefit was lower when the 
pooled values of sensitivity and specificity were analyzed than when optimal test characteristics 
were used. 
 
Sensitivity analysis 
Varying the willingness-to-pay threshold from $25,000 to $75,000 per QALY increased the 
maximum net health benefit that could be achieved with EBCT and moved the optimal operating 
point to a higher sensitivity and a lower associated specificity, resulting in a higher net health 
benefit (Table 2). At a higher sensitivity of EBCT more patients will be selected for coronary 
angiography, which is more expensive, but also results in higher effectiveness, in spite of the risks 
associated with angiography. 
 
 
Table 2: Maximum net health benefits (NHBmax) obtained using optimal operating points for EBCT 
compared with the net health benefits (NHB) obtained using the pooled published values of sensitivity and 
specificity (93% and 51% respectively) of EBCT for two cohorts of patients with atypical chest pain using 
willingness-to-pay thresholds of $25,000, $50,000, and $75,000 per QALY. 
 
 Optimal operating point EBCT Pooled values EBCT 
Willingness-to-pay 
$/QALY 
Sensitivity 
% 
Specificity 
% 
NHBmax 
QALYs 
NHB  
QALYs 
 
Men, 55 years, atypical angina 
25,000 0 100 11.605 11.548 
50,000 93 34 12.232 12.230 
75,000 99 14 12.464 12.458 
Women, 65 years, atypical angina 
25,000 0 100 10.449 10.373 
50,000 87 63 10.918 10.917 
75,000 95 44 11.098 11.098 
 
NHB, net health benefit; max, maximum; QALY, quality-adjusted life year 
 
 
Discussion 
 
We demonstrated that the optimal sensitivity and specificity of EBCT accounting for long-term 
costs and effectiveness differed from the pooled published values of sensitivity and specificity. 
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Furthermore, the optimal test characteristics depended on the setting in which the test was used 
and on the willingness-to-pay threshold. Although the differences were small, our results suggest 
that the net health benefit of a diagnostic test could be improved by adjusting the interpretation of 
the test result so as to optimize the test characteristics. Moreover, using optimal test characteristics 
instead of fixed values of sensitivity and specificity in a cost-effectiveness analysis of diagnostic 
test strategies could potentially change the decision with respect to the optimal test strategy. For 
example, if NHB-SROC curves are plotted for more than one test the curves may cross, which 
implies that one test may maximize net health benefit at a low FPR, whereas the other test may 
provide the same net health benefit at a higher FPR. In cohorts with a high probability of disease, 
the optimal operating point moved to a higher sensitivity and a lower associated specificity 
compared to a cohort with low probability of disease. In clinical practice this would result in more 
patients being referred to coronary angiography, which yielded better outcomes in terms of 
effectiveness and higher costs than if the pooled sensitivity and specificity values were considered. 
A higher sensitivity results in fewer patients with CAD that are misdiagnosed (false negatives), 
but, because of the associated lower specificity, more patients also unnecessarily undergo coronary 
angiography (false positives). On the contrary, in patients with a lower probability of disease the 
optimal test characteristics moved to a lower sensitivity and higher specificity. In patients with 
non-specific chest pain for example, our model suggested that a sensitivity of 0% and specificity of 
100% would be optimal implying that EBCT testing would lead to unnecessary coronary 
angiography. 
SROC curves reflect the discriminatory power of a diagnostic test in different settings whereas 
the pooled values of sensitivity and specificity reflect a fixed setting. Conventional ROC curves 
take into account the variation in sensitivity and specificity when the cut-off value of the diagnostic 
test is varied within one patient group. SROC curves, however, are derived from published studies 
in various patient cohorts in different settings, each with its own methods for performing and 
interpreting the tests, and chosen cut-off value of the test variable. In the meta-analysis that we 
used for our SROC analysis, for example, a standardized calcium scoring method was used in each 
source study. However, variations between the study protocols existed, which included different 
definitions of the minimum area of tissue attenuation required for a lesion to be considered 
calcium and not artifact; minimum areas ranged in size from 0.5 to 2 mm.12 Furthermore, the 
number of tomograms obtained in each examination (range 20-40) and whether a standard 
inspiration or expiration breath-hold was used during image acquisition varied across studies. 
SROC curves reflect this variation in study protocols and populations studied in addition to 
potential differences in cut-off values.  
Due to the variation in patient populations and disparity in methods for performing and 
interpreting the test results we were, unfortunately, unable to calculate the explicit cut-off value of 
the calcium score corresponding to the optimal sensitivity and specificity. The ease of altering cut-
off values through adjusting minimum size criteria for lesions or calcium scores is an advantage of 
EBCT compared with traditional tests such as exercise echocardiography or exercise single-photon 
emission computed tomography, which yield categorical rather than continuous test results. In 
general, our results suggest that more lenient criteria should be applied for patients with high risk 
factors and stricter criteria for patients with low risk factors for CAD. For EBCT this would mean 
that a low calcium score should be used as cut-off value for high-risk patients with severe chest 
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pain, while a high calcium score should be used as cut-off value for low-risk patients with mild 
chest pain, to get the maximum net health benefit from the test. This implies that for women, who 
have a lower pre-test probability of CAD than men, the calcium cut-off should be set at a higher 
value than for men. Rumberger et al. attempted to define ranges for EBCT calcium scores to 
predict the severity of CAD.19 Although their definition of the optimal operating point did not 
account for the long-term outcome, the authors found the same principle in optimizing sensitivity 
or specificity for high- and low-risk patients respectively.  
We assumed that the societal willingness-to-pay threshold can be defined, although we 
recognize that the threshold value is difficult to determine because it may fluctuate with time, 
differs across countries, and may differ across types of interventions. The results of the sensitivity 
analysis in which the willingness-to-pay threshold was varied suggested that the optimal test 
characteristics of EBCT for the diagnosis of CAD depended highly on what society is willing to pay 
for health care. At a willingness-to-pay of $50,000 per QALY, for example, our results suggest that 
if the test characteristics of EBCT are optimized, EBCT was a cost-effective test for patients with 
atypical angina. However, if the willingness-to-pay threshold was set at $25,000 per QALY, EBCT 
was too expensive for the same patient cohorts. On the other hand, the optimal sensitivity 
increased and specificity decreased if the willingness-to-pay threshold increased to $ 75,000 per 
QALY. This finding suggests that more coronary angiographies could and should be performed if 
society is willing to pay more, and this will lead to a higher effectiveness despite increased risks 
and cost.  
The results of our study should be interpreted in the context of the following limitations. The 
input variables in our Markov model were retrieved from various data sources and assumptions 
were required to model the diagnostic workup and treatment of patients suspected of CAD. We 
derived the test characteristics from a meta-analysis, which included studies that varied widely in 
demographics, prevalence of CAD, and EBCT protocol. Verification bias and publication bias may 
have affected these estimates. Furthermore, test characteristics, risks and cost variables may change 
over time, when the test is applied to a wider patient spectrum. We did not explore the uncertainty 
of all the variables in our model, because we wanted to demonstrate the differences in outcome of 
the model depending on the flexibility of the test characteristics alone.  
 
 In conclusion, this analysis suggest that flexible test characteristics should be analyzed in 
cost-effectiveness models of diagnostic tests instead of using one set of fixed values of sensitivity 
and specificity. Optimal test characteristics based on cost-effectiveness analysis differ from pooled 
values of sensitivity and specificity. They depend on the setting in which the test is used and on 
the willingness-to-pay threshold. This study suggests that, where possible, the interpretation of 
test results should be adjusted to optimize the use of such tests.  
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The optimal peak systolic velocity threshold on duplex ultrasonography for the 
indication carotid endarterectomy: a decision analytic approach 
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Abstract 
 
Purpose: To determine the optimal peak systolic velocity (PSV) threshold on duplex 
ultrasonography for the indication of carotid endarterectomy based on the long-term cost-
effectiveness of diagnostic testing and treatment. 
Materials and Methods: From January 1997 to January 2000, a prospective study was conducted 
including 350 patients with symptoms of amaurosis fugax, TIA, or minor stroke, who underwent 
duplex ultrasonography and digital subtraction angiography. In total 236 non-occluded carotid 
arteries were available for evaluation by both imaging modalities. Receiver operating characteristic 
(ROC) curves were constructed for the diagnosis of either a 70-99% or a 50-99% stenosis. Based on 
the lifetime costs and quality-adjusted life-years, obtained from a cost-effectiveness analysis, and 
the prevalence of disease, the optimal likelihood ratio was calculated. Finally, the associated 
optimal sensitivity, specificity and threshold PSV were derived from the ROC-curves.  
Results: For the diagnosis of a 70-99% stenosis the optimal likelihood ratio was 0.21, which was 
associated with a threshold PSV of 220 cm/s, a sensitivity of 97%, and specificity of 49%. For the 
diagnosis of a 50-99% stenosis the optimal likelihood ratio was 0.38, which was associated with a 
threshold PSV of 180 cm/s, a sensitivity of 95%, and specificity of 69%.  
Conclusion: Based on the lifetime consequences of diagnostic testing and subsequent treatment, 
the optimal threshold PSV for the diagnosis of a 70-99% carotid artery stenosis in patients with 
amaurosis fugax, TIA, or minor stroke is 220 cm/s and for the diagnosis of a 50-99% stenosis the 
optimal threshold PSV is 180 cm/s. 
The optimal peak systolic velocity threshold on duplex ultrasonography for the indication carotid endarterectomy 
 
93 
Introduction 
 
Two large randomized trials, the North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) and the European Carotid Surgery Trial (ECST), have shown a considerable 
benefit for carotid endarterectomy in patients with a 70-99% stenosis, but also a small benefit for 
patients with a 50-69% stenosis 1-6. In these trials, severe carotid artery stenosis was diagnosed by 
cerebral angiography, the reference standard. However, cerebral angiography carries a risk of 
mortality and morbidity and has a financial cost. Its routine use in patients with amaurosis 
fugax, transient ischemic attack (TIA), or minor stroke who are potential endarterectomy 
candidates is therefore undesirable. Consequently, many clinicians nowadays use noninvasive 
studies, such as duplex ultrasonography (DUS), magnetic resonance angiography, and 
computed tomographic angiography, to select patients for carotid endarterectomy 7. We recently 
showed that DUS was the optimal test strategy to select patients for carotid entarterectomy in a 
cost-effectiveness analysis 8.   
Moreover, the Society of Radiologists in Ultrasound published recommendations for the 
interpretation of DUS results in the diagnosis of internal carotid artery stenosis 7. That study was 
based on the test characteristics and diagnostic accuracy of DUS obtained from the literature. 
Maximization of accuracy as criterion to define the optimal threshold of the peak systolic 
velocity (PSV) assumes that a false-negative test result has the same importance as a false-
positive result. However, because the DUS result determines whether or not carotid 
endarterectomy is performed, the consequences of missing a significant stenosis may be more 
harmful with respect to cost and/or effectiveness outcomes than performing endarterectomy for 
a non-significant stenosis. Therefore, it is more clinically relevant to account for the cost and 
effectiveness associated with false-positive or false-negative test results when selecting an 
optimal threshold for referral for endarterectomy.  
Accordingly, the aim of this study was to determine the optimal peak systolic velocity 
threshold on duplex ultrasonography for the indication of carotid endarterectomy taking into 
account the cost-effectiveness outcomes of diagnostic testing and subsequent treatment. 
 
 
Methods 
Study population 
From January 1997 to January 2000 a prospective diagnostic study was performed in two 
academic hospitals and one non-academic hospital in the Netherlands 9. After informed consent 
was obtained, patients with symptoms of amaurosis fugax, TIA, or minor stroke underwent 
carotid duplex ultrasonography and carotid digital subtraction angiography within a time frame 
of 4 weeks. Patients were enrolled at the University Medical Center Utrecht, Erasmus Medical 
Center Rotterdam, and Medical Spectrum Twente. The medical ethical committee approved the 
study for each hospital. 
Carotid duplex ultrasonography  
The peak systolic velocity (PSV) was measured on a continuous scale in cm/s in the proximal 
part of the symptomatic internal carotid artery of each patient. A carotid artery was called 
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symptomatic if the neurological symptoms, i.e. amaurosis fugax, TIA, or minor stroke 
corresponded with the stenosed side. If no detectable flow was present patients were classified 
as having an occlusion (100% stenosis). Slow flow in combination with a visualized severe 
stenosis was defined as a near occlusion. Arteries with an occlusion or near occlusion on 
ultrasonography were excluded from the analysis, because peak systolic velocity cannot reliably 
be measured in these arteries.  
Digital subtraction angiography (DSA) 
DSA was performed by selective positioning of an intra-arterial catheter in the common 
carotid artery. From the carotid bifurcation, three projections (lateral, posteroanterior, and 
oblique) were acquired. Additional projections of occasionally performed rotational DSA 
examinations were not used in the context of this study.  
The DSA test results were read by one observer for each hospital. The observers were 
blinded for clinical information and for the duplex results. The observers used printed hard 
copies to read the DSA images. The percentage stenosis was measured according to the 
NASCET criteria 1. The degree of stenosis is defined as the remaining lumen at the site of the 
stenosis as percentage of the normal lumen distal to the stenosis. The maximum degree of 
stenosis of the three projections was used in the analyses. Angiography was considered the 
standard of reference. 
Markov Model 
The lifetime costs and quality-adjusted life years following a true or false, positive or 
negative DUS test result (TP, FP, TN, FN) were derived from a previously published Markov 
model 8. These included the costs and utilities associated with subsequent treatment, 
complications of treatment and progression of disease. Several health states were modeled for 
the severity of neurological disease (TIA, minor stroke, major stroke either as presenting 
symptom or as complication) for patients with initially less than 50% stenosis, 50-69% stenosis, 
and 70-99% stenosis. Medical therapy including aspirin treatment was assumed to be the 
optimal treatment for patients with less than 50% stenosis. For patients with more than 50% 
stenosis two criteria for carotid endarterectomy were considered: 70-99% stenosis and 50-99% 
stenosis. Progression of disease and death were modeled by allowing patients to transition to 
more severe health states during follow-up. The Markov model was built in DATA Pro 11.0 
(TreeAge). 
The lifetime costs and effects were integrated into one measure: the net health benefit (NHB), 
which is defined as the lifetime effects in quality-adjusted life years minus the lifetime costs, the 
latter divided by the amount that society is willing to pay (WTP threshold) for saving one 
quality-adjusted life year (QALY) 10. In formula: 
 
  
 thresholdWTP
Cost -QALYs  NHB =    (eq 1) 
 
We assumed two threshold amounts that society would be willing to pay for saving one 
quality-adjusted life year: $25,000 and $50,000 per QALY. 
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Recommended PSV thresholds 
The recommended PSV thresholds of 230 cm/s for the diagnosis of a 70-99% stenosis and 125 
cm/s for a 50-99% stenosis were applied to our study data 7. For both PSV thresholds, we 
calculated the associated sensitivity and specificity. 
Optimal PSV threshold 
  We calculated the sensitivities and specificities associated with different PSV-thresholds 
(Ri) using DSA as the reference standard. We used two definitions of carotid disease, in 
agreement with the two indications for carotid endarterectomy: for a 70-99% and for a 50-99% 
angiographic stenosis. Using receiver operating characteristic (ROC) analysis, all combinations 
of sensitivity and specificity were plotted in a graph in which the y-axis represents sensitivity 
and the x-axis represents 1-specificity 11. Smooth ROC curves were created using the methods of 
summary ROC analysis 12-14. For each combination of sensitivity and specificity on the smooth 
curves the result-specific likelihood ratio (LRRi), i.e. the probability of a specific test result in the 
group with the disease divided by the probability of that specific test result in the group without 
the disease, was calculated which is equal to the tangent or slope of the curve 15, 16. In formula: 
 
Disease) No|P(R
Disease)|P(RLR
i
i
Ri =     (eq 2) 
 
Taking into account the lifetime consequences of diagnostic testing and subsequent 
treatment the optimal likelihood ratio (LRopt) depends on the prevalence of disease (p) and the 
ratio of the net loss due to false-positive test results compared with true-negative results (NHBTN 
– NHBFP) and the net loss due to false-negative results compared with true-positive results 
(NHBTP-NHBFN), in formula 15, 16: 
 
FNTP
FPTN
opt
NHBNHB
NHBNHB
p
pLR
−
−
∗
−
>
1
   (eq 3) 
 
The optimal combination of sensitivity and specificity (the optimal operating point) was 
derived from the smooth ROC curve at the operating point where the result-specific likelihood 
ratio (eq 2) equals the optimal likelihood ratio based on the Markov model (eq 3). Subsequently, 
we selected the observed PSV value closest to the point on the smooth curve, which we define as 
the optimal threshold PSV. 
For the summary ROC curve analysis we used the statistical package SPSS 11.0 and for the 
construction of the ROC curves we used Excel 2000. 
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Results 
Study population 
In the prospective study 350 patients were included having a mean age of 67 (range 39-88) 
and 76% being male 9. The symptomatic carotid artery could be imaged in 323 patients with 
DSA and in 330 with DUS. Both tests were available in 313 patients. 
In table 1 the categorized angiographic and duplex results are cross-tabulated. Angiographic 
stenosis of 0-49% stenosis was found in 14% of the patients, 50-69% stenosis in 19% of the 
patients, 70-98% stenosis in 41%, near occlusions (99% stenosis) in 5%, and occlusions in 20%. 
Duplex ultrasonography identified 61 occlusions. The sensitivity and specificity of diagnosing 
an occlusion by duplex ultrasound were 94% and 99% respectively. Slow flow in combination 
with a visualized severe stenosis on DUS was found in 16 arteries, indicating a near occlusion. In 
total 236 arteries without (near) occlusions on DUS were available for the analysis. In figure 1 (A 
and B) the absolute PSV measurements are plotted against the angiographic degree of stenosis. 
The figure shows that the relationship between the PSV and the degree of stenosis is non-linear. 
In figure A the indication for endarterectomy is set at a minimum angiographic stenosis of 70% 
and in figure B at 50% (horizontal lines). Shifting the PSV threshold (vertical lines) to the left will 
result in an inversely related increase of the true-positive test results and a decrease of true-
negative test results. Thus, lowering the PSV threshold is associated with a higher sensitivity 
and lower specificity. Conversely, shifting the PSV threshold upwards will result in a lower 
sensitivity and higher specificity. 
Markov Model 
The long-term outcomes of the cost-effectiveness analysis (Table 2) showed that referral for 
carotid endarterectomy instead of medical therapy resulted in a loss in QALYs and increase in 
costs in patients with a 0-49% stenosis. A small gain in QALYs and slight cost-savings were 
obtained with endarterectomy in patients with a 50-69% stenosis and a relatively large gain in 
QALYs and large cost-savings in patients with a 70-99% stenosis (Table 2).  
Recommended PSV thresholds 
The Society of Radiologists in Ultrasound recommended the use of a PSV of 230 cm/s for the 
diagnosis of a 70-99% stenosis and a PSV of 125 cm/s for the diagnosis of a 50-99% stenosis 7. 
Applying the recommended threshold of 230 cm/s in our population for diagnosing a 70-99% 
stenosis would result in a sensitivity of 95% and specificity of 51%. If we would apply a 
threshold of 125 cm/s to our population for detecting a 50-99% stenosis the sensitivity would be 
99%, whereas the specificity would be 36%. 
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Table 1: Categorized measurements of the internal carotid artery: duplex versus digital subtraction 
angiography. 
 
    DSA stenosis categories 
  PSV cm/s 0-49% 50-69% 70-98% 99% Occlusion Total 
0-124 16 1    17 
125-230 20 17 5 1  43 
>230 8 42 117 8 1 176 
Near  occl 1 1 5 6 3 16 
 
DUS 
categories 
 
 Occlusion   1 1 59 61 
 Total 45 61 128 16 63 313 
DSA, digital subtraction angiography; DUS, duplex ultrasonosgraphy; PSV, peak systolic velocity; Near occl, near 
occlusion 
 
 
Table 2: Lifetime costs, quality-adjusted life years (QALYs), and net health benefits (NHB) for the base 
case with a positive or negative duplex ultrasonography result for several stenosis categories.# 
 
 Stenosis category 
 0-49% 50-69% 70-99% 
Negative test result: medical therapy    
Cost ($)  30,599 36,427 46,444 
QALYs 11.36 11.09 10.71 
NHB $25k 10.14 9.63 8.85 
NHB $50k 10.75 10.36 9.78 
Positve test result: carotid endarterectomy*    
Cost ($) 35,638 35,638 35,638 
QALYs 11.12 11.12 11.12 
NHB $25k 9.70 9.70 9.70 
NHB $50k 10.41 10.41 10.41 
Endarterectomy vs medical therapy    
∆ Cost ($) 5,139 -789 -10,806 
∆ QALYs -0.24 0.03 0.41 
∆ NHB $25k -0.44 0.06 0.85 
∆ NHB $50k -0.34 0.05 0.63 
 
# Source: Buskens et al 8. Modified data from table 3: data include treatment and follow-up for patients with TIA or 
stroke. 
* Risks and prognosis following carotid endarterectomy were assumed to be independent of the underlying stenosis 
category. 
NHB $25k and NHB $50k indicate that the net health benefit was calculated with a willingness-to-pay threshold of 
$25,000 and  $50,000 per QALY respectively. 
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Optimal PSV threshold  
For a 70-99% stenosis indication for endarterectomy the optimal result-specific likelihood 
ratio based on the Markov model (calculated with equation 3) was 0.21. Figure 2A shows the 
observed ROC curve and the smooth ROC curve. Each dot on the observed curve represents the 
sensitivity and 1-specificity for a specific PSV threshold for predicting a 70-99% angiographic 
stenosis, i.e. eligible for endarterectomy. The optimal likelihood ratio or slope of the ROC curve 
is indicated in this figure. The associated optimal sensitivity and specificity were 97% and 49% 
respectively. The optimal threshold PSV that corresponded with this sensitivity and specificity 
was 220 cm/s (figure 2A). The optimal PSV threshold is also shown in figure 1A. The south-east 
quadrant of this figure represents the large number of false-positive test results as compared 
with the north-west quadrant which contains a small number of false-negative test results using 
the optimal PSV threshold. 
If a 50-99% stenosis was used as indication for endarterectomy the optimal result-specific 
likelihood ratio was 0.38. The associated optimal sensitivity and specificity were 95% and 69% 
respectively (figure 2B). The optimal threshold PSV that corresponded with this sensitivity and 
specificity was 180 cm/s (figure 1B and 2B).  
Changing the willingness-to-pay threshold from $25,000 to $50,000 per QALY hardly 
affected the optimal likelihood ratio and thus, had no effect on the optimal threshold PSV. If a 
higher willingness-to-pay threshold is accepted the net health benefit (eq 1) increases. The ratio 
of the difference in net health benefits associated with specific test results, however, only 
changed minimally if a higher willingness-to-pay threshold was used (eq 3). 
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Figure 1: Scatterplot of absolute PSV measurements and angiographic stenosis measurements. In figure 1A the 
threshold PSV (220 cm/s) for the indication to operate a 70-99% stenosis is shown and in figure 1B the threshold PSV 
(180cm/s) for the indication to operate a 50-99% stenosis. FN, false negative; TP, true positive; TN, true negative; FP, 
false positive 
 
FN TP
TN FP
FN TP
TN FP
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1B 
 
Figure 2: Observed and smooth receiver operating characteristic curves for (1A) the indication to operate a 70-99% 
stenosis and (1B) for the indication to operate a 50-99% stenosis. The optimal likelihood ratio (LR) or slope of the 
ROC curve is indicated with the associated sensitivity and specificity and the optimal threshold PSV. 
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Discussion 
 
We found that the optimal threshold PSV to select symptomatic patients for carotid 
endarterectomy was 220 cm/s if the indication for endarterectomy was a 70-99% stenosis and 180 
cm/s if the indication for endarterectomy was a 50-99% stenosis. The first result is close to the 
threshold recommended by the Society of Radiologists in Ultrasound (230 cm/s for a 70-99% 
stenosis), but the latter result is higher than recommended (125 cm/s for a 50-99% stenosis) 7.  
The Society of Radiologists in Ultrasound based their recommendations on a literature 
review, focused on optimizing accuracy, and did not take into account the variable impact of 
false-negative test results as opposed to false-positive test results. In our study we determined 
the optimal threshold values based on the long-term consequences of false test results in costs 
and effects using a Markov model. The results of our model showed that referring a non-
significant stenosis (<50%) for endarterectomy is more harmful than missing a diagnosis of 50-
69% stenosis, which explains the fairly high PSV threshold for discriminating a 50-99% stenosis 
from a 0-49% stenosis. If we would use the recommended threshold of 125 cm/s in our 
population the sensitivity for selecting a 50-99% stenosis would increase to 99%, whereas the 
specificity would decrease dramatically to only 36%. 
 
The natural history of the disease to be identified and the efficacy of treatment play a major 
role in determining the relative importance of sensitivity and specificity. Especially in high-
grade carotid stenosis (>70%), undiagnosed severe carotid disease has a high cost in monetary 
terms and in life expectancy 8. To identify such patients, DUS criteria should be highly sensitive, 
with a minimum number of false-negatives, since these patients carry a high excess morbidity 
and mortality if left untreated. Therefore, in identifying patients with a 70-99% stenosis a high 
sensitivity of the diagnostic test is more important than a high specificity. 
In identifying patients with a 50-99% stenosis suitable for endarterectomy a relatively high 
number of patients will benefit from the procedure. However, the overall losses associated with 
missing a diagnosis are smaller, because most of these patients have a 50-69% stenosis for which 
the missed benefit is smaller than for a 70-99% stenosis. This led to a somewhat lower optimal 
sensitivity and a higher optimal specificity as compared with identifying a 70-99% stenosis. 
 
The prior probability in the population being evaluated also plays a critical role in defining 
the optimal test criterion. Ideally, if the ROC analysis were performed on measurements in 
unselected carotid endarterectomy candidates, the prior probability would be known. In our 
study population the prevalence of 70-99% stenoses was 46% and the prevalence of 50-99% 
stenoses was 66%. If the prior probability would be lower the derived slope would be steeper 
(eq 3) and the optimum cut point on the ROC curve would shift to the left, implying lower 
sensitivity, higher specificity, and thus a higher threshold PSV. 
Varying the societal willingness-to-pay threshold from $25,000 to $50,000 per QALY did not 
influence the choice of the optimal PSV threshold in our study. Although the net health benefit 
for a particular test result changed when varying the WTP threshold, the ratio of the differences 
in net health benefits in equation 3 hardly changed. Note, however, that this does not necessarily 
always apply. In fact, the optimal likelihood ratio can either increase or decrease, depending on 
the proportions of true and false test results in a particular test situation, which can lead to both 
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a higher or lower threshold of the test under investigation in other studies when increasing the 
WTP-threshold.  
 
Various methods have been reported in the literature to determine the optimal diagnostic 
cut point on the receiver operating characteristics curve. Some investigators have used the point 
on the curve that is closest to the upper left corner of the ROC curve as ‘optimal’ cut point 17 or 
the cut point with a likelihood ratio equal to 1 18. Other criteria for determining the optimal cut 
point include selection of the Q-point: the point where sensitivity equals specificity 19, 
maximizing accuracy or the sum of sensitivity plus specificity 20, 21, or accepting a preset level of 
sensitivity or specificity and determining the corresponding operating characteristic 22. All these 
methods minimize the number of false-positive and false-negative test results. However, none of 
these methods takes into consideration the prevalence of disease or the consequences of 
correctly or incorrectly classifying a test result as positive or negative in terms of costs and 
quality of life.  
 
The decision analytic approach of determining the optimal diagnostic threshold that we 
applied was described many years ago 15. Practical applications of this method, however, are 
scarce. In carotid artery disease publications we found only two studies that based their optimal 
test criteria on patient outcome rather than test accuracy 23, 24. Wilterdink and coworkers based 
their criteria on 2-year mortality and morbidity of a severe stenosis treated medically versus 
surgically as reported in NASCET. They found a slope or optimal likelihood ratio of 0.09, which 
is more lenient than the slope that we found, which implies a higher sensitivity and lower 
specificity 23. The difference can be ascribed to the fact that they used DUS to select patients for 
angiography, whereas we used DUS to select patients for endarterectomy. The harm of 
unnecessary angiography is much smaller than the harm of unnecessary endarterectomy in 
false-positives, whereas false-negative test results lead in both studies to a missed opportunity 
of reducing events by performing endarterectomy, which explains the lower slope compared 
with our results. Furthermore, we used the updated results from the NASCET study in our 
model, which show a small but significant benefit for patients with a 50-69% stenosis, we 
integrated both cost and effects on life expectancy, and we modeled lifetime outcomes. 
Kuntz et al. chose the PSV cut point that minimized the probability of stroke at 2 years for 
symptomatic patients. They found an optimal threshold PSV of 229 cm/s for one laboratory and 
an optimal threshold PSV of 340 cm/s for another laboratory 24. Unfortunately, they did not 
report the optimal likelihood ratio or slope of the ROC curve. We did not evaluate the potential 
differences between hospitals. However, we are aware that the optimal threshold PSV may 
depend on hospital equipment. If, however, hospitals do have data on angiography and PSV 
measurements they could construct their own ROC curve and determine their own optimal 
threshold using the optimal slope from our decision analysis. 
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In conclusion, based on the lifetime consequences of diagnostic testing and subsequent 
treatment, the optimal threshold for the diagnosis of a 70-99% carotid artery stenosis is a PSV of 
220 cm/s and for a 50-99% stenosis the optimal threshold PSV is 180 cm/s in patients with 
symptoms of amaurosis fugax, TIA, or minor stroke if duplex ultrasonography is used for 
referring patients to carotid endarterectomy. 
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Abstract 
 
Objective: To evaluate duplex ultrasonographic thresholds for the determination of 50-99% and 
70-99% stenosis of the symptomatic and asymptomatic internal carotid artery in patients with 
symptoms of amaurosis fugax, transient ischemic attack (TIA), or minor stroke based on two 
criteria: maximizing accuracy and optimizing cost-effectiveness and to compare these with 
current recommendations. 
Methods: From January 1997 to January 2000, a prospective multicenter study was conducted 
including 350 consecutive patients with symptoms of amaurosis fugax, TIA, or minor stroke, 
who underwent bilateral duplex ultrasonography and digital subtraction angiography. In total 
504 non-occluded carotid arteries were available for evaluation by both imaging modalities. A 
linear regression analysis was performed that estimated the degree of angiographic stenosis as a 
function of the peak systolic velocity (PSV). Potential differences between the symptomatic and 
asymptomatic arteries were evaluated. PSV thresholds were calculated for both the symptomatic 
and asymptomatic carotid arteries based on two criteria: maximizing accuracy and optimizing 
outcome in terms of cost-effectiveness. 
Results: The PSV measurements significantly overestimated the angiographic stenosis in the 
asymptomatic artery (9.5%; 95% CI 6.3-12.7%) compared with the symptomatic carotid artery. 
The recommended PSV threshold for the diagnosis of 70-99% stenosis is 230 cm/s. If separate 
PSV thresholds were used for the symptomatic and asymptomatic arteries the accuracy 
increased from 75.8% to 78% for symptomatic arteries and from 87.3 to 94% for asymptomatic 
arteries. Maximizing accuracy the optimal PSV threshold for the symptomatic artery was 
280cm/s and for the asymptomatic artery 370 cm/s for diagnosing a 70-99% stenosis. Optimizing 
cost-effectiveness, the optimal PSV threshold was 220 cm/sec for symptomatic and 290 cm/sec 
for asymptomatic carotid arteries.  
For the diagnosis of 50-99% stenosis the recommended PSV threshold was 125 cm/s. Maximizing 
accuracy, the optimal PSV threshold was 160 cm/s for symptomatic and 190 cm/s for 
asymptomatic arteries. Optimizing cost-effectiveness, the optimal PSV threshold was 180 cm/s 
for symptomatic and 230 for asymptomatic arteries.  
Conclusions: PSV measurements overestimate the degree of angiographic stenosis in the 
asymptomatic carotid artery in patients with symptoms of amaurosis fugax, TIA, or minor 
stroke. PSV thresholds that optimize cost-effectiveness differ from the recommended thresholds 
and from thresholds that maximize accuracy. 
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Introduction 
 
Duplex ultrasonography is currently the principal non-invasive test for evaluating carotid 
artery disease. Screening for this disease has become particularly important since publication of 
the results from the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and 
the European Carotid Surgery Trial (ECST).1-5 These large randomized trials demonstrated that 
carotid endarterectomy is not only beneficial in symptomatic patients with severe stenosis (70-
99%), but also in moderate stenosis (50-69%). 
 The reference standard for detection of significant carotid artery stenosis is digital 
subtraction angiography. Because of the risks and cost associated with this invasive procedure, 
there is a trend towards relying more on non-invasive imaging techniques for the diagnosis of 
carotid artery disease, such as duplex ultrasonography. Since the publication of the NASCET 
and ECST results, many studies aimed at determining optimal ultrasonographic criteria for 
identifying an angiographic carotid artery stenosis of 70-99% or 50-99%. However, the reported 
threshold values differ. For example, the optimal threshold value of the peak systolic velocity 
(PSV) has been reported at 175 cm/s, 200 cm/s, and 230 cm/s6-8 for the diagnosis of a 70-99% 
stenosis and at 130 cm/s and 140 cm/s8,9 for the diagnosis of a 50-99% stenosis. Based on a 
literature review, a recent consensus study recommended the use of a PSV of 230 cm/s in the 
internal carotid artery as the optimal threshold for the diagnosis of a 70-99% stenosis and a PSV 
of 125 cm/s for a 50-99% stenosis.10 These studies did not, however, evaluate potential 
differences between thresholds for the asymptomatic and symptomatic artery in symptomatic 
patients. Furthermore, various criteria were used in the reviewed studies to determine the 
optimal threshold value. Most studies maximized diagnostic accuracy. The consequences of a 
false-negative test, however, are probably more harmful and more expensive than the 
consequences of a false-positive test. Therefore, it is more clinically relevant to use clinical 
outcome and cost as criteria for the determination of the optimal threshold value for diagnosing 
a significant stenosis. In a previous study we calculated the optimal PSV threshold for the 
symptomatic carotid artery based on a cost-effectiveness analysis, which resulted in a PSV 
threshold of 220 cm/s for a 70-99% stenosis and 180 cm/s for a 50-99% stenosis.11 
The aim of this study was to evaluate potential differences in duplex ultrasonographic 
thresholds between the asymptomatic and symptomatic internal carotid artery for the 
determination of 50-99% or 70-99% stenosis in patients with symptoms of amaurosis fugax, 
transient ischemic attack (TIA), or minor stroke based on two criteria: maximizing accuracy and 
optimizing cost-effectiveness and to compare these thresholds with current recommendations. 
 
 
Methods 
Study population 
A prospective diagnostic study was performed in two academic hospitals and one non-
academic hospital in the Netherlands from January 1997 to January 2000.12 After informed 
consent was obtained, patients with symptoms of amaurosis fugax, transient ischemic attack, or 
minor stroke underwent bilateral carotid duplex ultrasonography and carotid digital subtraction 
angiography within a time frame of four weeks. Clinical data were collected on symptoms, 
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neurological examinations and test results. Patients were enrolled in the University Medical 
Center Utrecht, Erasmus University Medical Center Rotterdam, and Medical Spectrum Twente. 
The medical ethical committee approved the study for each hospital. 
 
Carotid duplex ultrasonography  
The peak systolic velocity was measured bilaterally in the proximal part of the internal 
carotid artery. A carotid artery was recorded as symptomatic if its perfusion territory was 
associated with the symptoms of amaurosis fugax, TIA, or minor stroke. If no detectable flow 
was present patients were classified as having an occlusion (100% stenosis). Slow flow in 
combination with a visualized severe stenosis was defined as a near occlusion. Arteries with a 
(near) occlusion on duplex ultrasonography were excluded from the analysis, because the peak 
systolic velocity is absent or not reliably measurable in these arteries. The hospital in which the 
patient was tested was recorded, because the results of duplex ultrasonography may depend on 
the equipment used, local imaging protocols, and the image-processing software used. 
Digital subtraction angiography (DSA) 
DSA was performed by selective positioning of an intra-arterial catheter sequentially in each 
common carotid artery. Each carotid bifurcation was imaged in three projections (lateral, 
posteroanterior, and oblique).  
The DSA test results were read by one observer in each hospital. The observers were blinded 
for clinical information and for the duplex results. Printed hard copies were used by the 
observers to read the DSA images. The percentage stenosis was determined according to the 
North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria.1 The degree of 
stenosis was defined as the percentage reduction in lumen diameter comparing the narrowest 
diameter of the residual lumen at the site of the stenosis to the normal lumen distal to the 
stenosis. The maximum degree of stenosis on the three projections was used in the analysis. 
DSA was considered the standard of reference. 
Linear regression analysis 
The absolute PSV values obtained with duplex ultrasonography were compared with the 
percentage stenosis measured with DSA, the reference standard, using linear regression 
analysis. The relationship between the absolute PSV and the percentage angiographic stenosis 
was non-linear. Therefore, the PSV was transformed to its natural logarithm (ln), for which a 
linear relationship with the degree of angiographic stenosis was found. Three linear models 
were assessed. In the first model the degree of angiographic stenosis was modeled as a function 
of the ln(PSV). In the second model, potential differences between the asymptomatic and 
symptomatic carotid artery were evaluated by adding a dummy variable to the first model. 
In formula:  
 
Sln(PSV)   stenosis icAngiograph 210 ∗+∗+= βββ   (eq. 1) 
 
in which the angiographic degree of stenosis is the dependent variable, 0β  is the intercept, 1β  
and 2β  are regression coefficients, ln(PSV) is the natural logarithm of the PSV, and S is the 
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dummy variable which takes the value 1 for symptomatic arteries and 0 for asymptomatic 
arteries. 
In the third model, variables were added to adjust for potential confounders, such as 
hospital, age, and sex. Variables were kept in the model if the model performance improved 
significantly, which was assessed by testing the change in R squared (F-test), and if the 
regression coefficient of the added variable had a significance level of p<0.05. The statistical 
package SPSS 11.0 was used for the regression analysis. 
 
Receiver operating characteristic analysis 
Receiver operating characteristic (ROC) analysis was performed to calculate sensitivities and 
specificities associated with each observed PSV result using DSA as the reference standard for 
the diagnosis of a 70-99% and a 50-99% stenosis. Separate ROC curves were drawn for the 
asymptomatic arteries and the symptomatic arteries. The statistical package SPSS 11.0 was used 
for the ROC analysis. 
Peak systolic velocity thresholds 
The recommended PSV thresholds of 230 cm/s for the diagnosis of a 70-99% stenosis and 125 
cm/s for a 50-99% stenosis were applied to our study data. For both PSV thresholds, we 
calculated the associated sensitivity, specificity, and accuracy for the symptomatic and the 
asymptomatic carotid arteries separately. 
We subsequently calculated our own PSV thresholds using two approaches: 1) maximizing 
overall accuracy and 2) optimizing outcome in terms of cost-effectiveness. The first approach, in 
which accuracy is maximized, assumes that a false-positive test result has the same importance 
as a false-negative test result. In the second approach we used outcomes from a previous study 
in which we calculated the optimal threshold PSV based on the prevalence of disease, the 
consequences of false-positive results relative to true-negative results, and the consequences of 
false-negative results relative to true-positive results in terms of costs and quality-adjusted life-
years saved.11 The consequences of the test results were based on a cost-effectiveness analysis 
which modeled lifetime outcome as a result of diagnostic testing and subsequent treatment of 
the symptomatic carotid artery in patients with amaurosis fugax, TIA, or minor stroke.13 Our 
previous analysis resulted in an optimal threshold PSV of 220 cm/s for the diagnosis of 70-99% 
stenosis and 180 cm/s for the diagnosis of 50-99% stenosis for symptomatic arteries.11 In the 
current study, we calculated the optimal threshold PSV for asymptomatic arteries by first 
substituting the optimal PSV of 220 cm/s and 180 cm/s respectively in equation 1. We assumed 
that the angiographic thresholds for symptomatic and asymptomatic arteries were equivalent. 
Subsequently, we derived the optimal PSV threshold for the asymptomatic arteries by 
rearranging equation 1: 
 
 


 −
=
1β
β  stenosis icAngiographexpPSV Threshold 0artery icasymptomat  (eq. 2) 
 
The sensitivities and specificities associated with each threshold PSV value were derived 
from the ROC analysis. In addition, the accuracy was calculated for each PSV threshold. The 
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outcomes were compared with the recommended threshold PSV values of 230 cm/s and 125 
cm/s for 70-99% and 50-99% stenosis respectively. 
 
 
Table 1: Linear regression models for the relationship between the degree of angiographic stenosis and 
the peak systolic velocity (PSV) with and without adjustment for asymptomatic and symptomatic arteries, 
hospital, age, and sex 
 
 Model 1 Model 2 Model 3 
Coefficients 
(95% confidence intervals) 
   
 Intercept -1.538 
(-1.638; -1.439) 
-1.410 
(-1.515; -1.304) 
-1.461 
(-1.567; -1.354) 
 Ln(PSV) 0.379 
(0.361; 0.398) 
0.346 
(0.325; 0.368) 
0.355 
(0.333; 0.376) 
 Symptomatic artery  0.095 
(0.063; 0.127) 
0.091 
(0.060; 0.122) 
 Hospital C vs A, B   0.093 
(0.049; 0.137) 
 Male sex   0.031 
(0.001; 0.061) 
 Age   0.0015 
(0.000; 0.003) 
Model performance    
 R2 0.760 0.775 0.786 
 R2 change 0.760 0.015 0.011 
 Sig. F change p=0.000 p=0.000 p=0.000 
 
Ln(PSV), natural logarithm of the PSV; R2, R squared; Sig. F change, significance of F-test for model change 
 
 
Results 
Study population 
In the prospective study 350 patients were included (mean age: 67 years (range 39-88); 76% 
male; 24% female).12 The carotid arteries could be imaged in 323 patients with DSA and in 330 
with duplex ultrasonography. Both tests were available for 621 arteries.  
Duplex ultrasonography identified 99 occlusions. The sensitivity and specificity of 
diagnosing an occlusion by duplex ultrasound were 95% and 99% respectively. Slow flow in 
combination with a visualized severe stenosis was found in 18 arteries, indicating a near 
occlusion. The analysis was performed on all arteries without (near) occlusions on duplex 
ultrasonography (n=504). Angiographic stenosis of 0-49% stenosis was found in 239 arteries 
(47%), 50-69% stenosis in 95 arteries (19%), 70-99% in 169 arteries (34%), and 100% stenosis in 1 
artery (0.2%). 
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Figure 1: Scatterplot of peak systolic velocity and angiographic stenosis for symptomatic and 
asymptomatic carotid arteries 
 
Linear regression analysis 
Figure 1 demonstrates the distribution of the angiographic stenosis as a function of the PSV. 
The figure shows that the relationship between angiographic stenosis and the PSV is non-linear. 
Therefore the natural logarithm of the PSV was used in the regression analysis, which shows a 
good linear relationship with angiographic stenosis (Table 1, Model 1: R2=0.76). In model 2 we 
added a variable to the regression model indicating whether the perfusion territory of the 
carotid artery was associated with symptoms of amaurosis fugax, TIA, or minor stroke. The 
angiographic stenosis was significantly more severe in the symptomatic artery than in the 
asymptomatic artery for a given peak systolic velocity (Table 1, Model 2: regression coefficient 
0.095; 95% confidence interval (CI) 0.063-0.127). In other words, the PSV was significantly higher 
in asymptomatic arteries than in symptomatic arteries for a given degree of angiographic 
stenosis (Figure 2). In model 3, we added variables to the regression model in order to adjust for 
potential confounders, such as differences between hospitals, age, and sex. Although these 
variables significantly influenced the degree of angiographic stenosis, the difference between 
symptomatic and asymptomatic arteries remained the same (Table 1, Model 3: regression 
coefficient 0.091; 95%CI: 0.060-0.122). Therefore, we used Model 2 to determine the optimal PSV 
thresholds for symptomatic and asymptomatic arteries. 
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Figure 2: Scatterplot of the natural logarithm of the peak systolic velocity and angiographic stenosis. Regression lines 
indicate relationships for symptomatic and asymptomatic arteries. 
 
ROC analysis 
In Figure 3 the ROC curves are presented for the symptomatic and asymptomatic arteries for 
A) the diagnosis of a 70-99% stenosis and B) the diagnosis of a 50-99% stenosis. The figures 
demonstrate that the area under the ROC curves is larger for the asymptomatic arteries than for 
the symptomatic arteries, indicating a higher diagnostic performance of duplex ultrasonography 
in asymptomatic arteries than in symptomatic arteries. This is a result of the large error range in 
PSV measurements in high-grade stenosis, which is primarily found in the symptomatic arteries, 
as compared with the relatively small error range in low-grade stenosis, which is mainly found 
in the asymptomatic arteries (Figure 1). For the same reason, lowering the diagnostic threshold 
from 70-99% to 50-99% stenosis resulted in a larger area under the ROC curve, and thus an 
increase in diagnostic performance of duplex ultrasonography in the symptomatic arteries 
(Figure 3B). 
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Figure 3: Receiver operating characteristic curves for PSV measurements in the symptomatic and 
asymptomatic arteries for prediction of A) a 70-99% stenosis and B) a 50-99% stenosis. 
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Table 2: Thresholds of the peak systolic velocity (PSV) and corresponding sensitivity, specificity, and 
accuracy for the diagnosis of 70-99% stenosis 
 
Threshold definition PSV threshold 
(cm/s) 
Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
Recommended threshold 10 
    
 Symptomatic artery 230 95.4 51.4 75.8 
 Asymptomatic artery 230 92.1 86.5 87.3 
Maximum accuracy 
    
 Symptomatic artery 280 84.7 69.5 78.0 
 Asymptomatic artery 370 71.1 97.8 94.0 
Optimal cost-effectiveness 
    
 Symptomatic artery 220 96.2 55.5 75.8 
 Asymptomatic artery 290 84.2 91.4 90.3 
 
 
Table 3: Thresholds of the peak systolic velocity (PSV) and corresponding sensitivity, specificity, and 
accuracy for the diagnosis of 50-99% stenosis 
 
Threshold definition PSV threshold 
(cm/s) 
Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
Recommended threshold 10 
    
 Symptomatic artery 125 99.5 35.6 87.3 
 Asymptomatic artery 125 95.9 74.4 80.2 
Maximum accuracy 
    
 Symptomatic artery 160 97.9 62.2 91.1 
 Asymptomatic artery 190 87.7 91.8 90.7 
 
Optimal cost-effectiveness 
    
 Symptomatic artery 180 95.3 68.9 90.3 
 Asymptomatic artery 235 74.0 93.9 88.4 
 
Box 1. Optimal peak systolic velocity (PSV) thresholds (cm/s) based on cost-effectiveness 
criteria. 
 
 Optimal PSV threshold (cm/s) 
 70-99% stenosis 50-99% stenosis 
Symptomatic artery 220 180 
Asymptomatic artery 290 235 
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PSV threshold analysis 
In Tables 2 and 3 the results of the threshold analyses are presented for the diagnosis of a 70-
99% stenosis and a 50-99% stenosis respectively. For both indications for carotid 
endarterectomy, the recommended PSV thresholds are highly sensitive and less specific for the 
symptomatic as well as the asymptomatic arteries. 
If maximization of accuracy is used as criterion for the determination of the PSV threshold, 
then specificity becomes more important than sensitivity in asymptomatic arteries. The accuracy 
increased with 7 percentage points for diagnosing a 70-99% stenosis and with 11 percentage 
points for diagnosing a 50-99% stenosis in the asymptomatic arteries.  
Using cost-effectiveness criteria for the determination of the optimal PSV threshold resulted 
in a high sensitivity for the evaluation of the symptomatic arteries and a high specificity for the 
evaluation of the asymptomatic arteries. For the symptomatic arteries, the optimal threshold 
was a PSV of 220 cm/s for the diagnosis of a 70-99% stenosis and 180 cm/s for a 50-99% stenosis 
(Box 1). For the asymptomatic side, the optimal PSV thresholds were 290 cm/s and 235 cm/s for 
diagnosing a 70-99% and 50-99% stenosis respectively.  
 
 
Discussion 
 
This study shows that the estimated angiographic stenosis in asymptomatic carotid arteries 
is overestimated if criteria are used based on the PSV measurements of symptomatic arteries. 
For a given degree of angiographic stenosis the PSV measurements were consistently higher in 
asymptomatic arteries than in symptomatic arteries. As a result, we found that the optimal PSV 
threshold for identifying 70-99% or 50-99% angiographic stenosis varied between asymptomatic 
and symptomatic arteries. Specifically, the optimal PSV threshold in asymptomatic carotid 
arteries was higher than in symptomatic arteries. Similar observations were made by Fujitani et 
al. and AbuRahma et al. for the peak systolic frequency in arteries with contralateral severe 
stenosis or occlusions.14,15 The physiologic mechanism for this observation has been referred to 
as the compensatory flow phenomenon, which explains that flow would have to be increased in 
the artery with contralateral stenosis to maintain the same level of blood volume to the brain as 
before the stenosis emerged.16 Since this increased volume of blood must pass through a vessel 
with a relatively fixed cross sectional area, the velocity of the blood must increase. This has been 
illustrated in studies that evaluated changes in peak systolic velocity in arteries before and after 
contralateral carotid endarterectomy16-19 and carotid stenting.20 In these studies the PSV 
measured in the asymptomatic artery significantly decreased after contralateral endarterectomy 
or stenting, which often led to reclassification of stenosis in the asymptomatic artery. These 
findings suggested that when duplex ultrasonography is used as the sole imaging modality 
before carotid endarterectomy, patients with severe bilateral carotid stenosis must have an 
additional duplex examination before operation on the second side. Our study shows that over 
the whole range of angiographic stenosis there is a consistent difference in peak systolic velocity 
for symptomatic versus asymptomatic arteries and therefore suggests that separate PSV 
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thresholds should be used for the diagnosis of significant stenosis in symptomatic and 
asymptomatic arteries in patients with symptoms of amaurosis fugax, TIA, or minor stroke. 
 
There are several limitations of our study. First, we focused on the presence or absence of 
amarousis fugax, TIA, or minor stroke in the perfusion territory of the carotid artery to define 
whether the artery was symptomatic or not. We did not take into account the severity of disease 
or the presence of actual stenosis. Several studies have shown that the hemodynamic effect is 
more pronounced if the contralateral artery is severely stenosed or occluded.14,15,17 However, 
since we do not know the actual severity of the contralateral stenosis at the time of duplex 
ultrasonography we cannot reliably adjust with the actual percentage. Our results show that the 
presence of contralateral symptoms of amaurosis fugax, TIA, or stroke, has an equivalent effect 
on stenosis estimation to that described for the presence of contralateral stenosis. 
Second, we assumed that the angiographic thresholds for the symptomatic and 
asymptomatic arteries were the same, implying that the indication for carotid endarterectomy 
(70-99% stenosis or 50-99% stenosis) was the same for both arteries. Recently, the results of the 
Asymptomatic Carotid Surgery Trial (ACST) showed that immediate carotid endarterectomy in 
asymptomatic patients with a more than 70% stenosis on ultrasound, halved the 5-year stroke 
risk from 12% to about 6%.21 This study included 24% of patients with previous contralateral 
symptoms and carotid endarterectomy. The Asymptomatic Carotid Artery Study showed 
similar results in asymptomatic patients with a more than 60% stenosis, also including 20% of 
patients with previous symptoms and contralateral endarterectomy.22 The indication for carotid 
endarterectomy for 50-99% stenosis, however, has not been evaluated in asymptomatic arteries. 
Third, verification bias may have influenced our results. Verification bias may exist if 
patients are referred to the reference test based on the results of the test under investigation. 
Sensitivity may be inflated and specificity deflated if selection for the reference standard takes 
place. This may have been the case in our study for the symptomatic arteries: only patients with 
a clinical indication for carotid endarterectomy and a high PSV were included in the study. 
Indeed, we did see a high sensitivity and low specificity in the symptomatic arteries. By 
including both the symptomatic and the asymptomatic carotid artery of each patient in our 
analysis, representing the whole spectrum of arterial stenoses, we partially corrected for 
verification bias. We showed that sensitivity decreased and specificity increased, which is equal 
to the effect of mathematically correcting for verification bias based on the probability of 
verification.23 However, our results may not be applicable for patients without a clinical 
indication for carotid endarterectomy, because these patients were not included in this study.  
Finally, several studies have shown that different laboratories should establish their own 
thresholds24-26 and update them regularly.27 PSV measurements tend to differ due to differences 
in manufacturers or technologists. In our study we also observed that one hospital measured 
consistently higher PSV values than the other two hospitals. However, when corrected for type 
of hospital the difference between asymptomatic and symptomatic arteries remained significant. 
Therefore, our results show that if laboratories establish their own laboratory specific duplex 
criteria the side of carotid disease should be taken into account. 
 
The recently published recommendations by the Society of Radiologists in Ultrasound 
advocate the use of a threshold of 230 cm/sec for determination of a 70-99% stenosis and 125 
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cm/s for a 50-99% stenosis.10 Application of these criteria to our data resulted in a high 
sensitivity, a moderate specificity and good overall diagnostic accuracy. We used two criteria for 
selecting the optimal threshold for the peak systolic velocity: 1) maximization of diagnostic 
accuracy and 2) optimization of outcome in terms of cost-effectiveness. In the first case, the goal 
is to minimize the number of false-positive and false-negative results. This approach assumes 
that a false-negative result has the same importance as a false-positive result. The second 
approach takes into account that missing a diagnosis may be more (or less) harmful than further 
work-up in a patient without disease. Although many of the studies that define duplex 
thresholds use accuracy maximization as their goal, an approach that balances the clinical 
consequences of missed diagnoses and unnecessary endarterectomies is clinically more relevant 
than an approach that maximizes accuracy. Because the majority of asymptomatic arteries have 
a non-significant stenosis, a highly specific threshold is clinically more relevant for the 
asymptomatic arteries compared with the symptomatic arteries, for which a highly sensitive 
threshold is desirable.  
This study showed that accuracy and the area under the ROC curve are higher for 
asymptomatic than for symptomatic arteries. Furthermore, our results also demonstrated that 
duplex ultrasonography is more accurate in diagnosing 50-99% stenosis than in diagnosing 70-
99% stenosis. Both these findings can be explained by the smaller error range in PSV 
measurements in less severe stenosis. 
 
In conclusion, PSV measurements overestimate the degree of angiographic stenosis in the 
asymptomatic carotid artery in patients with symptoms of amaurosis fugax, TIA, or minor 
stroke. Therefore, separate PSV thresholds should be used for the evaluation of the symptomatic 
and asymptomatic carotid arteries by duplex ultrasound. Optimal PSV thresholds, based on 
cost-effectiveness criteria, for diagnosing a 70-99% stenosis are 220 cm/s for symptomatic arteries 
and 290 cm/s for asymptomatic arteries. For the diagnosis of a 50-99% stenosis optimal PSV 
thresholds are 180 cm/s for symptomatic and 235 cm/s for asymptomatic arteries.  
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Bias in diagnostic test evaluations 
 
The performance of a diagnostic test can be evaluated by comparing its results with a 
reference standard. Measures of sensitivity, specificity and accuracy can then be used as 
summary estimates of the test’s performance. There are several limitations and threats to the 
internal and external validity of a diagnostic test evaluation.1,2 Like any other type of research, 
flaws in patient selection, study conduct and data analysis can lead to biased results. First, 
selection bias, referral bias or spectrum bias may occur if patients are not included consecutively 
in the study. In this case, the selected patient group is not representative of the target group of 
the diagnostic test. Verification or work-up bias, which is in fact a form of referral bias, may 
exist if the test under evaluation influences the decision to perform the reference test and not all 
patients tested undergo the reference standard. Disease progression may bias performance 
parameters if the time lag between the diagnostic test and the reference test is too long. 
Excluding indeterminate test results and patients lost to follow-up may further cause 
overestimation of the test characteristics. Intra- and interobserver variation, awareness of the 
results of the diagnostic test when interpreting the reference standard or vice versa, and 
awareness of clinical characteristics may also influence test performance.  
As long as reporting of the diagnostic test evaluation is complete, one can judge the potential 
for bias and the generalizability of the test results reported. The quality of reporting diagnostic 
test evaluations, however, is commonly suboptimal. Comparing publications reporting 
diagnostic test evaluations requires, at the very least, a complete description of the test, its 
positivity criterion, and the reference standard. Often this critical information is lacking. 
Especially for the purpose of meta-analysis, reporting critical information on the design and 
conduct of diagnostic studies is essential, so that statistical adjustments can be made. 
The Standards for Reporting of Diagnostic Accuracy (STARD) working group has developed 
a checklist and flow diagram that may help accurate and complete reporting of diagnostic test 
evaluations. Recommendations from the STARD working group can be found on their website: 
www.consort-statement.org/stardstatement.htm 
  
Adjusting for verification bias 
 
In this issue an article (Miller et.al.) deals with an example of referral and verification bias 
concerning SPECT testing in patients suspected of coronary artery disease. In 10 years time, a 
large patient population from the Mayo clinic underwent stress SPECT testing (N=14273). Only 
13% of all patients tested with SPECT were referred for coronary angiography. Whereas 26% of 
patients with positive SPECT results underwent coronary angiography, only 1% of the normal 
SPECT results were followed by angiography. The implication is that negative test results are 
less frequently verified by the reference standard test and thus false-negative and true-negative 
results will be missed yielding high apparent sensitivity and low apparent specificity.   
The authors of the paper, however, recognized the potential verification bias in their 
estimates and they, justifiably, estimated test parameters adjusted for this bias. They used the 
correction method described by Begg and Greenes and Diamond’s correction method.1 The Begg 
and Greenes method can correct for both pre- and post-test referral bias, that is, it corrects for 
both the patient characteristics and the test result that together determine whether a patient will 
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be referred for the reference test. The Diamond method corrects only for post-test referral bias, 
that is, only the bias due to the influence the test result has on the decision to refer the patient for 
the reference test.  
Figure: Apparent and adjusted point estimates (Diamond and Begg methods) of the Miller-report 
superimposed on SROC curve of SPECT from a published meta-analysis. 
 
 
Another difference between the Begg and Diamond methods is that whereas the Begg 
method can be applied to all types of ROC curves, the Diamond method can only be applied to 
symmetrical ROC curves.  
Technically Miller et al. used a modified version of the Begg method: they calculated the 
post-test probability or predictive value of CAD conditional on clinical factors and test results 
among those patients that underwent coronary angiography. Then they assumed that the 
derived prediction equation would also apply among those who did not undergo coronary 
angiography. In essence the assumption is that the predictive values of the diagnostic test are 
the same for the verified and source populations, which is equivalent to assuming that disease 
status and verification by the reference test are conditionally independent.1 
 
Implications  
 
The effect of correcting for verification bias on the point estimates of test performance can 
best be shown using a published meta-analysis of SPECT studies.3 Although one can never fully 
adjust for bias in the source studies, it is possible to evaluate several types of bias in meta-
analyses. Presence of verification bias was not a significant predictor of test performance in the 
cited meta-analysis. We superimposed the apparent and the adjusted operating points that 
Miller et al. reported on the SROC curve from the meta-analysis of SPECT studies (Figure). The 
SROC curve presented here was adjusted for age to be representative of the patient population 
from the Miller report. Whereas the correction for verification bias has a large effect on the 
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apparent point estimates of test performance, as reported by Miller, the figure shows that the 
apparent and corrected operating points lie along the same SROC curve. This suggests that the 
overall diagnostic performance as represented by an (S)ROC curve is not necessarily affected by 
verification bias but that the operating point corresponding to a particular positivity criterion 
(threshold value) is. This, in turn, implies that when we choose a positivity criterion for a test we 
need to take into account verification bias in the estimated test performance. 
To determine the optimal positivity criterion (threshold value for calling a test score 
positive) we first need to determine the optimal operating point on the (S)ROC curve. The 
optimal operating point on the (S)ROC curve represents the best combination of sensitivity and 
specificity for a patient population in terms of effectiveness and cost. The optimal operating 
point is determined by the prior probability of disease, the benefit of correctly diagnosing the 
disease compared with it going undetected (true-positive compared with false-negative), and 
the losses associated with incorrectly labelling a subject diseased compared with not doing so 
(false-positive compared with true-negative). In other words, we need to adjust our operating 
point so that it is consistent with the trade-offs in risks and benefits.4 Taking verification bias 
into account implies another adjustment when translating the derived optimal operating point 
to the threshold test score to be used in practice. After considering the risks and benefits we 
may, for example, conclude that we want a true-positive rate of 0.80 with a corresponding false-
positive rate of 0.50. Since the reported scoring system corresponded with an adjusted 
sensitivity of 0.67 we would need to use a more lenient criterion to achieve a sensitivity of 0.80. 
For example, instead of only considering reversible perfusion defects and moderate fixed defects 
as a positive test result, one could also take into consideration mild fixed defects in order to 
diagnose any coronary artery disease. In general, verification bias overestimates apparent 
sensitivity if positive test results are verified preferentially, which implies that to achieve a 
particular sensitivity we would need to use a more lenient criterion than it would seem based on 
the verified sample only. In diagnosing CAD we could achieve this by adjusting the scoring 
system, or the threshold score, based on the SPECT images.  
In summary, given that sensitivity and specificity estimates depend on the conduct of the 
test, the setting, characteristics of the patients involved, and interpretation of test results 
obtained, we should strive for accurately reporting how the test was evaluated and how the data 
were analyzed, so that bias can be recognized, validity can be judged, and appropriate 
adjustments made. 
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Abstract 
 
Background: Several imaging tests are available for the diagnosis of coronary artery disease 
(CAD) in patients with chest pain. Uncertainty exists about which imaging test is best for a 
patient given age, gender, and type of chest pain. Future clinical research could reduce this 
uncertainty and is therefore expected to result in better patient outcomes. 
Objective: To guide future clinical research pertaining to the choice between imaging tests for 
CAD. 
Methods: Decision modeling and value of information analysis were applied to estimate the 
benefit of future clinical research, using currently available evidence from the literature. The 
outcomes of interest for the imaging tests were quality-adjusted life expectancy and costs from 
the health care perspective. The benefit of future research was expressed in quality-adjusted life 
days (QALD) gained per patient and annual quality-adjusted life years gained for the USA. 
Results: For patients with a pre-test probability of CAD below 18% it was best not to test; above 
83% it is best to perform an angiography; for probabilities between these values, computed 
tomographic angiography (CTA) was the best test for most patients, although considerable 
uncertainty remained. The total expected value of perfect information (EVPI) – a ceiling for the 
harm of uncertainty – ranged from 0 to 13 QALD per patient. The annual population EVPI for all 
uncertain parameters – a ceiling for the benefit of future research – was 2891 quality-adjusted 
life years (QALYs). The annual population EVPI for obtaining information on the utilities of 
chest pain states was 1598 QALYs. Treatment effects, costs, and test characteristics had smaller 
but substantial associated annual population EVPIs. 
Conclusion: The optimal imaging test for patients with chest pain is uncertain for most patients. 
Our results suggest that more clinical research to reduce this uncertainty is justified. Resolving 
uncertainty about utilities of chest pain states is most beneficial. 
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Introduction 
 
Coronary artery disease (CAD) is the leading cause of death in the United States. Each year 
half a million patients are newly diagnosed with CAD, of whom about half initially present with 
chest pain.1 It is important to identify patients with CAD, since they can benefit from a coronary 
artery bypass graft (CABG) or a percutaneous coronary intervention (PCI). To diagnose CAD in 
patients with chest pain, various diagnostic imaging tests are available. 
Coronary angiography can perfectly distinguish patients with CAD from patients without 
CAD due to the high spatial resolution. Moreover, angiography makes direct intervention 
possible. Unfortunately, angiography has considerable drawbacks: it has a risk of mortality and 
morbidity, and it is expensive. Noninvasive imaging tests are less expensive and have, at most, a 
minimal risk. Their test characteristics (e.g., sensitivity and specificity), however, are imperfect: 
they misclassify both patients with CAD and those without CAD. The initial risk and cost of 
angiography versus the harm and cost of misclassifying patients with chest pain is the main 
trade-off when choosing between these imaging tests.  
Exercise echocardiography and exercise single-photon-emission computed tomography are 
well established noninvasive tests for asymptomatic or minimally symptomatic stages of CAD. 
Computed tomographic angiography (CTA) is a more recent but promising test for the detection 
of CAD.2 Sensitivity of four-detector row CTA, however, has been considered too low for 
routine clinical practice.3 16-detector row CTA appears to have better test characteristics, 
although these results are based on small samples.4,5 
Given a patient’s age, gender, and type of chest pain, substantial uncertainty remains about 
which imaging test is optimal. Future quantitative clinical research will - to some extent - resolve 
this uncertainty. This could result in better decisions, benefitting patients with chest pain and/or 
save money. Various uncertain parameters are responsible for the decision uncertainty, such as: 
test characteristics, treatment effects, and cost of tests and treatments. With value of information 
analysis we can estimate the benefit of obtaining more information on an uncertain parameter in 
future clinical research.6 This benefit varies across parameters; a higher benefit implies that a 
parameter is more important. The objective of this study was to estimate the benefit of collecting 
information on subsets of uncertain parameters to guide future clinical research pertaining to 
the choice between imaging tests for CAD. 
 
 
Methods 
 
Decision model 
We synthesized the available evidence regarding the costs and effects of imaging tests for 
diagnosing CAD into a decision model from the health care system perspective.7,8 The model 
extrapolated the evidence on costs and effects over the entire remaining lifetime of patients. We 
compared four imaging tests for the diagnosis of CAD: coronary angiography, exercise 
echocardiography, exercise single-photon-emission computed tomography (SPECT), and 16-
detector row computed tomographic angiography (CTA). In a fifth strategy patients with chest 
pain were not tested and received medical therapy only. We considered patients with chest pain 
without a history of myocardial infarction. 
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If a noninvasive test result was positive or uninterpretable, an angiography followed. 
Patients with a positive angiography received a PCI for one or two vessel disease and a CABG 
for three vessel disease and left main disease. Both treatments had an associated disutility and a 
short-term risk of mortality and myocardial infarction. The beneficial effects of treatment were 
three-fold: reduction in long-term mortality, reduction in long-term myocardial infarction, and 
reduction of chest pain severity. Age/gender-specific life tables were used to model the 
subsequent lifetime outcomes with Markov simulation. During this subsequent lifetime three 
chest pain states were distinguished: no, mild, and severe chest pain. Moreover, each year 
patients could suffer a myocardial infarction or undergo a CABG or PCI, depending on the 
extent of the coronary artery disease and treatment history. We modeled the cost of tests and 
treatments, as well as the annual cost – depending on chest pain severity and left ventricular 
ejection fraction - for patients with CAD. 
The effects and costs of the imaging tests depend on patient characteristics. Patients differ 
with respect to the pre-test probability of having CAD, the short-term mortality from CABG, 
and the age/gender-specific annual mortality rates. We distinguished the same 30 subgroups as 
the CASS-registry, based on: gender, age (30-39, 40-49, 50-59, 60-69, and 70-79), and type of chest 
pain (typical, atypical, and non-specific).9 Table 2 of the results section presents subgroup-
specific pre-test probabilities of CAD and the proportion of all chest pain patients residing in 
each subgroup. 
The model outcome of each imaging test was quality-adjusted life expectancy (QALE) and 
expected lifetime costs. We transformed this two-dimensional outcome into one composite 
dimension: net health benefit.10 The net health benefit is the QALE minus the QALE equivalent 
of the costs, which is the costs divided by the societal willingness-to-pay. For example, if the 
QALE is 0.3 quality-adjusted life years (QALY), the costs are $5000 and the willingness-to-pay is 
$50000/QALY, then the net health benefit equals 0.3-5000/50000 = 0.2 QALY. Multiplying the net 
health benefit with the willingness-to-pay yields the net monetary benefit. We used a – generally 
accepted – willingness-to-pay of $50,000 per QALY gained. 
 
Data sources 
From the literature we derived for all uncertain parameters a mean value and a probability 
distribution representing the uncertainty. If this information was unavailable in the literature, it 
was estimated by experts. Table 1 lists for all uncertain parameters the mean values, a 95%-
confidence interval, and the source of the data. 
 
Probabilistic sensitivity analysis 
We performed probabilistic sensitivity analysis (PSA, or 2nd order Monte Carlo simulation) 
to assess the uncertainty about the optimal test for each subgroup.11 PSA propagates the 
uncertainty about the input parameters through the model, resulting in probability distributions 
for the model outcomes. These distributions reflect the uncertainty about the effects and costs of 
each test strategy (including not testing). We used these distributions to calculate the probability 
that given the currently available evidence we would make the wrong decision. 
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Table 1A: Model parameters – test characteristics and pre-test probability of CAD 
 
nr. parameter mean (%) 95% confidence limits source 
      
 angiography: short-term risks     
1 myocardial infaction if 0-VD 0.02 0.02 0.03 24 
2 myocardial infaction if 1-VD 0.06 0.05 0.07 24 
3 myocardial infaction if 2-VD 0.08 0.07 0.10 24 
4 myocardial infaction if 3-VD 0.08 0.07 0.09 24 
5 myocardial infaction if LMD 0.17 0.15 0.18 24 
6 die if 0-VD 0.02 0.01 0.02 25 
7 die if 1-VD 0.05 0.04 0.06 25 
8 die if 2-VD 0.07 0.06 0.08 25 
9 die if 3-VD 0.12 0.11 0.13 25 
10 die if LMD 0.55 0.52 0.58 25 
 computed tomographic angiography     
11 sensitivity 99 95 100 4 
12 specificity 88 59 100 4 
13 percentage uninterpretable 1.69 0.04 6.16 4 
14 percentage morbidity 0.05 0.04 0.06 expert opinion 
 exercise echocardiography     
15 sensitivity 85 83 87 26 
16 specificy 77 74 80 26 
17 percentage uninterpretable 5 0 10 27 
18 percentage morbidity 0.05 0.04 0.06 expert opinion 
19 percentage mortality  0.005 0.004 0.006 expert opinion 
 exercise SPECT     
20 sensitivity 87 86 88 26 
21 specificity 64 60 68 26 
22 percentage uninterpretable 2 0 4 expert opinion 
23 percentage morbidity 0.05 0.04 0.06 expert opinion 
24 percentage mortality  0.005 0.004 0.006 expert opinion 
25 pre-test probability of CAD given age,  
gender, and chest pain type 
   see appendix B 
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Table 1B: Model parameters – costs 
  
nr. parameter mean (US$) credible interval ‡ source 
      
 cost tests     
26 cost angiography 3186 2230 4141 Medicare (30% inpatient) 
27 cost CTA 705 494 917 Medicare 
28 cost echocardiography 241 169 313 Medicare 
29 cost SPECT 599 419 779 Medicare 
 cost treatments     
30 cost CABG 23052 16136 29968 Medicare 
31 cost PCI 11795 8257 15334 Medicare (70% stents) 
 cost events     
32 cost myocardial infarction 6690 4683 8697 Medicare 
 annual costs chest pain patient     
33 no, abnormal LVEF 3870 2709 5031 Medicare 
34 mild, abnormal LVEF 5689 3982 7395 Medicare 
35 mild, normal LVEF 1818 1272 2363 Medicare 
36 severe, abnormal LVEF 9148 6403 11892 Medicare 
37 severe, normal LVEF 4105 2874 5337 Medicare 
      
‡ For costs we assumed a ±30% credible interval on Medicare estimates and correlations of 1 between the cost 
parameters. 
 
 
Table 1C: Model parameters – utilities 
 
nr. parameter mean 95% confidence limits  source 
      
 utilities chest pain states     
38 no 0.87 0.80 0.92 28 
39 mild 0.81 0.76 0.86 28 
40 severe 0.67 0.56 0.77 28 
 disutilities (in days lost)     
41 CABG 30 24 36 expert opinion 
42 angiography 1 0.8 1.2 expert opinion 
43 myocardial infarction 10 8 12 expert opinion 
44 PCI 2.5 2 3 expert opinion 
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 Table 1D: Model parameters – medical treatment 
 
nr. parameter ‡ mean 95% confidence limits source 
      
 effects medical treatment only     
45 risk myocardial infarction with 0-VD 1.0 0.7 1.5 29 
46 risk myocardial infarction with 1/2-VD 2.1 1.5 2.9 29 
47 risk myocardial infarction with 3-VD / LMD 2.7 2.1 3.5 29 
48 relative risk die with 1/2-VD * 2.3 1.9 2.8 30 
49 relative risk die with 3-VD * 3.6 3.1 4.1 30 
50 relative risk die with LMD * 9.6 6.2 14.3 30 
51 % for annual transitions between chest pain states 
after medical treatment    
see appendix A 
52 risk future procedure 0-VD 0.5 0.2 1.0 31 
53 risk future procedure 1-VD 1.0 0.5 1.7 31 
54 risk future procedure 2-VD 4.2 3.0 5.5 31 
55 risk future procedure 3-VD/LMD 7.5 6.0 9.2 31 
56 % CABG of future procedures 0/1-VD 16 13.8 18.3 31 
57 % CABG of future procedures 2-VD 58 55 61 31 
58 % CABG of future procedures 3-VD/LMD 87 85 89 31 
 LVEF (treatment independent)     
59 risk abnormal LVEF with 0-VD 0.5 0.4 0.7 29 
60 risk abnormal LVEF with 1-VD 2.0 1.7 2.3 29 
61 risk abnormal LVEF with 2-VD 5.0 4.5 5.5 29 
62 risk abnormal LVEF with 3-VD 6.0 5.5 6.5 29 
63 risk abnormal LVEF with LMD 6.0 5.5 6.5 29 
      
 
‡ All risks – except relative risks – are annual risks and expressed in %.  
* Relative risks of dying are in comparison to life table mortality. 
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Table 1E: Model parameters – PCI 
 
nr. parameter ‡ mean 95% confidence limits source 
      
 short-term risks with PCI     
64 myocardial infarction if 1-VD 3.5 2.7 4.4 32 
65 myocardial infarction if 2-VD 5.2 4.3 6.2 32 
66 die if 1-VD 0.2 0.1 0.5 33, 34 
67 die if 2-VD 0.9 0.5 1.4 33, 34 
 effects PCI     
68 reduction in myocardial infarction 17 12 22 35 
69 reduction in mortality if 1/2-VD 15 0 50 31 
70 % for annual transitions between chest pain 
states after PCI    
see appendix A 
71 relative risk chest pain improvement of PCI vs. 
CABG 0.85 0.80 0.90 
31 
72 relative risk of reprocedure for stent vs. PTCA 0.5 0.2 0.8 36 
73 % eligible for PCI 76 61 91 36 
74 annual risk of reprocedure after PCI 4 2 5 31 
75 % CABG of reprocedures 22 19 25 31 
      
 
‡ All values are expressed in %, except the relative risks. 
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Table 1F: Model parameters – CABG 
 
 
nr. parameter ‡ mean 95% confidence 
limits 
source 
      
 short-term risks CABG     
76 myocardial infarction if 3-VD 7.0 5.9 8.2 32 
77 myocardial infarction if LMD 7.0 5.9 8.2 32 
78 die if 35yr male 2.3 0.2 6.6 37 
79 die if 35yr female 2.9 0.1 10.9 37 
80 die if 45yr male 2.7 1.6 4.2 37 
81 die if 45yr female 3.5 1.6 6.1 37 
82 die if 55yr male 3.2 2.3 4.2 37 
83 die if 55yr female 4.1 2.6 5.8 37 
84 die if 65yr male 4.4 3.5 5.4 37 
85 die if 65yr female 5.7 4.1 7.5 37 
86 die if 75yr male 6.3 5.1 7.6 37 
87 die if 75yr female 8.0 6.0 10.3 37 
 effects CABG     
88 reduction in myocardial infarction 42 29 55 29 
89 reduction in mortality if 3-VD 48 29 64 30 
90 reduction in mortality if LMD 67 40 84 30 
91 % from mild to no angina 60 55 65 29 
92 % from severe to mild angina 70 65 75 29 
93 % from severe to no angina 10 7 13 29 
94 % for annual transitions between chest pain 
states after CABG 
   see appendix A 
95 annual risk of reprocedure after CABG 2 1 3 31 
96 % CABG of reprocedures 7 5 9 31 
      
 
‡ All values are expressed in %. 
VD, vessel disease; LMD, left main disease; SPECT, single-photon emission computed tomography; CAD, coronary 
artery disease; LVEF, left ventricular ejection fraction; CTA, computed tomographic angiography; CABG, coronary 
artery bypass grafting; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary 
angioplasty 
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Value of information analysis 
A substantial probability of making the wrong decision is not necessarily important if the 
difference between the outcomes of competing strategies is negligible. Estimation of the 
expected value of perfect information (EVPI) acknowledges this by considering both the 
probability and the consequences of making the wrong decision.12, 13 The EVPI is a measure for 
the importance of uncertainty to individual patients. The higher the EVPI, the more important 
the uncertainty is. The EVPI – or value of information (VOI) in general – is expressed in the same 
unit as the model outcome (e.g., QALY, life years, or $). An EVPI of 0.1 QALY means that if we 
would perform an infinitely large study to eliminate all uncertainty (that is, obtain perfect 
information), we can expect an increase in QALE of 0.1 QALY per patient. Because an infinitely 
large study is hypothetical, the EVPI is a ceiling value for the expected benefit of future 
research.13 
The population EVPI is the EVPI multiplied with the number of patients that can benefit 
from future clinical research.13 It is a measure for the importance of uncertainty to society from a 
utilitarian perspective. Population EVPI is expressed in the same unit as the model outcome: we 
used QALY and dollars. Expressing population EVPI in dollars enables comparison with 
research costs: it is the maximum amount that we should spend on future research to decrease 
current uncertainty. If the population EVPI does not exceed the estimated cost of future 
research, more research is not justified. We assumed that the annual population that could 
benefit from future clinical research on imaging tests for CAD would be 500,000 for the US.1 
Because the value of information differs across the subgroups, we calculated the population 
EVPI as a weighted sum of these subgroups. 
The partial expected value of perfect information (partial EVPI) is the EVPI of one or more 
uncertain parameters. The parameters with the highest partial EVPI yield the highest benefit if 
more information is collected on them and are therefore the most important parameters to 
measure in future studies. For six subsets of parameters we estimated the partial EVPI. Table 1 
presents these subsets as sub-tables A to F. Subset A includes the test characteristics of all 
imaging tests and the pre-test probability of CAD given age, gender, and type of chest pain. The 
cost parameters are grouped in subset B. The utilities of chest pain states and the disutilities of 
tests and events are in subset C. Parameters for the effects from medical treatment and the risk 
of an abnormal left ventricular ejection fraction reside in subset D. Subsets E and F represent 
parameters for the short-term risks and the effects of PCI and CABG, respectively. 
We estimated the (partial) expected value of perfect information of these subsets of 
parameters using many (1000 or more) “what if”-simulations. For each “what if”-simulation a 
value for each uncertain parameter of interest was randomly drawn from its distribution. Each 
resulting set of parameter values had a probability of being the “true” set of parameter values. 
For these values we then identified the optimal strategy and the loss in cost and/or effect if this 
strategy was better than the optimal strategy based on current evidence. The expected value of 
perfect information was determined by calculating the mean (=expected) loss in cost and/or 
effect. The algorithms to perform VOI analyses were recently described in detail.14,15 
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Results 
 
The best imaging test 
The model outcomes for the five strategies were compared for each subgroup, resulting in 
the subgroup-specific best strategies (Table 2). Exercise echocardiography and exercise SPECT 
were never the optimal test. For patients with a pre-test probability of CAD below 18% it was 
best not to test. Above a pre-test probability of CAD of 83%, angiography was always the 
optimal strategy. For pre-test probabilities between these values, CTA was often, but not always, 
the best test. Subgroups with similar pre-test probabilities could have different optimal tests. 
 
Uncertainty about the best test 
Probabilistic sensitivity analysis showed how certain we are that the test identified as best, 
really is the best test. In table 2 the uncertainty is presented as the probability that the best test 
truly is the best test. For most subgroups this probability was well below 95%. For subgroups 
where CTA was the best test, this probability never exceeded 76%. Figure 1 shows the 95% 
credible interval of the net health benefit of each strategy for the 6 largest subgroups. Because 
the outcomes of the different strategies are correlated, the probability that a strategy is optimal 
can be close to 100% regardless of overlapping intervals. Figure 1 also illustrates that the 
difference between the best test and the second best test tends to be only a few quality-adjusted 
life days. The benefit of testing compared with “not testing”, however, is for some subgroups as 
high as 4 quality-adjusted life months. 
 
Importance of uncertainty: total and population EVPI 
The total EVPI per patient - a measure of the importance of uncertainty for individual 
patients - differed considerably across subgroups (Table 2). If the probability of the best test 
being truly best exceeded 95%, the total EVPI was zero or very small. For lower probabilities, the 
total EVPI ranged from 2 to 13 quality-adjusted life days. The probability of the best test being 
truly best was not a good measure of the total EVPI per patient. For example, for a probability of 
the best test being truly best of 60-65%, the total EVPI per patient ranged from 2 to 13 quality-
adjusted life days. 
The annual population EVPI – a measure of the importance of uncertainty for society - was 
especially high for large subgroups with considerable uncertainty about the best test, for 
example, 40-49 yr men with typical or atypical chest pain. The population EVPI for all patients 
with chest pain was 2891 QALYs per year, which is equivalent to $145 million per year. 
 
Benefit of assessing subsets of parameters 
Figure 2 presents the population partial EVPI of the six subsets of parameters (A to F) 
corresponding to the subtables of Table 1. Subset C, representing the utilities of chest pain states 
and the disutilities of tests and events, was associated with the highest population partial EVPI. 
The population partial EVPI for test characteristics, costs, and treatment effects were similar. 
Only subset D – parameters related to medical treatment – had a much smaller population 
partial EVPI. 
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Table 2: Optimal test for each subgroup 
 
age-group angina type % of total ‡ % CAD § best test % best * EVPI/pat 
(QALD) ¶ 
popEVPI 
(QALY)† 
MEN        
30-39 nonspec 3 3 NO TEST 100 0 0 
40-49 nonspec 5 12 NO TEST 93 0 12 
50-59 nonspec 5 18 CTA 50 3 221 
60-69 nonspec 2 27 CTA 63 2 52 
70-79 nonspec 0 63 CTA 61 2 8 
        
30-39 atypical 2 46 NO TEST 78 2 67 
40-49 atypical 7 57 CTA 49 7 725 
50-59 atypical 11 71 CTA 56 2 296 
60-69 atypical 5 78 ANGIO 89 2 132 
70-79 atypical 1 94 ANGIO 99 0 1 
        
30-39 typical 1 83 NO TEST 64 11 124 
40-49 typical 5 88 ANGIO 77 5 353 
50-59 typical 10 95 ANGIO 97 1 109 
60-69 typical 7 95 ANGIO 100 0 0 
70-79 typical 1 97 ANGIO 100 0 1 
WOMEN        
30-39 nonspec 2 4 NO TEST 99 0 1 
40-49 nonspec 5 4 NO TEST 100 0 0 
50-59 nonspec 7 6 NO TEST 98 0 4 
60-69 nonspec 3 10 NO TEST 61 2 71 
70-79 nonspec 0 0 NO TEST 100 0 0 
        
30-39 atypical 0 20 NO TEST 76 2 16 
40-49 atypical 3 31 NO TEST 62 4 178 
50-59 atypical 5 30 CTA 55 4 249 
60-69 atypical 3 48 CTA 76 2 95 
70-79 atypical 0 56 CTA 76 2 12 
        
30-39 typical 0 70 NO TEST 64 13 22 
40-49 typical 1 56 NO TEST 77 3 39 
50-59 typical 2 68 CTA 63 3 78 
60-69 typical 2 81 ANGIO 91 1 22 
70-79 typical 0 96 ANGIO 94 2 6 
 
‡ % of all chest pain patients in each subgroup. 
§ Pre-test probability of CAD given age, gender, and angina type for patients with chest pain. 
* Probability that the optimal test given available evidence is the “true” best test. 
¶ Total EVPI per patient in quality-adjusted life days. 
† Population EVPI in quality-adjusted life years per year for the USA. 
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men, 50-59 yr, atypical
NO_TEST
ANGIO
CTA
EXSP
EXEC
95% CI
12.412.312.212.1
men, 50-59 yr, typica l
NO_TEST
ANGIO
CTA
EXSP
EXEC
95% CI
11.010.910.810.710.6
 
 
w omen, 50-59 yr, non-specific
NO_TEST
ANGIO
CTA
EXSP
EXEC
95% CI
15.6015.5015.40
men, 40-49 yr, atyp ical
NO_TEST
ANGIO
CTA
EXSP
EXEC
95% CI
15.7015.6015.50
 
 
men, 60-69 yr, typical
NO_TEST
ANGIO
CTA
EXSP
EXEC
95% CI
7.97.87.77.67.57.47.3
men, 50-59 age , non-spec
NO_TEST
ANGIO
CTA
EXSP
EXEC
95% CI
14.5014.4014.30
 
 
 
Figure 1: Credible intervals (95%) for the net health benefit of all strategies for the six  
largest subgroups 
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Figure 2: Population EVPI in QALYs per year of the subsets of parameters of Table 1 
 
 
Discussion 
 
We used a decision model and value of information analysis to assess the uncertainty, and 
the importance of uncertainty, pertaining to the choice between imaging tests to diagnose 
coronary artery disease for 30 patient subgroups. In addition, we explicitly estimated the 
expected benefit of resolving uncertainty of subsets of uncertain parameters.  
For most subgroups the decision is uncertain: the probability that with current evidence we 
would choose the “true” best strategy was below 95%. For the subgroups where CTA was the 
best test, this probability did not exceed 76%. This uncertainty, however, is in itself not 
worrisome if the harm of choosing a suboptimal test is negligible. Value of information analysis 
showed that for many subgroups the expected harm of uncertainty was substantial, ranging 
from 0 to 13 quality-adjusted life days per patient. These may seem small losses but they are in 
the same range as, for example, the benefits of breast cancer or colon cancer screening 
programs.16 The importance of uncertainty for individual patients was highest for men and 
women, aged 30-39 years, with typical chest pain and men, aged 40-49 years, with atypical or 
typical chest pain. The probability of choosing the “true” best test was not a good measure for 
the importance of uncertainty: for similar probabilities of choosing the “true” best test EVPIs 
differed up to 6-fold. 
The annual population EVPI was 2891 QALYs for the US, which is equivalent to $145 
million. Uncertainty of the utilities of the chest pain states (no, moderate, severe) and the 
disutilities of tests and events was most important. Although a study with a finite sample size 
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will result in a smaller benefit than estimated for perfect information, obtaining better estimates 
of the utilities seems the best allocation of research funds. The importance of the utilities can be 
explained by the considerable uncertainty in the literature about their values and covariance 
structure, in combination with their impact on false-negative test results. 
Obtaining better estimates of test characteristics, costs, and treatment effects was associated 
with similar population partial EVPIs. The research cost for these subsets of parameters, 
however, may differ considerably.  Most of these parameters could be assessed in observational 
studies, though some of the treatment effects need to be addressed in randomized controlled 
trials. In further analyses we will compare the benefit of various study designs. 
Our analyses have some limitations that are inherent to value of information analyses. The 
medical literature generally contains little evidence regarding correlations between input 
parameters for a decision model. Due to this lack of information, correlations are generally 
ignored (i.e., implicitly set to zero). Alternatively, prefect correlations can be assumed, as we did 
for the cost parameters. Unfortunately, the value of information is very sensitive to correlations. 
In addition, uncertainty about the structure of the decision model is a generally ignored source 
of uncertainty that could influence the value of information. Uncertainty about the number of 
future patients that could benefit from future clinical research is another important issue. It is 
not clear whether we should consider all patients world-wide, limit the analysis to one country, 
or limit it to a particular local setting. Moreover, the number of years during which patients are 
expected to benefit from future clinical research is uncertain. These problems, however, are not 
drawbacks of value of information analysis, but are inherent to the underlying decision problem 
of how to allocate our limited resources for clinical research wisely.  
The well-known alternative to value of information analysis is to apply the arbitrary cut-off 
for the p-value (0.05) – or its Bayesian analogue: the probability of optimality – to decide 
whether more research is justified. P-values below 0.05 are often considered as sufficient proof 
for superiority of a health care intervention and p-values above 0.05 as justification to embark on 
a future, often larger and more expensive, study. The p-value, however, only tells us how 
certain we are that two interventions differ in outcome. The medical importance of the 
uncertainty depends on both the probability and the consequences of not choosing the “true” 
best imaging test given current available evidence. A substantial probability that the best 
strategy is not really the best is of little importance if the difference between these strategies is 
infinitesimal. On the other hand, a small probability could be of great concern, if being wrong 
has huge consequences. 
Value of information analysis is a method from decision theory that was described several 
decades ago12,17,18 and is now increasingly applied to decisions in health care and medicine.19-22 It 
considers research as an investment and estimates the expected return on investment. 
Analogous to requiring that health care interventions are cost-effective, value of information 
analysis requires that clinical research is cost-effective. This idea is not new in the medical 
literature: Detsky used a method to estimate the benefit of clinical trials, to enable comparison 
with the cost of these trials.23 His method, however, was applied after the trials were carried out 
and used an arbitrary cut-off for the p-value as well as for the minimum clinically important 
difference. 
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In conclusion, for most subgroups of patients considerable uncertainty exists about the 
optimal imaging test to diagnose coronary artery disease. The expected harm of this uncertainty 
ranged from 0 to 13 quality-adjusted life days per patient, depending on age, gender, and type 
of chest pain. Future clinical research could reduce this uncertainty to some extent. An 
observational study yielding more precise estimates of the quality-of-life weights for varying 
severity of chest pain seems most beneficial. In addition, patients could benefit from more 
precise estimates of test characteristics, costs, and treatment effects. In further analyses we will 
compare the benefit of various study designs. Value of information analysis seems a practical 
method to prioritize and guide future clinical research using available evidence. 
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Appendix A 
 
Dirichlet distributions were used to represent uncertainty about the annual transition probabilities between 
chest pain severity states. These transitions depend on the extent of vessel disease and the treatment. 
The parameters of the dirichlet distributions are the number of patients that transit to each health state. 
For example, for patients with 1 vessel disease, medical treatment, and no chest pain, 26 out of 164 
patients had mild chest pain at the end of the year. These numbers were derived and extrapolated from 
the CASS-registry.9,29 
 
 
 sample size none mild severe 
   
Medical treatment, 1-VD   
none 164 136 26 2 
mild 309 46 244 19 
severe 20 5 7 8 
     
CABG/PCI, 1-VD    
none 263 226 34 3 
mild 188 43 134 11 
severe 18 5 6 7 
     
Medical treatment, 2-VD   
none 193 154 37 2 
mild 449 49 359 40 
severe 42 8 10 23 
     
CABG/PCI, 2-VD    
none 428 376 47 4 
mild 262 34 225 3 
severe 14 3 4 8 
     
Medical treatment, 3-VD/LMD   
none 202 135 65 2 
mild 360 86 259 14 
severe 31 3 3 25 
     
CABG/PCI, 3-VD/LMD    
none 316 262 51 3 
mild 208 31 164 12 
severe 15 4 5 6 
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Appendix B 
 
Dirichlet distributions representing uncertainty about pre-test probability of CAD were based on 
observational study results.9 The probabilities depend on gender, age, and type of chest pain. For 
example, 249 men with non-specific chest pain were observed of whom 5 had one vessel disease. 
 
subgroup sample size 0-VD 1-VD 2-VD 3-VD LMD 
NON-SPECIFIC       
Men       
30-39 249 242 5 0 2 0 
40-49 391 344 35 8 4 0 
50-59 440 361 48 18 4 9 
60-69 129 94 15 12 6 1 
>70 22 8 2 7 5 0 
Women       
30-39 135 130 3 1 0 1 
40-49 425 408 13 4 0 0 
50-59 585 550 23 12 0 0 
60-69 215 194 15 2 2 2 
>70 23 23 0 0 0 0 
ATYPICAL       
Men       
30-39 171 92 32 31 12 3 
40-49 568 244 131 80 85 28 
50-59 919 267 221 221 147 64 
60-69 434 95 91 104 100 43 
>70 46 3 10 11 15 7 
Women       
30-39 39 31 4 2 0 2 
40-49 257 177 46 18 5 10 
50-59 414 290 54 37 25 8 
60-69 264 137 58 34 24 11 
>70 34 15 5 5 8 1 
TYPICAL       
Men       
30-39 66 11 25 15 10 5 
40-49 402 48 109 105 96 44 
50-59 840 42 168 244 269 118 
60-69 539 27 86 129 199 97 
>70 67 2 6 10 33 16 
Women       
30-39 10 3 1 3 2 1 
40-49 70 31 15 12 12 0 
50-59 161 52 35 31 31 13 
60-69 137 26 19 34 44 14 
>70 23 1 5 2 13 2 
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Discussion 
 
In this thesis various methods of diagnostic test evaluations have been described and 
applied to specific clinical problems. Each of these methods has its advantages and 
disadvantages that should be understood in order to correctly interpret the available evidence 
and to select the best methodology for a specific research question. Furthermore, the diagnostic 
performance of various tests has been evaluated for the diagnosis of coronary, carotid, 
peripheral, and renal artery disease. Each of these tests also has its merits and limitations, which 
should be taken into account in order to choose the best test for a specific clinical problem. In 
this chapter the methodology and the results of the diagnostic test evaluations will be discussed. 
 
Methods of diagnostic test evaluations 
 
The methods applied in this thesis for the assessment of diagnostic imaging technology 
include systematic reviews, cost-effectiveness analyses, optimization of test characteristics, 
optimization of cut-off values of a test, correction for verification bias, and value of information 
analysis.  
Systematic reviews were used to summarize the available evidence. The aim of a systematic 
review is to collect all available evidence and by integrating the results of independent studies 
that on their own may have contradictory or non-significant results to increase power so that an 
overall conclusion can be made1. In- and exclusion criteria are used to select relevant articles 
from the published literature. An advantage of a systematic review is that in principal all 
available evidence from multiple studies on a specific subject is taken into account. A 
disadvantage is that studies may be excluded from a systematic review because data are missing 
or the quality of reporting of the study was insufficient2. Studies may also have been missed, 
because the search criteria may not have detected them. Furthermore, in systematic reviews 
publication bias may play a role, which implies that studies with positive results are more likely 
to be published than studies with negative or non-significant results, which could result in 
overestimation of the diagnostic performance of a test3. However, statistical methods exist to 
correct for potential publication bias.  
We evaluated the potential influence of publication bias by including the year of publication 
in the regression analyses. This method gives information about potential trends over time in 
published estimates of diagnostic performance of a test, but cannot detect whether studies with 
negative results are missing in the literature. Other recently developed methods, which we did 
not perform in this thesis, include the trim and fill method 4. We did evaluate a correction 
method for verification bias, which is often present in the evaluation of point estimates of 
diagnostic performance5. In our systematic reviews, however, we used a summary receiver 
operating characteristic (SROC) analysis to integrate the estimates of sensitivity and specificity 
of individual studies. We showed that the point estimates of sensitivity and specificity may shift 
along the SROC curve as a result of verification bias. In our SROC analyses we also accounted 
for the heterogeneity among study settings by using a random effects model, in contrast to a 
fixed effects model6. The inverse of the variance of the diagnostic odds ratio was used as 
weighting factor giving more weight to studies with more precise estimates in the regression 
analysis. The random effects meta-analytical model differs from the mainly used fixed effects 
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model in that apart from the individual study variances it also takes into account the between-
study variance6. 
An advantage of SROC analysis over independent pooling of sensitivity and specificity 
estimates is that the inverse relationship between sensitivity and specificity is taken into account 
associated with differences in cut-off values of the test and the potential influence of multiple 
study characteristics on diagnostic performance can be determined. A limitation of SROC 
analysis is that it can only use one pair of estimates of sensitivity and specificity from each 
study. Furthermore, if SROC curves of two or more tests cross, it is still unclear which test has 
the best diagnostic performance and which test should be used in a specific clinical setting. In 
particular, it does not provide information on the consequences of the test in terms of cost and 
effectiveness and the applicability of the test in clinical practice. Therefore, a cost-effectiveness 
analysis is essential to define the clinical role of a diagnostic test.  
The cost-effectiveness analyses in this thesis were based on decision-analytical models. The 
advantage of modelling studies is that many alternative test strategies can be compared, which 
cannot be realized in a clinical study for ethical and logistical reasons. A disadvantage of a cost-
effectiveness analysis is that input variables come from multiple sources and assumptions have 
to be made to keep the model tractable. Furthermore, the differences in cost and consequences 
associated with diagnostic test results may be too small to detect when studied using a lifetime 
time horizon and a societal perspective. Therefore, uncertainty about the best test strategy for a 
clinical setting may remain. However, a cost-effectiveness analysis provides more opportunities 
to explore the diagnostic performance of a test.  
As we have shown in our analyses the outcomes of a cost-effectiveness analysis in 
combination with a SROC analysis can be used for the optimization of test characteristics and 
cut-off values of a test in different clinical settings. By maximizing the net health benefit of a test, 
a measure that integrates both costs and effectiveness, for each combination of sensitivity and 
specificity along the SROC curve the optimal test characteristics can be determined7. For this 
optimal operating point on the SROC curve there is an optimal balance between the trade-offs of 
cost and effectiveness associated with true-positive and false-negative test results in diseased 
patients and with true-negative and false-positive test results in non-diseased subjects. This 
method is therefore more clinically relevant than the various methods used in the literature in 
which the accuracy of a test is maximized. In the latter case the total number of false test results 
is minimized, which implies that the consequences of a false-positive test result are assumed 
equal to the consequences of a false-negative test. In clinical practice, however, the consequences 
of missing a diagnosis may be far more harmful than referring a patient for treatment of a non-
significant stenosis or vice versa.  
In addition, we have shown how the optimal operating point on the ROC curve of a single 
study can be translated into the optimal cut-off value of a test, using the optimal likelihood ratio 
of the test. The likelihood ratio of a test, which is related to a certain cut-off value, is equal to the 
slope of the ROC curve. Using this method based on cost and effectiveness outcomes, we found 
different optimal cut-off values of the peak systolic velocity on duplex ultrasonography for the 
indication carotid endarterectomy than those recommended in the literature, which were again 
based on optimizing accuracy8.   
Methods from cost-effectiveness analysis can also be applied to explore the uncertainty of 
the test variables, namely using probabilistic sensitivity analysis and value of information 
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analysis9. These methods help guide future research by identifying those variables that should 
be evaluated in a future study. In probabilistic sensitivity analysis a cost-effectiveness analysis is 
repeated at least 1000 times, each time drawing the parameter values randomly from probability 
distributions representing the uncertainty that surrounds each point estimate in the model. In 
contrast to point estimates of cost and effectiveness, this analysis will result in probability 
distributions for the model outcomes, which reflect the uncertainty about the costs and effects of 
a test strategy. We then used these distributions in a value of information analysis in which we 
calculated the probability that, given the currently available evidence, we would make the 
wrong decision. The larger this probability, the higher the uncertainty and the more we would 
be prepared to pay to collect more information in a future study. A future study is justified as 
long as its expected value does not exceed the research cost. Again, basing decisions on the 
trade-offs between the benefits and harms associated with diagnostic testing is more clinically 
relevant than calculating an arbitrary p-value for decision making in health care. 
 
In general, all methods used in this thesis provide complementary information on the 
performance of diagnostic tests. The choice of which methodology to use depends on the 
research question. If the question is to find out which test is best in terms of test accuracy, i.e. 
prevention of missing diagnoses and unnecessary treatments, a systematic review including 
SROC analysis should be performed. If the results are inconclusive or if a clinician wants to 
know which test should be used in a specific clinical setting a cost-effectiveness analysis should 
follow the SROC analysis. If the question is how to make optimal use of a new test than the test 
characteristics and cut-off values of the test should be optimized for the patient population that 
will undergo the new test. Finally, if a new clinical study is planned the results of a cost-
effectiveness analysis should be evaluated using value of information analysis to determine the 
optimal study design. 
 
 
Comparison of diagnostic tests for cardiovascular disease and future research 
 
Coronary artery disease 
In this thesis various diagnostic imaging tests were evaluated for the diagnosis of coronary 
artery disease. In a systematic review of meta-analyses, we found little differences between 
stress echocardiography, stress SPECT, and EBCT, in the relative diagnostic odds ratios. If 
differences in diagnostic performance are inconclusive a cost-effectiveness analysis is crucial to 
find out the clinical role of each of the tests. Therefore, we evaluated the same tests using a cost-
effectiveness analysis. We found that exercise SPECT was dominated by other test strategies and 
that the role of EBCT in clinical practice was very small in comparison with exercise 
echocardiography.  
We also evaluated the clinical role of pharmacological stress in combination with either 
echocardiography or SPECT. The results suggested that dipyridamole and dobutamine 
echocardiography were cost-effective tests in patients with atypical chest pain at intermediate 
risk of coronary artery disease. Adenosine SPECT was also cost-effective, but at a higher pre-test 
risk and at a higher willingness-to-pay threshold. In both cost-effectiveness analyses, the no 
imaging strategy was optimal for patients with non-specific chest pain, who are at low risk of 
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coronary artery disease. Both analyses also showed that coronary angiography, the reference 
test, was the optimal test strategy in patients with typical angina, who are at high risk of 
coronary artery disease.  
Several studies have shown that EBCT is a very sensitive test, but not very specific, which 
may explain why EBCT was not very cost-effective for diagnostic purposes10, 11. Therefore, we 
evaluated whether the test characteristics of EBCT could be optimized for several cohorts of 
patients defined by age, sex, and type of chest pain. The results of this study suggested that 
using optimal test characteristics for specific patient populations did improve the net health 
benefit that can be obtained with EBCT. In our study, however, this did not lead to a greater role 
for EBCT in patients with chest pain for the diagnosis of coronary artery disease.  
Another CT technology that is currently being investigated is multi-detector (MD-) 
computed tomographic angiography (CTA) adapted for imaging the coronary arteries12. In 
addition, contrast-enhanced magnetic resonance angiography (MRA) is currently being 
investigated for the diagnosis of coronary artery disease13. Preliminary results show that both 
MD-CTA and contrast-enhanced MRA are promising techniques13, 14. Using value of information 
analysis, we studied which test variables of MD-CTA are worth the research cost for evaluation 
in a future study and what study design should be used. We found that we should learn more 
about the test characteristics of MD-CTA and about the quality of life of patients with several 
types of chest pain. 
 
Overall, our results suggest that, although differences in test accuracy were non-significant, 
exercise and pharmacological stress echocardiography showed a better diagnostic performance 
than exercise and pharmacological SPECT and EBCT for the diagnosis of coronary artery disease 
in patients with atypical chest pain, if evaluated from a health care perspective. Furthermore, 
future research should concentrate on new techniques like MD-CTA and contrast-enhanced 
MRA for the diagnosis of coronary artery disease. Finally, value of information analysis is a 
useful tool to guide the design of future studies and should be used to allocate research funding 
efficiently. 
 
Peripheral, Renal, and Carotid artery disease 
In a systematic review using SROC analysis we compared duplex ultasonography, 
computed tomographic angiography (CTA) and (contrast-enhanced) magnetic resonance 
angiography (MRA). This study showed a significantly better diagnostic performance with CTA 
and contrast-enhanced MRA compared with non-enhanced MRA and duplex ultrasonography. 
Furthermore, we found that imaging tests perform significantly better in the diagnosis of 
peripheral arterial disease than in renal or carotid artery disease. The number of subdivisions of 
the arterial tree into arterial segments significantly influenced the diagnostic performance. 
Therefore, we advocate standardization of the subdivision of the arterial tree for the purpose of 
diagnostic test evaluations in cardiovascular disease. A limitation of this study was that the 
number of CTA-studies was small and only available for renal artery disease. However, if test 
accuracy is used as criterion to select the best available test this study suggests that CTA and 
contrast-enhanced MRA should be used in clinical practice. Furthermore, the technological 
developments of imaging tests should concentrate on renal and carotid artery disease, because 
these areas could benefit the most from further improvements.    
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Because imaging time on CT and MR equipment is often limited and especially in the case of 
MR expensive, it may still be relevant to study the diagnostic performance of duplex 
ultrasonography for selected indications. In a recently published cost-effectiveness analysis, for 
example, a test strategy using duplex ultrasonography as sole imaging test to select patients for 
carotid endarterectomy was the most cost-effective strategy in patients with symptoms of 
amaurosis fugax, transient ischemic attack, or minor stroke15. We showed that the outcomes of 
the cost-effectiveness analysis in combination with a ROC curve from a clinical trial comparing 
duplex ultrasonography with coronary angiography can be used to define optimal test 
characteristics and optimal cut-off values of duplex ultrasonography. The point on the ROC 
curve where the net health benefit reached its maximum was defined as the optimal operating 
point on the ROC curve. This method accounts for the trade-offs in benefits and harms 
associated with diagnostic testing as opposed to methods that use maximization of accuracy7. 
Using this method, the optimal cut-off values that we found for the indication carotid 
endarterectomy for a more than 70% or 50% stenosis were higher than the ones published by the 
Society of Radiologists in Ultrasound 8.  
This analysis was followed by a regression analysis, in which we showed that the optimal 
test characteristics and cut-off values of carotid duplex ultrasonography depended on whether 
the side of the carotid artery was symptomatic or not in patients with symptoms of minor 
stroke, transient ischemic attack, or amaurosis fugax. This implies that using different cut-off 
values for the symptomatic and asymptomatic carotid artery in these patients, the clinical use of 
duplex ultrasonography can be optimized. However, the optimal cut-off values should be 
validated in clinical practice. 
 
In summary, the diagnostic performance of CTA and contrast-enhanced MRA is better than 
that of non-enhanced MRA and duplex ultrasonography for the diagnosis of peripheral, renal, 
and carotid artery disease in terms of test accuracy. The subdivision of the arterial tree into 
arterial segments should be standardized in future studies. SROC-analysis in combination with 
cost-effectiveness analysis can be used for the optimization of a diagnostic test in a specific 
clinical setting. Value of information analysis should be performed to design future studies on 
the diagnostic performance of imaging tests.   
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Summary 
 
 
This thesis describes studies on the assessment of diagnostic imaging technologies for 
cardiovascular disease. In chapter 1, the rationale for this research project is presented. Because 
cardiovascular disease is still the leading cause of death in industrialized countries, it is 
important to diagnose this disease accurately, so that adequate treatment can be initiated. The 
accepted reference standard for the diagnosis of arterial stenosis is conventional angiography, 
which carries a risk of morbidity and mortality. Therefore, research currently focuses on the 
development and improvement of non-invasive imaging technologies. An enormous variety of 
non-invasive imaging technologies is available and numerous diagnostic studies have been 
published. The question remains which studies provide the best-available evidence for the 
clinician and which diagnostic test should be chosen in a particular clinical setting. Therefore, 
the aim of this thesis was to assess diagnostic imaging technologies for cardiovascular disease 
using various methods of diagnostic test evaluations and to determine the optimal diagnostic 
test strategy in specific clinical settings. A secondary aim was to develop the methods available 
for the assessment of diagnostic imaging technology, including meta-analytical and decision 
analytical techniques.   
  
To summarize the currently available evidence on the diagnostic performance of non-
invasive imaging tests published in the literature a systematic review can be performed. Using 
summary receiver operating characteristic (SROC) analysis the diagnostic performance of 
various tests can be compared and study characteristics can be determined that may influence 
the diagnostic performance.  
In chapters 2 and 3 a systematic review was performed of meta-analyses evaluating 
diagnostic imaging tests for coronary, peripheral, renal, and carotid artery disease. Each meta-
analysis provided sensitivity and specificity estimates of the tests reported in the source studies. 
A SROC analysis was performed on the data from the source studies. Relative diagnostic odds 
ratios were compared in which measures of sensitivity and specificity were integrated into one 
measure of diagnostic performance. The influence of potential confounders was evaluated by 
adding variables to the regression models. Assessing the coronary tests (chapter 2) we found 
that differences between tests were small and that the diagnostic performance of the coronary 
tests diminished over the years.  
Comparing tests for peripheral, renal, and carotid artery disease (chapter 3), we found that 
diagnostic performance of computed tomographic angiography (CTA) and contrast-enhanced 
magnetic resonance angiography (MRA) were significantly better than non-enhanced MRA and 
duplex ultrasonography. Furthermore, our results suggested that studies in which the vascular 
tree was subdivided into a high number of arterial segments the diagnostic performance was 
inflated compared with studies with no, or less, subdivisions into arterial segments. 
 
 A large number of diagnostic imaging tests exist that have shown a good diagnostic 
performance for the diagnosis of cardiovascular disease. From a health care policy perspective, 
however, the value of a diagnostic test should not only reflect the diagnostic performance, but 
also the cost and risks associated with the test and the treatments that may be induced by the 
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test, the pre-test probability of disease, and the health related quality of life of the patient. Cost-
effectiveness analysis can be performed to integrate these variables and to guide decisions on 
which test should be used in specific clinical settings. 
In chapters 4 and 5 cost-effectiveness analyses were performed for comparison of various 
coronary imaging tests. In chapter 4 the cost-effectiveness of electron beam computed 
tomography (EBCT) was compared with exercise echocardiography and exercise single-photon 
emission computed tomography (SPECT) in patients suspected of coronary artery disease. Our 
results suggested that, in general, EBCT was not a cost-effective test for the diagnosis of 
coronary artery disease. Only if society is willing to pay a relatively high dollar amount per 
quality-adjusted life-year (QALY) gained, can a small subset of patients at intermediate 
probability of coronary artery disease benefit from this test. In chapter 4 three types of 
pharmacological stress, i.e. adenosine, dipyridamole, and dobutamine, in combination with 
either echocardiography or SPECT were compared with a no imaging strategy and routine 
coronary angiography. The cost-effectiveness analysis showed that dipyridamole and 
dobutamine echocardiography were cost-effective in patient subsets at intermediate pre-test 
probability of coronary artery disease, whereas adenosine SPECT was cost-effective for patients 
with at intermediate risk in specific clinical situations or at higher willingness-to-pay thresholds. 
Routine coronary angiography was the optimal test strategy for patients with typical angina. 
 
The diagnostic performance of a test cannot be expressed in a single fixed estimate of test 
performance. The diagnostic performance of a test depends on the setting in which a test is used 
and on the perspective from which the test is evaluated. Several methods have been described to 
optimize the diagnostic performance of a test, such as the determination of the optimal 
sensitivity and specificity and the optimal cut-off value of a test to discriminate between the 
diseased patients and the non-diseased patients. Chapters 6, 7, and 8 describe analyses 
performed to determine the optimal sensitivity and specificity and cut-off value of tests for 
coronary and carotid artery disease.  
In chapter 6 the sensitivity and specificity of EBCT were optimized for six cohorts of patients 
defined by age, sex, and type of chest pain from the health care perspective. First a SROC 
analysis was performed based on a published meta-analysis. The regression model obtained 
from this analysis was integrated into a cost-effectiveness analysis comparing the cost-
effectiveness of EBCT, no imaging, and coronary angiography for patients with chest pain. The 
results of this study show that if optimal estimates of sensitivity and specificity are used for 
specific cohorts in a cost-effectiveness analysis instead of pooled fixed values, the net health 
benefit of a test may be improved.  
Chapters 7 and 8 focus on the optimal cut-off value of duplex ultrasonography for the 
diagnosis of carotid artery disease based on a cost-effectiveness analysis. We found that optimal 
cut-off values based on cost-effectiveness differ from cut-off values based on maximum accuracy 
of a test and from recently published recommended cut-off values (chapter 7). Furthermore, we 
found that a significant difference existed in the optimal cut-off value between the 
asymptomatic and the symptomatic carotid artery in patients with symptoms of amaurosis 
fugax, transient ischemic attack, or minor stroke (chapter 8). The cut-off value of the 
asymptomatic carotid artery was optimal at a significantly higher peak systolic velocity than the 
optimal cut-off value of the symptomatic carotid artery.  
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The results of comparing diagnostic imaging tests may be affected by biases, in particular 
verification bias. Verification bias exists if patients are referred to the reference test based on the 
results from the test under evaluation. As a result of verification bias sensitivity may be inflated 
and specificity deflated if positive test results are verified preferentially. Methods have been 
developed to correct for verification bias. 
In chapter 9 we discuss the potential influence of verification bias on point estimates of 
sensitivity and specificity and on the SROC curve. We found that if correction for verification 
bias was performed, point estimates of the test characteristics may shift along the SROC curve, 
implying that the cut-off value of a test may change. We stated that we should strive for accurate 
reporting of how the test was evaluated and how the data were analyzed so that bias can be 
recognized, validity can be judged, and appropriate adjustments can be made. 
 
Despite substantial clinical research, uncertainty remains about which test is best in a 
specific clinical setting. Future quantitative clinical research can help resolve this uncertainty. 
Using value of information analysis the expected benefit of research on various subsets of study 
parameters can be estimated. 
In chapter 10 six subsets of uncertain parameters in a cost-effectiveness analysis comparing 
imaging technology for coronary artery disease, namely exercise echocardiography, exercise 
SPECT, computed tomographic angiography, and coronary angiography, were assessed using 
value of information analysis. Our results suggested that an observational study yielding more 
precise estimates of the quality-of-life weights for the severity of chest pain seems most 
beneficial. In addition, patients could benefit from more precise estimates of test characteristics, 
costs, and treatment effects. Value of information analysis seems a practical method to prioritize 
and guide future clinical research using available evidence. 
 
 This thesis concludes with a general discussion on the methodology of the presented studies 
and the clinical implications (chapter 11). This final chapter also provides recommendations on 
further diagnostic test evaluations. 

  
Samenvatting 

Samenvatting 
 
165 
Samenvatting 
 
Dit proefschrift beschrijft studies naar de evaluatie van diagnostische beeldvormende 
technieken voor hart- en vaatziekten. In hoofdstuk 1 wordt de aanleiding voor dit proefschrift 
gegeven. Omdat hart- en vaatziekten nog altijd de belangrijkste doodsoorzaak vormen in de 
geïndustrialiseerde landen, is het belangrijk om deze ziekte nauwkeurig te diagnosticeren, zodat 
een adequate behandeling kan worden ingesteld.  
De geaccepteerde referentie standaard voor het diagnosticeren van stenoses in de slagaders 
is de conventionele angiografie, welke een morbiditeits- en mortaliteitsrisico met zich 
meebrengt. Daarom richt het onderzoek zich vandaag de dag op het ontwikkelen en verbeteren 
van niet-invasieve beeldvormende technieken. Er is een enorme variëteit aan niet-invasieve 
beeldvormende technieken beschikbaar en talrijke diagnostische studies zijn gepubliceerd. De 
vraag blijft welke studies het best beschikbare bewijs leveren voor de clinicus en welke test 
uitgevoerd moet worden in een specifieke klinische setting. Daarom was het doel van dit 
proefschrift om diagnostische beeldvormende technieken voor hart- en vaatziekten, waarbij 
verschillende methoden van diagnostische testevaluaties worden gebruikt, te evalueren en om 
vast te stellen wat de optimale diagnostische teststrategie is in een specifieke klinische setting. 
Een tweede doel was om de methoden die beschikbaar zijn voor de evaluatie van diagnostische 
beeldvormende technieken te verbeteren, waaronder meta-analytische en besliskundige 
technieken. 
 
Om de nu beschikbare bewijsvoering over de diagnostische accuratesse van niet-invasieve 
beeldonderzoeken die gepubliceerd is in de literatuur samen te vatten, kan een systematisch 
literatuuronderzoek worden uitgevoerd. Met behulp van de zogenaamde summary receiver 
operating characteristic (SROC) analyse kan de diagnostische accuratesse van meerdere tests 
worden vergeleken en kunnen determinanten van de studie worden gevonden die van invloed 
kunnen zijn op de diagnostische accuratesse. 
In de hoofdstukken 2 en 3 werd een systematisch literatuuronderzoek naar meta-analyses 
uitgevoerd die diagnostische beeldonderzoeken bestudeerden voor ziekten van de 
kransslagaders, de perifere slagaders, de nierslagaders, en de halsslagaders. Iedere meta-analyse 
presenteerde de schattingen van de sensitiviteit en specificiteit van de tests die waren 
gerapporteerd in de bronstudies. Relatieve diagnostische odds ratios werden vergeleken waarin 
de maten van sensitiviteit en specificiteit werden geïntegreerd in één maat van diagnostische 
accuratesse. De invloed van potentieel verstorende variabelen werd geëvalueerd door 
variabelen aan het regressiemodel toe te voegen. Bij het bestuderen van de tests voor de 
kransslagaders (hoofdstuk 2) vonden wij dat de verschillen tussen de tests klein waren en dat de 
diagnostische accuratesse van deze tests over de jaren verminderde. 
Bij het vergelijken van de tests voor perifere slagaders, nierslagaders en halsslagaders 
(hoofdstuk 3), vonden wij dat de diagnostische accuratesse van CTA en MRA met contrast-
toediening significant beter waren dan die van MRA zonder contrast-toediening en duplex 
echo-onderzoek. Verder suggereerden onze resultaten dat studies waarin de vaatboom was 
onderverdeeld in een groot aantal slagadersegmenten de diagnostische accuratesse hoger was 
vergeleken met studies waarin geen of minder onderverdelingen werden gemaakt. 
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Er bestaat een groot aantal diagnostische beeldonderzoeken die een goede diagnostische 
accuratesse hebben gedemonstreerd voor de diagnostiek van hart- en vaatziekten. Vanuit het 
maatschappelijk perspectief, echter, zou de waarde van een diagnostische test niet alleen de 
diagnostische accuratesse moeten weergeven, maar ook de kosten en risico’s verbonden aan de 
test en de behandelingen die worden ingesteld op basis van de test, de kans op ziekte 
voorafgaand aan de test, en de aan gezondheid gerelateerde kwaliteit van leven van de patiënt. 
Een kosten-effectiviteitanalyse kan worden uitgevoerd om deze variabelen te integreren en om 
beslissingen te helpen maken over welke test gebruikt zou moeten worden in een specifieke 
klinische setting. 
In de hoofdstukken 4 en 5 werden kosten-effectiviteitanalyses uitgevoerd voor het 
vergelijken van verscheidene beeldonderzoeken voor de kransslagaders. In hoofdstuk 4 werd de 
kosten-effectiviteit van elektronenbundel tomografie (EBT) vergeleken  met inspannings-
echocardiografie en inspannings-single-photon-emission computed tomografie (inspannings-
SPECT test) bij patiënten bij wie ziekte van de kransslagaders werd verondersteld. Onze 
resultaten suggereerden dat de EBT test in het algemeen niet een kosten-effectieve test was voor 
de diagnose van ziekte van de kransslagaders. Alleen als de maatschappij bereid is een relatief 
hoge prijs te betalen per levensjaar aangepast voor kwaliteit van leven, kan een kleine subgroep 
van de patiënten met een middelmatige kans op ziekte van de kransslagaders profiteren van 
deze test. In hoofdstuk 4 werden drie soorten van medicamenteuze stress, te weten adenosine, 
dipyridamol, en dobutamine in combinatie met ofwel echocardiografie of de SPECT test 
vergeleken met een strategie zonder beeldonderzoek en een strategie met routinematige 
angiografie van de kransslagaders. De kosten-effectiviteitanalyse liet zien dat dipyridamol en 
dobutamine echocardiografie kosten-effectief waren in subgroepen van patiënten met een 
middelmatige kans op ziekte van de kransslagaders voorafgaand aan de test, terwijl de 
adenosine SPECT test kosten-effectief was voor patiënten met een middelmatig risico in 
specifieke klinische situaties of wanneer de gezondheidszorg bereid is tot het betalen van een 
hogere prijs. Routinematige angiografie van de kransslagaders was de optimale teststrategie 
voor patiënten met typische pijn op de borst. 
 
De diagnostische accuratesse van een test kan niet worden uitgedrukt in een enkele vaste 
schatting van de testaccuratesse. De diagnostische accuratesse van een test is afhankelijk van de 
setting waarin een test wordt toegepast en vanuit welk perspectief een test wordt onderzocht. 
Verscheidene methoden zijn beschreven om de diagnostische accuratesse van een test te 
optimaliseren, zoals het bepalen van de optimale sensitiviteit en specificiteit en het optimale 
afkappunt van een test om onderscheid te maken tussen zieke patiënten en niet-zieke patiënten. 
Hoofdstukken 6, 7, en 8 beschrijven analyses die werden uitgevoerd om de optimale sensitiviteit 
en specificiteit en het afkappunt van tests voor ziekten van de kransslagaders en halsslagaders te 
bepalen. 
In hoofdstuk 6 werden de sensitiviteit en specificiteit van de EBT test geoptimaliseerd voor 
zes cohorten van patiënten die werden gedefinieerd door leeftijd, geslacht, en type pijn op de 
borst, vanuit het perspectief van de gezondheidszorg. Eerst werd een SROC analyse uitgevoerd 
die was gebaseerd op een gepubliceerde meta-analyse. Het regressiemodel dat door deze 
analyse werd verkregen werd geïntegreerd in een kosten-effectiviteitanalyse die de kosten-
effectiviteit van de EBT test vergeleek met de strategie zonder beeldonderzoek en met de 
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strategie met angiografie van de kransslagaders voor patiënten met pijn op de borst. De 
resultaten van deze studie laten zien dat de netto gezondheidswinst van een test verbeterd zou 
kunnen worden, wanneer optimale schattingen van de sensitiviteit en specificiteit worden 
gebruikt voor specifieke cohorten in een kosten-effectiviteitanalyse in plaats van vaste 
samengevoegde waarden.  
De hoofdstukken 7 en 8 focussen op het optimale afkappunt van het duplex echo-onderzoek 
voor de diagnostiek van ziekte van de halsslagaders die gebaseerd werd op een kosten-
effectiviteitanalyse. We vonden dat optimale afkappunten die gebaseerd zijn op kosten-
effectiviteitanalyse verschilden van afkappunten die waren gebaseerd op de maximale 
nauwkeurigheid van een test en van recent gepubliceerde aanbevolen afkappunten (hoofdstuk 
7). Verder vonden wij dat er een significant verschil bestond in het optimale afkappunt voor de 
asymptomatische en de symptomatische halsslagaders bij patiënten met symptomen van 
amaurosis fugax, een TIA, of een kleine beroerte (hoofdstuk 8). Het afkappunt voor de 
asymptomatische halsslagader was optimaal bij een significant hogere maximale systolische 
bloedstroomsnelheid dan het optimale afkappunt voor de symptomatisch halsslagader.  
 
De resultaten van het vergelijken van diagnostische beeldonderzoeken kunnen worden 
beïnvloed door bias, in het bijzonder door verificatie bias. Er is sprake van verificatie bias als 
patiënten worden verwezen naar de referentietest op basis van de resultaten van de test die 
wordt onderzocht. Het gevolg van verificatie bias is dat de sensitiviteit hoger wordt en de 
specificiteit lager als positieve testuitslagen met voorkeur worden geverifieerd. Er zijn methoden 
ontwikkeld om voor verificatie bias te corrigeren. 
 
In hoofdstuk 9 wordt de potentiële invloed van verificatie bias op de puntschattingen van 
sensitiviteit en specificiteit en op de SROC curve bediscussieerd. Wij vonden dat, wanneer de 
correctie voor verificatie bias was uitgevoerd, de puntschattingen van de testkarakteristieken 
langs de SROC curve kunnen verschuiven, wat impliceert dat het afkappunt van de test kan 
veranderen. We stelden dat we moeten streven naar een nauwkeurige rapportage van hoe de 
test werd onderzocht en hoe de data werden geanalyseerd, zodat bias kan worden herkend, de 
validiteit kan worden beoordeeld, en geschikte aanpassingen kunnen worden gemaakt. 
 
Ondanks de aanzienlijke hoeveelheid klinisch onderzoek, blijft er onzekerheid bestaan over 
welke test de beste is in een specifieke klinische setting. Toekomstig kwantitatief klinisch 
onderzoek kan helpen deze onzekerheid te verminderen. Met gebruikmaking van het 
zogenaamde value-of-information onderzoek kan de verwachte opbrengst van onderzoek naar 
verschillende subgroepen van studieparameters worden ingeschat. 
In hoofdstuk 10 werden 6 subgroepen van de onzekere parameters onderzocht met behulp 
van value-of-information analyse afkomstig uit een kosten-effectiviteitanalyse van 
beeldvormende technieken voor ziekte van de kransslagaders, namelijk inspannings-
echocardiografie, inspannings-SPECT, CT-angiografie, en conventionele angiografie. De 
resultaten suggereren dat een observationele studie die preciezere schattingen bevat van de 
kwaliteit-van-leven voor de ernst van pijn op de borst het meest gunstig lijkt. Daarnaast zouden 
patiënten kunnen profiteren van preciezere schattingen van de testkarakteristieken, kosten, en 
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behandelingseffecten. Value-of-information analyse lijkt een praktische methode te zijn om 
prioriteiten te stellen in toekomstig klinisch onderzoek op basis van de beschikbare kennis. 
 
Dit proefschrift eindigt met een algemene discussie over de methodologie van de besproken 
studies en de klinische implicaties (hoofdstuk 11). Dit laatste hoofdstuk verschaft ook 
aanbevelingen voor verder diagnostisch testonderzoek.   
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